{"meta":{"query_hash":"598cba118836","filters":{"venue":"Antiviral Therapy"},"cohort_total":150,"direct_labels_cover":1,"predictions_cover":150,"exported":150,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/598cba118836","api":"https://metacan.xera.ac/api/v1/cohort?venue=Antiviral+Therapy"},"results":[{"id":"W101727076","doi":"10.1177/135965350701200709","title":"Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Receiver operating characteristic; Support vector machine; Univariate; Covariate; Population; Artificial intelligence; Sensitivity (control systems); Biology; Computational biology; Statistics; Medicine; Internal medicine; Mathematics; Multivariate statistics; Computer science","score_opus":0.0380916285824094,"score_gpt":0.3250282618337816,"score_spread":0.2869366332513722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W101727076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658656,0.0013057853,0.00007388634,0.00027536025,0.00012741821,0.00021449971,0.000037159458,0.00001587434,0.0013634654],"genre_scores_gemma":[0.9974952,0.0016857589,0.0000847365,0.0001236961,0.00003477573,0.0000042178513,0.000016603793,0.000007507651,0.0005475267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913156,0.00022598407,0.00021981934,0.00015763452,0.00003527306,0.0002297256],"domain_scores_gemma":[0.9987711,0.000963801,0.00006719106,0.00015801072,0.000024767693,0.0000151407385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006714858,0.00008996436,0.00015871345,0.000034929693,0.000119100616,0.0000068264317,0.00010451743,0.00009410189,0.000296168],"category_scores_gemma":[0.000068632326,0.000050255858,0.000066901586,0.00006509898,0.0003203256,0.00001991676,0.000025782705,0.0001715554,0.00021994178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006047361,0.00025648912,0.8493536,0.0000019344059,0.0003059233,0.0000060890225,0.00020119984,6.200885e-8,0.04171074,0.00032361646,0.00090015127,0.10633546],"study_design_scores_gemma":[0.0017114595,0.0012245307,0.85912335,0.00001679759,0.000011702241,0.000004575575,0.00011287952,0.0000030734545,0.13173415,0.00008125559,0.0059106685,0.00006557371],"about_ca_topic_score_codex":0.000050337425,"about_ca_topic_score_gemma":0.0000149682965,"teacher_disagreement_score":0.10626989,"about_ca_system_score_codex":0.0000059523127,"about_ca_system_score_gemma":0.00001868002,"threshold_uncertainty_score":0.32428318},"labels":[],"label_agreement":null},{"id":"W105581188","doi":"10.1177/135965350400900314","title":"Psychosocial Determinants of Adherence to Highly Active Antiretroviral Therapy among Injection Drug Users in Vancouver","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria; Centre for Advancing Health Outcomes; University of British Columbia; HIV Legal Network; St. Paul's Hospital","funders":"","keywords":"Medicine; Psychosocial; Psychological intervention; Logistic regression; Internal medicine; Social support; Family medicine; Psychiatry; Psychology","score_opus":0.02763876814259041,"score_gpt":0.3531195655408389,"score_spread":0.3254807973982485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W105581188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967744,0.00009260336,0.00008539616,0.00011229015,0.00021596008,0.00076785416,0.000015990145,0.000035730547,0.0018998231],"genre_scores_gemma":[0.99637777,0.0005103363,0.00014778202,0.00012523883,0.00011787155,0.00005071511,0.000005904061,0.000027996592,0.002636375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846107,0.00010447069,0.0003649883,0.0003147852,0.00036373278,0.00039097533],"domain_scores_gemma":[0.9993937,0.000029229173,0.00011474054,0.00023695745,0.00012041964,0.00010495004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021608108,0.00018608001,0.00038455837,0.00034729458,0.00007243791,0.000018635943,0.0001669063,0.00009567797,0.00008927808],"category_scores_gemma":[0.000045750974,0.00015606005,0.00022668664,0.00067065604,0.00016000499,0.00038642186,0.000021981965,0.00027932503,0.000035577235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031573207,0.0010063612,0.6029377,0.000020224168,0.00007906876,0.00003677432,0.0038287132,0.000003948667,0.05614112,0.000040687228,0.003342416,0.32940567],"study_design_scores_gemma":[0.008328881,0.020452078,0.69601554,0.000562756,0.0000073821,0.0000031785755,0.0010806036,0.000039560033,0.27188826,0.00048722667,0.00085729227,0.00027723354],"about_ca_topic_score_codex":0.0045057656,"about_ca_topic_score_gemma":0.0064159306,"teacher_disagreement_score":0.32912844,"about_ca_system_score_codex":0.0001202171,"about_ca_system_score_gemma":0.00012983766,"threshold_uncertainty_score":0.68114},"labels":[],"label_agreement":null},{"id":"W121874703","doi":"10.1177/135965350701200701","title":"The association of bone mineral density with HIV infection and antiretroviral treatment in women","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention","keywords":"Medicine; Lopinavir; Bone mineral; Confidence interval; Odds ratio; Confounding; Internal medicine; Femoral neck; Osteoporosis; Human immunodeficiency virus (HIV); Antiretroviral therapy; Gastroenterology; Viral load; Immunology","score_opus":0.011322236836392503,"score_gpt":0.28635020929502053,"score_spread":0.27502797245862803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W121874703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981234,0.00026972152,0.000027759103,0.00040384167,0.000022103806,0.00035953376,0.0000020813186,0.000015612593,0.0007759589],"genre_scores_gemma":[0.996691,0.0021177575,0.00008308751,0.000058724745,0.000026830368,0.00001749453,0.000008446246,0.000007709511,0.0009889806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993408,0.00003629377,0.00018799267,0.000116618416,0.00011210821,0.00020623388],"domain_scores_gemma":[0.9995992,0.00008118881,0.00011557004,0.00011623443,0.00005174269,0.000036039342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030242253,0.000085884865,0.00018321887,0.00007624793,0.00010016754,0.0000075058074,0.00001178629,0.00005653236,0.0000016595326],"category_scores_gemma":[0.000009065637,0.000049751394,0.000024472785,0.00016320698,0.000036803518,0.00005020982,0.0000039415277,0.00007082734,0.0000038330895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008109046,0.0002749991,0.92704403,0.000004656449,0.000061708706,0.000010665811,0.0007286728,2.2811861e-7,0.0016627469,0.0000675231,0.0000143637935,0.069319524],"study_design_scores_gemma":[0.0035592641,0.0018212553,0.9913874,0.000025655863,0.000012729059,0.000008100933,0.000058141733,0.000027197137,0.0016837443,0.000048586997,0.0013227544,0.000045162862],"about_ca_topic_score_codex":0.00041890168,"about_ca_topic_score_gemma":0.00032831548,"teacher_disagreement_score":0.06927436,"about_ca_system_score_codex":0.00029186212,"about_ca_system_score_gemma":0.000039355647,"threshold_uncertainty_score":0.2028803},"labels":[],"label_agreement":null},{"id":"W133318803","doi":"10.1177/135965350400900522","title":"Management of Antiviral Resistance in Patients with Chronic Hepatitis B","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"","keywords":"Medicine; Hepatitis B virus; Drug resistance; Antiviral drug; Context (archaeology); Hepatitis B; Immunology; Antiviral therapy; Viral load; Internal medicine; Virology; Virus; Chronic hepatitis; Biology","score_opus":0.011217361470056192,"score_gpt":0.2543613498727539,"score_spread":0.24314398840269769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W133318803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057895,0.0009318513,0.0000518734,0.0002108971,0.000054688797,0.0006306038,0.000012756384,0.00003203056,0.007496364],"genre_scores_gemma":[0.994336,0.003729243,0.001477886,0.000083901796,0.00002840477,0.000025954594,0.000014022525,0.000026947246,0.00027763107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988562,0.000026511258,0.0002588235,0.00024866257,0.00032806865,0.00028173227],"domain_scores_gemma":[0.99954015,0.0000104302135,0.00009127008,0.00026711522,0.000067665416,0.000023391349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083710445,0.00016934963,0.00035613705,0.00010223888,0.000047972964,0.000006001705,0.00008150932,0.000041308944,0.000014689753],"category_scores_gemma":[0.0000034919856,0.00013231169,0.000054653854,0.00034354272,0.00013883623,0.00012453453,0.000027452443,0.0001047854,0.000021097154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006260448,0.0004153032,0.9845196,0.00009877323,0.0001402847,0.00009550419,0.00024392486,0.0000011932507,0.00014334798,0.0013018523,0.000037147678,0.012376994],"study_design_scores_gemma":[0.0075034443,0.0010153147,0.9843489,0.000743445,0.0000158143,2.014045e-7,0.000007032454,6.4329197e-7,0.0047786096,0.00024087708,0.0012020466,0.00014366447],"about_ca_topic_score_codex":0.000877024,"about_ca_topic_score_gemma":0.0049748644,"teacher_disagreement_score":0.01223333,"about_ca_system_score_codex":0.00016128655,"about_ca_system_score_gemma":0.00004101082,"threshold_uncertainty_score":0.5395514},"labels":[],"label_agreement":null},{"id":"W1343435","doi":"10.1177/135965350501000608","title":"A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Toronto General Hospital; St. Thomas Hospital; University Health Network; Ottawa Hospital","funders":"Malmö Högskola; Sahlgrenska Universitetssjukhuset; Temple University; University of Miami","keywords":"Ritonavir; Lopinavir; Discontinuation; Lopinavir/ritonavir; Medicine; Saquinavir; Internal medicine; Adverse effect; Randomized controlled trial; Gastroenterology; Intention-to-treat analysis; Population; Viral load; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.03754823925892261,"score_gpt":0.33972346927245534,"score_spread":0.30217523001353275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1343435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97438765,0.0003478178,0.000016588752,0.009813822,0.0013099686,0.010327349,0.000019946507,0.0001384966,0.0036383744],"genre_scores_gemma":[0.9884389,0.0006076664,0.00073499343,0.001089163,0.0013091989,0.0014697827,0.00025931792,0.00008329651,0.006007673],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99571484,0.0008764951,0.0010499406,0.00069342164,0.00091118895,0.0007540844],"domain_scores_gemma":[0.9980193,0.0007843576,0.00022604862,0.00063067576,0.00016508273,0.00017457666],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015277847,0.00059471634,0.0013580578,0.00032489226,0.00019946016,0.00008540003,0.00031227063,0.00021229262,0.00027537576],"category_scores_gemma":[0.00037899983,0.00037006155,0.00056756975,0.0007820242,0.000197398,0.00026760748,0.00008391598,0.00043672716,0.0009486838],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94093764,0.0021633937,0.0010895934,0.0000059012946,0.00038036314,0.00003218383,0.0012608436,0.0000024113617,0.00020053623,0.00014144985,0.0021420408,0.051643617],"study_design_scores_gemma":[0.94381726,0.0026955483,0.002003658,0.00011582239,0.00017740847,0.0000022707702,0.0000640755,0.000072359246,0.001354329,0.0000663819,0.049214672,0.0004162052],"about_ca_topic_score_codex":0.00007164688,"about_ca_topic_score_gemma":0.0000712217,"teacher_disagreement_score":0.051227413,"about_ca_system_score_codex":0.00035051533,"about_ca_system_score_gemma":0.0002719139,"threshold_uncertainty_score":0.9998751},"labels":[],"label_agreement":null},{"id":"W136034343","doi":"10.1177/135965350400900218","title":"Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Hazard ratio; Population; Drug; Immunology; Confidence interval; Pharmacology","score_opus":0.031223057954219847,"score_gpt":0.3249935126038499,"score_spread":0.29377045464963003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W136034343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949532,0.0007035885,0.00037323707,0.00053539505,0.000080088284,0.00083211303,0.000024443829,0.00013944988,0.002358479],"genre_scores_gemma":[0.98162735,0.0021088293,0.00026512303,0.00036368798,0.000119241406,0.00004897388,0.000029250643,0.000038928087,0.0153986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833083,0.00016737885,0.0002833163,0.000397859,0.00037407666,0.00044652086],"domain_scores_gemma":[0.99918944,0.000066039356,0.00007212784,0.00031518936,0.00015211542,0.0002050997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003448308,0.00023741004,0.0003125207,0.00031856803,0.0002018559,0.00010100141,0.00012810613,0.00009022887,0.0001529481],"category_scores_gemma":[0.000081189864,0.00019108177,0.0001692782,0.0005232689,0.00020445244,0.00034583145,0.000033407152,0.00031210683,0.00016268698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043804604,0.00088523503,0.5444023,0.00003626852,0.00013362024,0.00008031552,0.0024454354,0.0000035988858,0.34592506,0.00018102526,0.011118107,0.090408534],"study_design_scores_gemma":[0.01289883,0.051551353,0.6227966,0.00054753205,0.000025665251,0.000047230904,0.00097071996,0.00014049989,0.29851544,0.0003334144,0.01152682,0.00064588734],"about_ca_topic_score_codex":0.001656214,"about_ca_topic_score_gemma":0.00019049631,"teacher_disagreement_score":0.08976264,"about_ca_system_score_codex":0.00008701549,"about_ca_system_score_gemma":0.00014270216,"threshold_uncertainty_score":0.77920884},"labels":[],"label_agreement":null},{"id":"W139360933","doi":"10.1177/135965350400900613","title":"Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Didanosine; Stavudine; Ribavirin; Pegylated interferon; Gastroenterology; Internal medicine; Medicine; Asymptomatic; Immunology; Hepatitis C virus; Concomitant; Biology; Virology; Zidovudine; Viral disease; Virus","score_opus":0.018135878339821943,"score_gpt":0.31147816091440433,"score_spread":0.2933422825745824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W139360933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964816,0.00024597443,0.000111641464,0.0001289496,0.00010573225,0.002562746,0.00006107313,0.000056011664,0.00024630237],"genre_scores_gemma":[0.99849504,0.00057805487,0.00019458725,0.00005648208,0.000030154702,0.00012921086,0.00027207128,0.000048867692,0.00019553551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983867,0.0000972099,0.0005462233,0.00035145797,0.0002792062,0.00033922825],"domain_scores_gemma":[0.99889284,0.00014640923,0.0003083305,0.00044428592,0.000105389016,0.0001027495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000037939342,0.00035143996,0.0007703715,0.00024431513,0.000056169312,0.0000082929855,0.0000883812,0.0001244038,0.000025600062],"category_scores_gemma":[0.000011376221,0.00021535701,0.000108376735,0.00040716177,0.0001079147,0.000081380196,0.000009904391,0.00015089691,0.00002921024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023970041,0.02721765,0.91105103,0.0004459584,0.0009950662,0.00023202434,0.0022759996,0.000050685307,0.009398026,0.000039816525,0.00008324622,0.024240443],"study_design_scores_gemma":[0.05706181,0.048035704,0.85662186,0.0025467628,0.00015095517,0.000008974112,0.000017245518,0.00006103905,0.03523953,0.000011725439,0.00003558631,0.00020883518],"about_ca_topic_score_codex":0.00018669011,"about_ca_topic_score_gemma":0.00012792375,"teacher_disagreement_score":0.054429203,"about_ca_system_score_codex":0.0003560126,"about_ca_system_score_gemma":0.00029998395,"threshold_uncertainty_score":0.8782004},"labels":[],"label_agreement":null},{"id":"W1483464410","doi":"10.1177/135965350701200405","title":"Plasma Concentrations of the HIV-Protease Inhibitor Lopinavir are Suboptimal in Children Aged 2 Years and Below","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Cmin; Lopinavir; Pharmacokinetics; Cmax; Lopinavir/ritonavir; Medicine; Regimen; Ritonavir; Human immunodeficiency virus (HIV); Area under the curve; Pharmacology; Internal medicine; Viral load; Immunology; Antiretroviral therapy","score_opus":0.011341620185126057,"score_gpt":0.25182638738981433,"score_spread":0.24048476720468828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1483464410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979957,0.00023299138,0.000008540857,0.0008262401,0.000038073922,0.0006330029,0.00001542578,0.000014837464,0.00023519468],"genre_scores_gemma":[0.99821913,0.00018335464,0.00036573317,0.00009774293,0.000049577196,0.000009065999,0.00002399668,0.000011028437,0.0010403927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930876,0.000032121887,0.00018783385,0.00014776141,0.00014871648,0.00017482182],"domain_scores_gemma":[0.9997104,0.000026689884,0.00007175417,0.0001337051,0.000018744688,0.000038709386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014234714,0.00010766851,0.00017813244,0.000060271363,0.000049816892,0.0000080189275,0.00004936675,0.000052866482,0.000017578708],"category_scores_gemma":[0.000011557397,0.000073754585,0.000051004812,0.0001866526,0.00010886589,0.00005823711,0.000017170672,0.00011521565,0.000009703248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020089615,0.00019703775,0.98765564,0.000004167303,0.00005365813,0.000022430893,0.0006890568,3.377698e-7,0.0045227823,0.0000560893,0.00030147156,0.0062964195],"study_design_scores_gemma":[0.0035302087,0.000065941436,0.9517524,0.000085406624,0.000012187114,0.000009036337,0.00010837798,0.000006937593,0.04397892,0.000016169448,0.00035875294,0.000075644035],"about_ca_topic_score_codex":0.00002113522,"about_ca_topic_score_gemma":0.000029138588,"teacher_disagreement_score":0.039456137,"about_ca_system_score_codex":0.000028455586,"about_ca_system_score_gemma":0.000051130726,"threshold_uncertainty_score":0.30076244},"labels":[],"label_agreement":null},{"id":"W1528578169","doi":"10.1177/135965350701200810","title":"Amphipathic DNA Polymers are Candidate Vaginal Microbicides and Block Herpes Simplex Virus Binding, Entry and Viral Gene Expression","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; National Institute of Allergy and Infectious Diseases","keywords":"Herpes simplex virus; Biology; Virology; Microbicides for sexually transmitted diseases; HeLa; Viral entry; Virus; Viral shedding; DNA; Avidity; Molecular biology; Viral replication; Immunology; Cell; Biochemistry; Antibody; Medicine; Population","score_opus":0.015303283359318784,"score_gpt":0.2860751315980268,"score_spread":0.270771848238708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1528578169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960431,0.0027844077,0.00004702515,0.00013243823,0.00012145099,0.00029219995,0.000038904964,0.00007480131,0.00046570197],"genre_scores_gemma":[0.9952762,0.003247028,0.000284768,0.00044238067,0.00015559941,0.000008032137,0.0000254841,0.000036416794,0.0005240763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987826,0.000053052554,0.00023614458,0.00036848133,0.00015058382,0.00040918277],"domain_scores_gemma":[0.99946,0.000046436013,0.00011158793,0.0002004068,0.000029864783,0.00015170264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020304446,0.0002694877,0.0003216853,0.00018169281,0.0002790689,0.00005197587,0.000044809945,0.00014358597,0.00006740265],"category_scores_gemma":[0.000007759382,0.00020801747,0.00006875122,0.00014534897,0.00017535508,0.00014526713,0.0000354999,0.00015283935,0.000016616626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005453409,0.00030178876,0.14592725,0.000018719122,0.00015920305,0.0001985105,0.00035736416,7.900407e-8,0.6237861,0.000013324374,0.00014613626,0.2285462],"study_design_scores_gemma":[0.0036350698,0.0003956631,0.119658746,0.00013188692,0.000055715336,0.00013873835,0.00014021505,0.000004497173,0.841781,0.000042248437,0.033772755,0.0002434333],"about_ca_topic_score_codex":0.0004989587,"about_ca_topic_score_gemma":0.00009642677,"teacher_disagreement_score":0.22830276,"about_ca_system_score_codex":0.00004048127,"about_ca_system_score_gemma":0.00003109596,"threshold_uncertainty_score":0.84827065},"labels":[],"label_agreement":null},{"id":"W1560982094","doi":"10.1177/135965350601100509","title":"Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic","funders":"","keywords":"Lamivudine; HBsAg; Medicine; Cohort; Internal medicine; Human immunodeficiency virus (HIV); Cohort study; Hepatitis B; Virology; Hepatitis B virus; Virus","score_opus":0.021099107068077202,"score_gpt":0.30463682028091765,"score_spread":0.28353771321284044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1560982094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642706,0.0005424096,0.000020972864,0.00016409576,0.00001339197,0.00041755466,0.0011004487,0.000018177625,0.0012959109],"genre_scores_gemma":[0.9967619,0.0027665761,0.00008500767,0.000046917976,0.000034578665,0.000007518277,0.00021493013,0.000017339136,0.000065192915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982984,0.0003802329,0.0005398628,0.00032136223,0.00025556106,0.00020457034],"domain_scores_gemma":[0.9986074,0.00055372,0.0003322389,0.00037082066,0.000104580424,0.000031253807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006218784,0.00021531584,0.0007054809,0.00031499824,0.000053108604,0.00001046984,0.00010487766,0.000100804944,0.000037577604],"category_scores_gemma":[0.00013965249,0.00012916554,0.0002276352,0.0006581802,0.00018557334,0.000098107455,0.000037015256,0.00023852276,0.0000043455234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083366357,0.00048257358,0.98741186,0.0000020724044,0.0028786766,0.000018145969,0.0021947983,0.00002075586,0.0027854315,0.00006203494,0.00010983312,0.00320015],"study_design_scores_gemma":[0.0022630766,0.0013780226,0.98718995,0.00011381013,0.0004932429,6.4787065e-7,0.00006226978,0.0006515443,0.0074468716,0.0002741176,0.000009554727,0.00011689835],"about_ca_topic_score_codex":0.07091729,"about_ca_topic_score_gemma":0.004735373,"teacher_disagreement_score":0.06618192,"about_ca_system_score_codex":0.000053709347,"about_ca_system_score_gemma":0.000031116713,"threshold_uncertainty_score":0.93526953},"labels":[],"label_agreement":null},{"id":"W1576163479","doi":"10.1177/135965350801300802","title":"Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of Calgary","funders":"National Institute on Alcohol Abuse and Alcoholism","keywords":"Medicine; Internal medicine; Hazard ratio; Confidence interval; Prospective cohort study; Gastroenterology; Cohort; Anemia; Antiretroviral therapy; Proportional hazards model; Human immunodeficiency virus (HIV); Viral load; Immunology","score_opus":0.027629529567991664,"score_gpt":0.3344858308340465,"score_spread":0.30685630126605484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1576163479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955423,0.0024035748,0.000004938047,0.000051788385,0.000030864438,0.0014630379,0.000050679446,0.000029044348,0.00042378175],"genre_scores_gemma":[0.9942683,0.0051194606,0.00026906224,0.00005560935,0.000010680719,0.00006206488,0.00013315452,0.000018405079,0.000063259075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844766,0.000104108214,0.000628466,0.00031319764,0.0002696509,0.00023690522],"domain_scores_gemma":[0.9982042,0.0001224171,0.00044259246,0.00028133576,0.00090884144,0.000040665687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015017469,0.00019114329,0.0008326576,0.00040658866,0.00009330945,0.000002573196,0.00006417933,0.00007629709,0.000017405484],"category_scores_gemma":[0.00012189964,0.00014692935,0.0001095801,0.0033939183,0.00019953867,0.00010491606,0.000014906215,0.00014018286,0.000003905418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067869877,0.0011075664,0.9903788,0.00001941497,0.0029162616,0.000014906211,0.002717548,0.000007652079,0.00073681626,0.00005259204,0.000052365256,0.0013174004],"study_design_scores_gemma":[0.0031720467,0.0021020747,0.9916365,0.00009242535,0.0002479712,4.4039376e-7,0.00019821734,0.00016574001,0.0022205943,0.00003918314,0.000015509844,0.00010930974],"about_ca_topic_score_codex":0.00009069327,"about_ca_topic_score_gemma":0.000042497682,"teacher_disagreement_score":0.0029873296,"about_ca_system_score_codex":0.00011548322,"about_ca_system_score_gemma":0.00018705073,"threshold_uncertainty_score":0.5991605},"labels":[],"label_agreement":null},{"id":"W15969640","doi":"10.1177/135965350000500112","title":"The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan","year":2000,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Regimen; Internal medicine; Medicine; Drug resistance; Genotyping; Confounding; Viral load; HIV drug resistance; Observational study; Odds ratio; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Genotype; Biology","score_opus":0.052429182704700567,"score_gpt":0.34540640566846403,"score_spread":0.2929772229637635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W15969640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908755,0.005173685,0.00026268337,0.0024128843,0.000013215625,0.00074969896,0.00036251757,0.00003535549,0.00011444753],"genre_scores_gemma":[0.9846761,0.007385265,0.0023191238,0.000055731154,0.00004276688,0.000014388652,0.00016216097,0.00002231491,0.0053221076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758023,0.0004901853,0.00050616544,0.0006744497,0.00048456743,0.00026437597],"domain_scores_gemma":[0.99815893,0.00063006347,0.00020187527,0.0007334727,0.00020089261,0.000074745396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022096143,0.00028052862,0.0010865681,0.00049058284,0.0003993859,0.00005497195,0.00014181744,0.00005905097,0.00002733526],"category_scores_gemma":[0.00017330828,0.00017819273,0.00016010678,0.002367121,0.00025719704,0.00020822197,0.00006167585,0.00014300026,0.0000014874892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015460408,0.00008058695,0.9444903,0.0000061737314,0.023310075,0.000016453898,0.007753913,0.0000058352443,0.001278422,0.000028537113,0.0004057873,0.0071634836],"study_design_scores_gemma":[0.0038471697,0.0003151297,0.9838695,0.00007246486,0.0052513373,7.273121e-7,0.0012353215,0.0007506815,0.002108373,0.00014924932,0.0021382996,0.0002617413],"about_ca_topic_score_codex":0.000045023226,"about_ca_topic_score_gemma":0.00026594725,"teacher_disagreement_score":0.03937918,"about_ca_system_score_codex":0.00015484526,"about_ca_system_score_gemma":0.00008467973,"threshold_uncertainty_score":0.72664887},"labels":[],"label_agreement":null},{"id":"W168560548","doi":"10.3851/imp2572","title":"Safety and Efficacy of Chop for Treatment of Diffuse Large B-Cell Lymphoma with Different Combination Antiretroviral Therapy Regimens: Sculpt Study","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Université de Montréal; McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Diffuse large B-cell lymphoma; Antiretroviral therapy; Lymphoma; CHOP; Internal medicine; Oncology; Human immunodeficiency virus (HIV); Virology; Viral load","score_opus":0.01528697986025719,"score_gpt":0.2682580903614997,"score_spread":0.25297111050124255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W168560548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948283,0.0016529526,0.000048386388,0.00017321453,0.000046508532,0.0029714534,0.000026057487,0.000030378953,0.00022275692],"genre_scores_gemma":[0.9942651,0.0048905774,0.000031845164,0.000085467844,0.000025183546,0.00009922851,0.00003929246,0.00003817334,0.0005251809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987889,0.00007528368,0.00032762115,0.0002907255,0.00024578342,0.00027166717],"domain_scores_gemma":[0.9992012,0.00008077244,0.00025888873,0.00027652632,0.00012915864,0.000053486274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009105645,0.00026171104,0.00067535555,0.00009812985,0.000089488334,0.000015838072,0.0000634714,0.00007923388,0.000015922367],"category_scores_gemma":[0.0000063367397,0.00016094114,0.00014903408,0.00015267101,0.00009220764,0.00011007527,0.000009071706,0.00002992792,9.953504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015128563,0.07029399,0.625682,0.000068170026,0.001080107,0.0000041524268,0.0054496885,5.1331756e-7,0.03469668,0.00021029681,0.00013904915,0.2472468],"study_design_scores_gemma":[0.23467942,0.045493666,0.69222087,0.00005362512,0.000105919906,8.065742e-7,0.0014459558,0.00012488087,0.025220158,0.00005610725,0.0003883634,0.00021020246],"about_ca_topic_score_codex":0.00031352052,"about_ca_topic_score_gemma":0.00001593075,"teacher_disagreement_score":0.2470366,"about_ca_system_score_codex":0.000074468146,"about_ca_system_score_gemma":0.0000457101,"threshold_uncertainty_score":0.65629894},"labels":[],"label_agreement":null},{"id":"W1687303282","doi":"10.1177/135965350601100208","title":"Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4 <sup>+</sup> T-Cell Count and HIV-1 Rna Load","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic","funders":"","keywords":"Biology; Reverse transcriptase; Drug resistance; Virology; Seroconversion; Mutation; Interquartile range; Population; Wild type; Virus; Viral load; Genetics; Gene; Medicine; Internal medicine; RNA; Mutant","score_opus":0.006189843537791374,"score_gpt":0.2233159166469177,"score_spread":0.21712607310912632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1687303282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975074,0.0076228175,0.00013186982,0.00033115066,0.000013763995,0.00059865904,0.00009132218,0.000012630785,0.0014470652],"genre_scores_gemma":[0.99814546,0.0007576827,0.00004591376,0.000041281553,0.000009537155,0.000051594685,0.00007994071,0.000010632682,0.00085794914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891347,0.00033717116,0.00019329366,0.00020862451,0.000103394406,0.00024406612],"domain_scores_gemma":[0.99927795,0.0003554771,0.00008624714,0.00020971516,0.00006231578,0.000008302731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021838103,0.00015704597,0.00023111576,0.0000876082,0.00009312414,0.000007647274,0.00013909422,0.00006975277,0.000016740581],"category_scores_gemma":[0.000004735174,0.000093436836,0.00005235334,0.00023213401,0.00033020155,0.00006509789,0.0000044773747,0.00015818953,0.000036850615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006728028,0.0031044693,0.12185256,0.00013272036,0.00033362885,0.00005770053,0.008459211,0.00017723706,0.8388123,0.0024555891,0.0033258947,0.01456066],"study_design_scores_gemma":[0.015594167,0.0017122581,0.30577445,0.00022859212,0.000021502789,0.000007168102,0.00083525997,0.000027706885,0.66962004,0.0008947138,0.005002039,0.00028209382],"about_ca_topic_score_codex":0.00037168962,"about_ca_topic_score_gemma":0.0001473324,"teacher_disagreement_score":0.18392187,"about_ca_system_score_codex":0.000039289698,"about_ca_system_score_gemma":0.000084430256,"threshold_uncertainty_score":0.38102436},"labels":[],"label_agreement":null},{"id":"W1703585126","doi":"10.1177/135965350200700407","title":"Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Viral load; Discontinuation; Antiretroviral therapy; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Virology; Intensive care medicine; Immunology","score_opus":0.10938389424447433,"score_gpt":0.35304386302550805,"score_spread":0.24365996878103374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1703585126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632204,0.002027894,0.000021799335,0.00025469004,0.00004436902,0.0008569998,0.00003145501,0.00001221187,0.0004285225],"genre_scores_gemma":[0.9975253,0.0015164141,0.0004446418,0.000046329253,0.000027841623,0.000023378174,0.000036889625,0.00001775768,0.00036145755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666315,0.0004520195,0.001508021,0.00032833245,0.00080422446,0.00024422802],"domain_scores_gemma":[0.99817705,0.00023596121,0.0009801111,0.0003663943,0.00020453751,0.000035925503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016212667,0.000276546,0.0019553436,0.00058531715,0.000021690605,0.0000059515423,0.00014148052,0.00018675874,0.00021330029],"category_scores_gemma":[0.00019952834,0.00018591995,0.00064762693,0.0009768971,0.0001892928,0.00014527599,0.000031007505,0.00014070247,0.0000020707312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005618596,0.003051837,0.6488753,0.00003821447,0.0028827868,0.000009286155,0.0036613885,0.000009202594,0.30526057,0.000024217474,0.0000399442,0.030528696],"study_design_scores_gemma":[0.009976742,0.001423007,0.5454181,0.0002655409,0.000524678,4.8867776e-7,0.00007866185,0.0001863196,0.44189018,0.000020491569,0.00005675202,0.0001590198],"about_ca_topic_score_codex":0.00004843053,"about_ca_topic_score_gemma":0.000014401902,"teacher_disagreement_score":0.13662963,"about_ca_system_score_codex":0.000060964652,"about_ca_system_score_gemma":0.000047447553,"threshold_uncertainty_score":0.7581596},"labels":[],"label_agreement":null},{"id":"W172708961","doi":"10.1177/135965350601100108","title":"Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; AIDS Vancouver; University of British Columbia; Providence Health Care","funders":"","keywords":"Nephrotoxicity; Antiretroviral therapy; Medicine; Mitochondrial toxicity; Human immunodeficiency virus (HIV); Lentivirus; Mechanism (biology); Kidney; Virology; Immunology; Internal medicine; Pharmacology; Viral load; Viral disease","score_opus":0.020830012184985775,"score_gpt":0.2323322019368617,"score_spread":0.2115021897518759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W172708961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950071,0.0000173722,0.00028094987,0.00031053027,0.00083277526,0.0015693735,0.000041152492,0.00016362226,0.001777106],"genre_scores_gemma":[0.9957047,0.00028616234,0.00025612328,0.00023952578,0.000502188,0.00014566684,0.00041191062,0.00006490847,0.0023887914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977818,0.00013555882,0.00045935428,0.0005207419,0.0006604006,0.00044210962],"domain_scores_gemma":[0.99905765,0.000038879843,0.0002699012,0.00031806968,0.00017723191,0.00013827629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008294287,0.00043662236,0.0005647065,0.00032568883,0.0001776828,0.0000431035,0.000111010246,0.0001582843,0.00008214364],"category_scores_gemma":[0.000035282064,0.00034398216,0.0003062339,0.0003913477,0.00010277726,0.0006277448,0.000026029495,0.0002419087,0.00008183837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021655949,0.007230993,0.27689928,0.000038232036,0.0011817667,0.0001498509,0.0012370368,0.0000054091834,0.635271,0.00247892,0.0037943583,0.050057177],"study_design_scores_gemma":[0.016627237,0.0033286866,0.22387694,0.00013025198,0.0000562674,0.0000024904525,0.0000518591,0.00004297377,0.75395995,0.00034324895,0.001233037,0.00034706015],"about_ca_topic_score_codex":0.00034848787,"about_ca_topic_score_gemma":0.000005470412,"teacher_disagreement_score":0.11868891,"about_ca_system_score_codex":0.00014243339,"about_ca_system_score_gemma":0.00015220749,"threshold_uncertainty_score":0.99990124},"labels":[],"label_agreement":null},{"id":"W176944265","doi":"10.1177/135965350100600206","title":"Avanti 3: A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Lamivudine plus Zidovudine versus Lamivudine plus Zidovudine plus Nelfinavir in HIV-1-Infected Antiretroviral-Naive Patients","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; St. Paul's Hospital","funders":"","keywords":"Lamivudine; Nelfinavir; Zidovudine; Medicine; Tolerability; Placebo; Gastroenterology; Internal medicine; Adverse effect; Pharmacology; Randomized controlled trial; Indinavir; Virology; Sida; Viral load; Human immunodeficiency virus (HIV); Viral disease; Antiretroviral therapy; Virus","score_opus":0.04664450726182794,"score_gpt":0.318903719057104,"score_spread":0.27225921179527607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176944265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98379445,0.0007409641,0.00014134929,0.003511677,0.0006985451,0.008483175,0.000057486523,0.00012657975,0.0024457895],"genre_scores_gemma":[0.99132854,0.0034677335,0.0003293212,0.00025271976,0.0003636444,0.00025655935,0.0005580632,0.00009432205,0.0033491252],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99539024,0.00041261452,0.0014937914,0.00089862227,0.0008547531,0.0009499534],"domain_scores_gemma":[0.9971493,0.0010076724,0.0005072646,0.0007171005,0.00032275036,0.00029593954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001070355,0.000846529,0.0026241976,0.000624424,0.00026809436,0.00006923658,0.00035208088,0.00018748666,0.00016046182],"category_scores_gemma":[0.00037462698,0.00055846246,0.00040495908,0.0015686437,0.00045104392,0.0002689743,0.00020945483,0.00049970334,0.00009731507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.926188,0.0012517396,0.062457908,0.00004008229,0.0009174234,0.00013152312,0.0020890061,0.000063072825,0.000291459,0.00027297324,0.0013621616,0.004934684],"study_design_scores_gemma":[0.9569485,0.0024981112,0.032212425,0.00037016446,0.00033953658,0.000013570074,0.00017076611,0.00064271013,0.0011620257,0.000020974008,0.0050377916,0.0005834281],"about_ca_topic_score_codex":0.0003139797,"about_ca_topic_score_gemma":0.00012232126,"teacher_disagreement_score":0.030760529,"about_ca_system_score_codex":0.0004629776,"about_ca_system_score_gemma":0.0003961962,"threshold_uncertainty_score":0.99968666},"labels":[],"label_agreement":null},{"id":"W1828979694","doi":"10.3851/imp2768","title":"Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medical Research Council; European Commission; Stichting HIV Monitoring; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Institut National de la Santé et de la Recherche Médicale; Styrelsen för Internationellt Utvecklingssamarbete; Michael Smith Health Research BC; GlaxoSmithKline; National Science Foundation; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs; Office of Research and Development","keywords":"Medicine; Cart; Hazard ratio; Demography; Cohort; Antiretroviral therapy; Proportional hazards model; Mortality rate; Cohort study; Human immunodeficiency virus (HIV); Men who have sex with men; Cause of death; Viral load; Internal medicine; Immunology; Confidence interval; Disease; Syphilis","score_opus":0.022517346372524966,"score_gpt":0.26678252525695517,"score_spread":0.2442651788844302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1828979694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969507,0.0006311362,0.0000023064558,0.0005986944,0.00005060431,0.0007104666,0.000011270815,0.000022827999,0.0010219808],"genre_scores_gemma":[0.99069333,0.008359997,0.0000068926056,0.00066163565,0.000038273483,0.000033212953,0.000023289447,0.00001851116,0.00016488349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861884,0.000284795,0.00029291888,0.00034040277,0.0001891378,0.000273879],"domain_scores_gemma":[0.9993132,0.00018236076,0.00008810305,0.00030398212,0.000043363496,0.0000690077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002221913,0.00020370737,0.00039757544,0.00008880416,0.000109826426,0.00002834309,0.00007358911,0.00006821643,0.000010204917],"category_scores_gemma":[0.000020584037,0.00012213044,0.000022840375,0.00029444572,0.00017722651,0.00006559332,0.000015176477,0.00027611703,0.0000030724643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006442136,0.00015836894,0.98308027,0.000007751921,0.00003690712,0.000023292361,0.00041744582,5.4431536e-7,0.000062069535,0.00046816713,0.00008661097,0.015014354],"study_design_scores_gemma":[0.00949515,0.0005953435,0.9881909,0.00011453924,0.0000052598725,0.0000034946775,0.000019806084,0.00068476005,0.00007923963,0.000082029066,0.0006100724,0.00011939713],"about_ca_topic_score_codex":0.2049794,"about_ca_topic_score_gemma":0.11134238,"teacher_disagreement_score":0.09363703,"about_ca_system_score_codex":0.000045867047,"about_ca_system_score_gemma":0.00008320992,"threshold_uncertainty_score":0.9048733},"labels":[],"label_agreement":null},{"id":"W184261913","doi":"10.1177/135965350801300109","title":"Prospective Cohort Study of HIV Post-Exposure Prophylaxis for Sexual Assault Survivors","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Sexual Assault and Victimization Studies","field":"Social Sciences","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Ontario HIV Treatment Network; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Prospective cohort study; Odds ratio; Cohort; Confidence interval; Logistic regression; Cohort study; Risk assessment; Internal medicine","score_opus":0.03995670463885869,"score_gpt":0.32735074145387444,"score_spread":0.28739403681501574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W184261913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931932,0.00011753592,0.00010431713,0.00016296304,0.0002571242,0.0023797313,0.000026544356,0.00008860688,0.003669948],"genre_scores_gemma":[0.9945822,0.0001563157,0.00010472699,0.00005178774,0.00022267844,0.00018043953,0.000010771462,0.000018512685,0.0046726144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998355,0.00022955665,0.00026193928,0.0003179998,0.00056675,0.0002687877],"domain_scores_gemma":[0.9986985,0.0001738296,0.00014971432,0.00016206127,0.00077926496,0.000036646423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005966689,0.00015501899,0.00033555483,0.00007559791,0.00081832905,0.000021417834,0.0001897117,0.00010463821,0.000029198722],"category_scores_gemma":[0.00014088184,0.00012620511,0.00006220275,0.00044324654,0.00028071567,0.0002178718,0.000021850916,0.00010413628,0.000008975701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001985958,0.00077528,0.93496907,0.0000033401545,0.00016532266,0.0000018105766,0.060650244,0.0000037949094,0.00028183585,0.000250281,0.0004653592,0.0022350843],"study_design_scores_gemma":[0.0016101173,0.0033721183,0.93773806,0.000002558213,0.000012979889,3.1010515e-7,0.052945767,0.0000072506973,0.0004618708,0.0000816564,0.0035576222,0.00020968614],"about_ca_topic_score_codex":0.0035076786,"about_ca_topic_score_gemma":0.0033471247,"teacher_disagreement_score":0.007704478,"about_ca_system_score_codex":0.000032672124,"about_ca_system_score_gemma":0.000102582635,"threshold_uncertainty_score":0.62940085},"labels":[],"label_agreement":null},{"id":"W1845536215","doi":"10.1177/135965350300800406","title":"Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Amprenavir; Regimen; Drug resistance; Protease inhibitor (pharmacology); Internal medicine; Medicine; Viral load; Pharmacology; Virology; Immunology; Biology; Protease; Virus; HIV-1 protease; Antiretroviral therapy; Microbiology","score_opus":0.009401912719932652,"score_gpt":0.25375400540812737,"score_spread":0.24435209268819472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1845536215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932172,0.00032744007,0.000026063564,0.0020880548,0.00015486093,0.0010197621,0.000010815527,0.00012849433,0.0030273506],"genre_scores_gemma":[0.9623465,0.00013342766,0.0015043187,0.0005559731,0.000029734685,0.00013383327,0.00005220255,0.000046224355,0.035197772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977456,0.0003658013,0.0004223197,0.00053690746,0.00039433126,0.0005350629],"domain_scores_gemma":[0.9990316,0.0001678827,0.00010236588,0.00040929965,0.00013637847,0.00015249425],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047955042,0.00032809807,0.00045159692,0.00029404042,0.00013618193,0.000032973567,0.0001264227,0.0000745236,0.000060633527],"category_scores_gemma":[0.00020113161,0.00027127462,0.00009344477,0.0006656883,0.00006647845,0.00016840656,0.00002461267,0.00017837969,0.0001311323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01449845,0.0010955061,0.92768157,0.000017037828,0.00016394306,0.0002239943,0.028044289,0.0000033323358,0.014817442,0.000248868,0.010178045,0.0030275483],"study_design_scores_gemma":[0.01890196,0.00069967145,0.67073655,0.0005538296,0.00003891552,0.0000039849606,0.0012579625,0.000010589847,0.11479717,0.000106988635,0.19206944,0.0008229084],"about_ca_topic_score_codex":0.000019791456,"about_ca_topic_score_gemma":0.00008002074,"teacher_disagreement_score":0.25694495,"about_ca_system_score_codex":0.00021888445,"about_ca_system_score_gemma":0.00018244538,"threshold_uncertainty_score":0.99997395},"labels":[],"label_agreement":null},{"id":"W1881862380","doi":"10.1177/135965350501002s02","title":"Possible Ways Nucleoside Analogues Can Affect Mitochondrial Dna Content and Gene Expression during HIV Therapy","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Mitochondrial toxicity; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Mitochondrial DNA; Toxicity; Biology; Nucleoside analogue; Mitochondrion; Reverse-transcriptase inhibitor; Nucleoside; Mitochondrial respiratory chain; Virology; Affect (linguistics); Pharmacology; Gene; Human immunodeficiency virus (HIV); Polymerase chain reaction; Medicine; Genetics; Internal medicine; Psychology","score_opus":0.03792874157312286,"score_gpt":0.2623311100440043,"score_spread":0.2244023684708814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1881862380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336857,0.002287129,0.00004107505,0.0027004122,0.00013673183,0.00069812336,0.000014572389,0.00012756724,0.0006258498],"genre_scores_gemma":[0.9852581,0.005891414,0.0028500971,0.0003475291,0.00055500766,0.0000469915,0.0000759214,0.000046698642,0.0049282513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859744,0.00006191484,0.00026424837,0.00041564825,0.0002697806,0.00039097408],"domain_scores_gemma":[0.99942744,0.00004195486,0.00008526051,0.00026691894,0.00004482658,0.00013358063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008882336,0.00031371604,0.00042098484,0.00014250894,0.00021910488,0.000052886866,0.000084339095,0.000102063794,0.00008326428],"category_scores_gemma":[0.000007700563,0.00021611224,0.0001349857,0.00012717635,0.000079938916,0.00016720526,0.000029983414,0.00013605479,0.000048171038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012266306,0.000336877,0.0810407,0.000009562666,0.0001982275,0.000077255885,0.0015474515,5.1732536e-7,0.8929082,0.000022434844,0.0011887013,0.021443415],"study_design_scores_gemma":[0.009178155,0.0002778288,0.108705945,0.00011369113,0.000021231475,0.000030495823,0.000102806756,0.000018999497,0.8764383,0.000027447646,0.004839365,0.0002457385],"about_ca_topic_score_codex":0.000030428977,"about_ca_topic_score_gemma":0.000031833573,"teacher_disagreement_score":0.027665244,"about_ca_system_score_codex":0.00007084923,"about_ca_system_score_gemma":0.000050526392,"threshold_uncertainty_score":0.8812802},"labels":[],"label_agreement":null},{"id":"W1962555342","doi":"10.1177/135965350501002s01","title":"Mitochondria, HIV Infection and Its Treatment: Where Do We Go from Here?","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Mitochondrion; Medicine; Virology; Internal medicine; Immunology; Biology; Genetics","score_opus":0.02467248099761497,"score_gpt":0.3138175768285701,"score_spread":0.2891450958309551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1962555342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594955,0.029843736,0.000030164716,0.0065241177,0.00008168489,0.000555456,0.000032987176,0.00009545273,0.0033409018],"genre_scores_gemma":[0.92852056,0.06522774,0.00043466123,0.00015474224,0.00029502367,0.000060573257,0.000046587465,0.000025082612,0.0052350536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991881,0.00004246296,0.00018880548,0.0002851045,0.00009607216,0.00019945424],"domain_scores_gemma":[0.99952704,0.00004159837,0.000064107226,0.00023136947,0.000040146755,0.000095749645],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002531874,0.00017600213,0.00023732321,0.000069760434,0.00015167698,0.000023652981,0.000028721774,0.00011496345,0.00023473172],"category_scores_gemma":[0.000002744486,0.00013186027,0.00006915517,0.00013256034,0.000023152625,0.00014030698,0.0000073030956,0.00010296714,0.0008909337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036581157,0.0011775715,0.24664573,0.000016694046,0.0003664722,0.000019070683,0.0011585648,0.0000016622936,0.007995914,0.00044802137,0.0023533786,0.7394511],"study_design_scores_gemma":[0.010851665,0.0014305054,0.20045778,0.00030590274,0.0001313537,0.00003254892,0.00004847726,0.0005552972,0.0078111077,0.000554448,0.7775397,0.00028126326],"about_ca_topic_score_codex":0.00022743715,"about_ca_topic_score_gemma":0.00008679262,"teacher_disagreement_score":0.77518624,"about_ca_system_score_codex":0.00009432893,"about_ca_system_score_gemma":0.00003907392,"threshold_uncertainty_score":0.999887},"labels":[],"label_agreement":null},{"id":"W1970848393","doi":"10.3851/imp1646","title":"Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis <i>in vivo</i>","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Provincial Laboratory of Public Health; University of Calgary","funders":"","keywords":"Oncolytic virus; In vivo; Viral replication; Biology; Virology; Protease inhibitor (pharmacology); In vitro; Virus; Protease; Viral load; Enzyme; Biochemistry","score_opus":0.014293093578494034,"score_gpt":0.29012677507396284,"score_spread":0.27583368149546883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970848393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977199,0.0009155479,0.000032737884,0.00017584565,0.000106800144,0.0002866516,0.000047942638,0.000009124101,0.0007054884],"genre_scores_gemma":[0.99620664,0.002429474,0.00035373558,0.00037119456,0.00019376256,0.000032539272,0.000012772789,0.00003803461,0.00036182263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870354,0.000081184284,0.00026142978,0.00041355257,0.0002271868,0.00031311487],"domain_scores_gemma":[0.9992818,0.000022724793,0.00008994149,0.00045056807,0.00008288635,0.00007207333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004320508,0.00019766387,0.00024841138,0.00010914243,0.000056673907,0.000021731204,0.00022615529,0.0002047638,0.000045946155],"category_scores_gemma":[0.000034960074,0.00017718904,0.00012128761,0.0002103631,0.00022905803,0.000007985391,0.000081370745,0.00017222701,0.0000073406445],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019609986,0.00025608545,0.0056125447,0.0000073185433,0.000049952945,0.0000060873526,0.00006793856,0.0000019492861,0.9486228,0.00003236029,0.00008705751,0.043294854],"study_design_scores_gemma":[0.001723599,0.002133822,0.0023657214,0.000009922719,0.000005111179,0.000008255779,0.000039084225,0.000016876247,0.98643446,0.00006238301,0.006997048,0.0002037434],"about_ca_topic_score_codex":0.00012897931,"about_ca_topic_score_gemma":0.00045481007,"teacher_disagreement_score":0.04309111,"about_ca_system_score_codex":0.00000766436,"about_ca_system_score_gemma":0.000114938295,"threshold_uncertainty_score":0.72255594},"labels":[],"label_agreement":null},{"id":"W1970961290","doi":"10.3851/imp2750","title":"Pharmacokinetics of Raltegravir in the Semen of HIV-Infectedmen","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Women's College Hospital; University of Toronto; Maple Leaf Medical Clinic; St. Michael's Hospital","funders":"Johnson and Johnson; Merck Canada; Abbott Canada; Gilead Sciences; Ontario HIV Treatment Network; Pfizer; ViiV Healthcare; Eli Lilly and Company","keywords":"Raltegravir; Pharmacokinetics; Semen; Medicine; Blood sampling; Blood plasma; Internal medicine; Venous blood; Pharmacology; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Andrology; Immunology; Antiretroviral therapy","score_opus":0.01959320124081224,"score_gpt":0.29079744455224044,"score_spread":0.2712042433114282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970961290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98808205,0.00026403856,0.000010037221,0.002132683,0.00002290212,0.0005911946,0.0000032244654,0.0000105265435,0.008883356],"genre_scores_gemma":[0.99628794,0.0008376126,0.00034608573,0.00019716487,0.000027789541,0.000031012776,0.000020683896,0.000010065434,0.0022416292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927896,0.00006125258,0.00023431628,0.000098968325,0.00018339437,0.00014311979],"domain_scores_gemma":[0.99963397,0.000056440564,0.00007411169,0.00016697777,0.000050436305,0.000018073355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014103214,0.00010657539,0.00023130087,0.00008272893,0.000013639661,0.000004576149,0.00009149728,0.00003180495,0.00018971882],"category_scores_gemma":[0.0000053489,0.00005975061,0.00006572749,0.00022818994,0.00005854354,0.000051075695,0.000010937368,0.00007859398,0.000049738574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018308514,0.0012270785,0.75792027,0.000047344052,0.00024707217,0.000019355997,0.0049214596,0.0000010720305,0.14328116,0.00039974932,0.010375415,0.08137693],"study_design_scores_gemma":[0.0072565214,0.00046668196,0.66372263,0.00011350992,0.000054951037,0.0000062633176,0.0005088546,0.0001235282,0.3105216,0.0005118804,0.016545007,0.00016856733],"about_ca_topic_score_codex":0.000051059844,"about_ca_topic_score_gemma":0.000003101433,"teacher_disagreement_score":0.16724044,"about_ca_system_score_codex":0.000010915757,"about_ca_system_score_gemma":0.000032095446,"threshold_uncertainty_score":0.24365592},"labels":[],"label_agreement":null},{"id":"W1973346526","doi":"10.3851/imp1558","title":"Use of Newer Antiretroviral Agents, Darunavir and Etravirine with or without Raltegravir, in Pregnancy: A Report of two Cases","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; St. Michael's Hospital; Hospital for Sick Children; University of Ottawa; Women's College Hospital; University of Toronto","funders":"","keywords":"Etravirine; Raltegravir; Darunavir; Medicine; Pregnancy; Regimen; Obstetrics; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Biology","score_opus":0.06270585587226628,"score_gpt":0.33928624158068993,"score_spread":0.27658038570842364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973346526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979953,0.00059070444,0.000016936343,0.0002974748,0.000023282197,0.00066176575,0.000009429621,0.00002515465,0.00037996063],"genre_scores_gemma":[0.98773485,0.0013273713,0.0035650276,0.000095511925,0.000018726085,0.000009257644,0.000037929705,0.000022145081,0.007189156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867964,0.0000479036,0.000443634,0.00030921208,0.00028010385,0.00023949989],"domain_scores_gemma":[0.9992994,0.000051669256,0.0002082867,0.0003119175,0.000069401176,0.0000593027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115696435,0.00024201331,0.0006364819,0.00019019167,0.000026974489,0.000012304063,0.000052358668,0.000056401248,0.000028292003],"category_scores_gemma":[0.000027751445,0.00014662175,0.00006187758,0.00035823925,0.00013618584,0.00021486187,0.000013264934,0.00011492527,0.0000013040367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022191696,0.00075707963,0.93222314,0.000032855874,0.00013370233,0.0032935962,0.00066515384,5.517664e-7,0.0067137154,0.00007380098,0.00011956869,0.053767692],"study_design_scores_gemma":[0.013879046,0.0059736543,0.91569674,0.0019200372,0.0001331415,0.0009831405,0.00012447555,0.000067921545,0.05880191,0.00008003149,0.001957802,0.00038211493],"about_ca_topic_score_codex":0.00033297148,"about_ca_topic_score_gemma":0.00010449689,"teacher_disagreement_score":0.053385578,"about_ca_system_score_codex":0.000023184079,"about_ca_system_score_gemma":0.0001381852,"threshold_uncertainty_score":0.5979061},"labels":[],"label_agreement":null},{"id":"W1982724696","doi":"10.3851/imp1936","title":"Pleconaril Revisited: Clinical Course of Chronic Enteroviral Meningoencephalitis after Treatment Correlates with <i>In Vitro</i> Susceptibility","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral Infections and Immunology Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leids Universitair Medisch Centrum; ZonMw; Egg Farmers of Canada","keywords":"Medicine; Antibody; Enterovirus; Immunology; Case fatality rate; Echovirus; Meningoencephalitis; Virology; Virus; Internal medicine; Epidemiology","score_opus":0.05374512684499121,"score_gpt":0.34881838741023474,"score_spread":0.2950732605652435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982724696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937956,0.0041434434,0.000033899454,0.00012112137,0.00008407805,0.0005334951,0.000021222886,0.000029759642,0.001237399],"genre_scores_gemma":[0.9945678,0.0045723044,0.0001236923,0.00012211895,0.000059130278,0.000057906025,0.000025353149,0.000020933905,0.00045073486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849665,0.00022101848,0.00046167587,0.0003567813,0.00011803988,0.00034584934],"domain_scores_gemma":[0.99924415,0.00007970889,0.000106380045,0.00042357785,0.00008920477,0.00005697769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035644262,0.00020026148,0.0005659421,0.00009798115,0.00004617867,0.000007750913,0.0000771507,0.00014030871,0.0004211208],"category_scores_gemma":[0.000012305241,0.00012909598,0.00019688258,0.00022385413,0.0005602776,0.000147289,0.000023978651,0.00023500934,0.000033954122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006723146,0.002042118,0.8969359,0.000014509104,0.00025109627,0.00007495833,0.0004747997,4.4778186e-8,0.011308287,0.000017290904,0.000033012893,0.08212483],"study_design_scores_gemma":[0.007063754,0.020013528,0.88800544,0.00013595041,0.00005016946,0.000033697972,0.00017193343,0.000049912636,0.082970396,0.000050657247,0.0012835017,0.00017103717],"about_ca_topic_score_codex":0.00046795805,"about_ca_topic_score_gemma":0.00011712615,"teacher_disagreement_score":0.081953794,"about_ca_system_score_codex":0.00009354394,"about_ca_system_score_gemma":0.00016714173,"threshold_uncertainty_score":0.5264381},"labels":[],"label_agreement":null},{"id":"W1987541968","doi":"10.3851/imp1752","title":"Antiviral Effects of Interferon-β are Enhanced in the Absence of the Translational Suppressor 4E-BP1 in Myocarditis Induced by Coxsackievirus B3","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral Infections and Immunology Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Myocarditis; Immune system; Interferon; Viral Myocarditis; Immunology; Context (archaeology); Virology; Coxsackievirus; Biology; Virus; Medicine; Enterovirus; Internal medicine","score_opus":0.018834269006448936,"score_gpt":0.31064841703811297,"score_spread":0.29181414803166406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987541968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966273,0.0004328073,0.000019136147,0.0008075029,0.0002564722,0.0007520578,0.000020628771,0.000008407936,0.0010757177],"genre_scores_gemma":[0.99925184,0.0004172887,0.000009690372,0.00014926874,0.00003948213,0.0000497417,0.000008152712,0.000014092534,0.00006046408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858695,0.00032737647,0.0003397104,0.00020802653,0.0002807007,0.0002572201],"domain_scores_gemma":[0.9991305,0.00026940156,0.00012401084,0.00038410115,0.00007708434,0.000014932443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042218648,0.00015274022,0.00038036055,0.00013223912,0.0000560906,0.000011269655,0.00029487695,0.00017012285,0.000029000375],"category_scores_gemma":[0.0001006599,0.00008962575,0.00015429304,0.0005271495,0.00040269643,0.0001473774,0.000029989582,0.00082514033,0.000005590007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003596317,0.00039393204,0.06225209,0.0000333034,0.00004550494,0.000004005557,0.00064463314,2.9966873e-7,0.9211018,0.00012935983,0.000078188044,0.014957238],"study_design_scores_gemma":[0.0016289013,0.00046080907,0.4472391,0.00011828161,0.0000041622884,0.0000028049992,0.00007211627,0.00001714009,0.55017036,0.00010442887,0.00012465878,0.00005724844],"about_ca_topic_score_codex":0.00033835624,"about_ca_topic_score_gemma":0.00016025009,"teacher_disagreement_score":0.384987,"about_ca_system_score_codex":0.000010891299,"about_ca_system_score_gemma":0.000065116634,"threshold_uncertainty_score":0.3654832},"labels":[],"label_agreement":null},{"id":"W1990570958","doi":"10.3851/imp2076","title":"Pill Burden in HIV Infection: 20 Years of Experience","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Medicine; Pill; Medical prescription; Cohort; Pharmacy; Dosing; Human immunodeficiency virus (HIV); Cohort study; Internal medicine; Pediatrics; Immunology; Pharmacology; Family medicine","score_opus":0.026215799350104187,"score_gpt":0.3016907207139864,"score_spread":0.2754749213638822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990570958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948672,0.00046670483,0.000012411642,0.00039056616,0.000095687516,0.00016042877,9.539756e-7,0.000019739184,0.0039862865],"genre_scores_gemma":[0.99381095,0.00064768636,0.00029507375,0.000058480775,0.00011052854,0.000017511613,0.000008330164,0.000008957872,0.0050424724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947006,0.000020927033,0.00013291472,0.00008929566,0.00011936155,0.00016743415],"domain_scores_gemma":[0.9997868,0.000017493288,0.00003202163,0.00011334563,0.000015214803,0.000035110574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008176767,0.000075442375,0.0001584963,0.00008057666,0.000013852563,0.0000029869966,0.000028993947,0.000036469388,0.00014249184],"category_scores_gemma":[0.000006589234,0.00006249964,0.00004350293,0.00017707127,0.000040093233,0.00012018373,0.000010264629,0.000053541466,0.00009839808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008485493,0.00022193046,0.956216,0.0000042157767,0.000034246263,0.000010517018,0.006570261,1.7114164e-7,0.007458044,0.00009811484,0.0004947647,0.028806886],"study_design_scores_gemma":[0.0021102305,0.00010086569,0.869156,0.000051738993,0.000007701771,0.000007645014,0.00019465813,0.0000065221147,0.06048375,0.000026012325,0.06774579,0.000109100416],"about_ca_topic_score_codex":0.00004389035,"about_ca_topic_score_gemma":0.0000043394966,"teacher_disagreement_score":0.08706001,"about_ca_system_score_codex":0.000024883138,"about_ca_system_score_gemma":0.000020870057,"threshold_uncertainty_score":0.25486612},"labels":[],"label_agreement":null},{"id":"W19918097","doi":"10.3851/imp1418","title":"Psycho-social Resilience and Risky HIV Behaviors among Black Males who have Sex with Males","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Homelessness and Social Issues","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Psychosocial; Men who have sex with men; Psychological resilience; Demography; Psychology; Human immunodeficiency virus (HIV); Gerontology; Social psychology; Medicine; Psychiatry; Sociology; Family medicine","score_opus":0.06380651931898393,"score_gpt":0.4061485044869769,"score_spread":0.34234198516799297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W19918097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864814,0.0004113288,0.00004396411,0.00035192943,0.00007903049,0.0005032396,0.00002426628,0.00008593826,0.012018884],"genre_scores_gemma":[0.9891416,0.00076111226,0.00006580747,0.00010981289,0.00040028617,0.000057151978,0.000010743352,0.000042885793,0.009410616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809486,0.00045197626,0.00028479748,0.0003549594,0.00031023513,0.0005031691],"domain_scores_gemma":[0.99926335,0.000091338195,0.0001790183,0.00020051729,0.00013124457,0.00013453185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004467021,0.00022684612,0.00047749327,0.00006381415,0.0007023997,0.00004032652,0.00018502101,0.00024109635,0.00005303018],"category_scores_gemma":[0.000012075923,0.00017047793,0.000041598105,0.00016005868,0.0005954692,0.00029024444,0.0000476472,0.00039871834,0.00006907929],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016952868,0.000058603695,0.915093,0.000018355817,0.000017789513,0.000013616713,0.07671351,3.9151877e-7,0.00009158732,0.000587703,0.0007732926,0.006462644],"study_design_scores_gemma":[0.0014796517,0.00021652755,0.84558326,0.000092001595,0.000013359846,1.4300736e-7,0.14844076,0.000036121968,0.00023404093,0.00045394665,0.0031688674,0.00028133174],"about_ca_topic_score_codex":0.0013989308,"about_ca_topic_score_gemma":0.0036540604,"teacher_disagreement_score":0.071727246,"about_ca_system_score_codex":0.00003749064,"about_ca_system_score_gemma":0.00009997586,"threshold_uncertainty_score":0.6951888},"labels":[],"label_agreement":null},{"id":"W2000115405","doi":"10.3851/imp2957","title":"Viral Shedding and Susceptibility to Oseltamivir in Hospitalized Immunocompromised Patients with Influenza in the Influenza Resistance Information Study (IRIS)","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Oseltamivir; Medicine; Viral shedding; Virus; Internal medicine; Influenza A virus; Neuraminidase inhibitor; Drug resistance; Virology; Resistance mutation; Immunology; Polymerase chain reaction; Biology; Coronavirus disease 2019 (COVID-19); Reverse transcriptase; Microbiology; Disease","score_opus":0.027255917356657555,"score_gpt":0.3361962305247872,"score_spread":0.30894031316812964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000115405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948714,0.0001368946,0.000020267438,0.00016650422,0.00002624275,0.003984968,0.00000743269,0.00004570035,0.00074058794],"genre_scores_gemma":[0.996526,0.000036439265,0.00024801822,0.002868432,0.00002524461,0.00025642957,0.000006921486,0.000019556692,0.000012976152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740386,0.0004570603,0.0006095511,0.00034795143,0.0006858247,0.000495778],"domain_scores_gemma":[0.99883574,0.00020719964,0.00013140663,0.0005589727,0.00020784655,0.00005880752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017405506,0.00029534346,0.0005105719,0.00033790842,0.00016880712,0.000115453346,0.0002512247,0.00007190569,0.000005959121],"category_scores_gemma":[0.00039801566,0.00018518127,0.00004652661,0.0006362897,0.00016886786,0.00081081234,0.00009695419,0.0004031276,0.000018719551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063044606,0.000567583,0.97007877,0.000039932132,0.000048130303,0.00000351031,0.013983581,0.000009821228,0.00045748465,0.000055724202,0.000048713046,0.0084022945],"study_design_scores_gemma":[0.017151987,0.0022047507,0.97504735,0.0001208181,0.000008534255,2.1080453e-7,0.001092551,0.000035980367,0.00017206158,0.00009569764,0.0038471562,0.00022290077],"about_ca_topic_score_codex":0.00040584203,"about_ca_topic_score_gemma":0.00034469616,"teacher_disagreement_score":0.01289103,"about_ca_system_score_codex":0.00012329852,"about_ca_system_score_gemma":0.00004860017,"threshold_uncertainty_score":0.75514734},"labels":[],"label_agreement":null},{"id":"W2001797772","doi":"10.3851/imp1614","title":"Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"National Institute on Drug Abuse; F. Hoffmann-La Roche; Canadian Institutes of Health Research; Abbott Laboratories","keywords":"Medicine; Odds ratio; Abstinence; Confidence interval; Logistic regression; Drug; Internal medicine; Cohort; Cohort study; Psychiatry","score_opus":0.018337812836971144,"score_gpt":0.3015202938073326,"score_spread":0.2831824809703614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001797772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969844,0.00011382134,0.0000050902827,0.0011928662,0.000155719,0.00055882253,0.00005912621,0.00005877217,0.00087137794],"genre_scores_gemma":[0.99593556,0.00040095978,0.00018239187,0.00035014795,0.0001328037,0.000026957257,0.00006733745,0.00004112908,0.0028627373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983155,0.00017411962,0.00027992527,0.00038135177,0.00025382114,0.00059527764],"domain_scores_gemma":[0.99906987,0.00019710387,0.00008133132,0.00028083904,0.000081227336,0.0002896059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004005825,0.00022948418,0.00034428108,0.00050987146,0.00021018632,0.00016727629,0.000121503,0.000118157404,0.00014079871],"category_scores_gemma":[0.00018953595,0.00018819417,0.00016105374,0.0003189794,0.00018095796,0.00090971304,0.000024522711,0.00081482134,0.00002005474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019806852,0.00009067846,0.886572,0.000003792058,0.000097864686,0.000039377293,0.002494176,1.5585358e-7,0.02940237,0.000034810502,0.00096992624,0.080096796],"study_design_scores_gemma":[0.0025538576,0.0005703889,0.97830594,0.00010436052,0.000007190918,0.0000036716478,0.00075411174,0.00044389142,0.014859142,0.00007618886,0.0021207933,0.00020045336],"about_ca_topic_score_codex":0.6836955,"about_ca_topic_score_gemma":0.65131074,"teacher_disagreement_score":0.09173396,"about_ca_system_score_codex":0.00010013137,"about_ca_system_score_gemma":0.00019403746,"threshold_uncertainty_score":0.7674335},"labels":[],"label_agreement":null},{"id":"W2005994369","doi":"10.3851/imp1416","title":"Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"International Development Research Centre; Wellcome Trust","keywords":"Drug resistance; Medicine; Population; Cohort; Internal medicine; Cohort study; Epidemiology; Virology; Immunology; Biology; Genetics; Environmental health","score_opus":0.01668746901360428,"score_gpt":0.26401004703574676,"score_spread":0.24732257802214247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005994369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656653,0.000437218,0.0000024905553,0.0009227248,0.000030329516,0.0007828761,0.000030590138,0.000023302544,0.0012039228],"genre_scores_gemma":[0.99489033,0.0009928236,0.00011929635,0.00018210961,0.000009627235,0.000021779282,0.000053344742,0.000011268375,0.003719424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988187,0.00014630737,0.00030727696,0.00019201708,0.00029727447,0.00023842562],"domain_scores_gemma":[0.9994581,0.000078995305,0.00011122879,0.0002512813,0.00007720774,0.00002323267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024759627,0.00015404142,0.00023685962,0.00015155677,0.00003699879,0.000010311978,0.0001698023,0.000045694123,0.00002880711],"category_scores_gemma":[0.000043695305,0.00009950741,0.000058218935,0.00058435125,0.000044936543,0.000092507245,0.000008555795,0.00012838599,0.000015198088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000411534,0.0019388373,0.9429409,0.0000084377125,0.00005015875,0.000014441501,0.044252563,0.0000029631085,0.0003357386,0.000022201422,0.0010397332,0.008982482],"study_design_scores_gemma":[0.005893519,0.0004138497,0.9903179,0.000099833116,0.00000963173,2.493784e-7,0.00021756992,0.000022290698,0.0019350789,0.00063459546,0.00034884387,0.000106672254],"about_ca_topic_score_codex":0.000024014766,"about_ca_topic_score_gemma":0.000027484017,"teacher_disagreement_score":0.047376957,"about_ca_system_score_codex":0.000051512816,"about_ca_system_score_gemma":0.000074368276,"threshold_uncertainty_score":0.40577942},"labels":[],"label_agreement":null},{"id":"W2006670989","doi":"10.3851/imp2680","title":"Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health","funders":"BioCryst","keywords":"Medicine; Tolerability; Neuraminidase inhibitor; Internal medicine; Oseltamivir; Neuraminidase; Viral shedding; Influenza A virus; Clinical endpoint; Randomized controlled trial; Adverse effect; Viral load; Dosing; Clinical trial; Virus; Virology; Coronavirus disease 2019 (COVID-19); Disease; Infectious disease (medical specialty)","score_opus":0.07120528762117101,"score_gpt":0.37553817732536693,"score_spread":0.3043328897041959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006670989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568146,0.00086232804,0.0000065138147,0.00013983513,0.000046194607,0.002452674,0.00001851377,0.000021136553,0.00077133445],"genre_scores_gemma":[0.99711096,0.0014731087,0.00039772427,0.00033312038,0.000046423418,0.00041070202,0.000013248832,0.00002338318,0.00019130416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894,0.00003836643,0.00029750736,0.00019096737,0.00019933598,0.0003338468],"domain_scores_gemma":[0.9993806,0.000080225385,0.00006691213,0.00020823641,0.00022226358,0.00004175642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000075232114,0.00016325721,0.00045095017,0.00013886717,0.00004202291,0.000011452053,0.00006375283,0.00006205374,0.00005327191],"category_scores_gemma":[0.00006294254,0.0001129259,0.00012730832,0.00012878791,0.000109660905,0.00011467288,0.000013623186,0.000039673825,0.000036593272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013304637,0.0020442037,0.75242704,0.000045260207,0.00020766805,0.0000031856841,0.0025057746,8.4328616e-7,0.011542453,0.0000922166,0.00023469841,0.22956622],"study_design_scores_gemma":[0.014812857,0.007249382,0.94535303,0.00004391399,0.000010302067,2.6630076e-7,0.00008013417,0.00004628889,0.023577843,0.00034708215,0.008348946,0.00012995681],"about_ca_topic_score_codex":0.0005595355,"about_ca_topic_score_gemma":0.000007360826,"teacher_disagreement_score":0.22943626,"about_ca_system_score_codex":0.00009632382,"about_ca_system_score_gemma":0.00004819053,"threshold_uncertainty_score":0.46049848},"labels":[],"label_agreement":null},{"id":"W200761781","doi":"10.1177/135965350400900404","title":"A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Zanamivir; Neuraminidase; Oseltamivir; Mutant; Virology; Virus; Neuraminidase inhibitor; Biology; Influenza A virus; Reverse genetics; Wild type; Viral replication; Resistance mutation; Orthomyxoviridae; Molecular biology; Gene; Reverse transcriptase; Genetics; Polymerase chain reaction; Medicine","score_opus":0.11300006086556541,"score_gpt":0.4166530347001304,"score_spread":0.30365297383456497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W200761781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693304,0.00092321675,0.0000023839573,0.00022824705,0.00006136184,0.0015138234,0.000012630263,0.000038942333,0.00028637875],"genre_scores_gemma":[0.99715996,0.00038615486,0.00037430125,0.0018126939,0.000089393005,0.000060898736,0.0000016532289,0.00003503257,0.000079943704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980134,0.0001420572,0.00048634238,0.0003901232,0.00055740186,0.00041071183],"domain_scores_gemma":[0.9989794,0.000047447258,0.00008921469,0.000566512,0.00019456862,0.00012289156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033030644,0.00022297222,0.00046339826,0.00033674744,0.00007406981,0.000018646699,0.00018632987,0.000072591145,0.000009366595],"category_scores_gemma":[0.00013181736,0.00019005188,0.00006428411,0.00069015793,0.00012338009,0.0001627731,0.00007735394,0.00026861185,0.00002937468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009119193,0.006566306,0.5428081,0.00007757267,0.00019359548,0.0006267714,0.032813612,0.0002583197,0.38526085,0.00007718454,0.00055663066,0.021641862],"study_design_scores_gemma":[0.016244655,0.009448295,0.76277184,0.00028215942,0.000024609168,0.0000020879756,0.0042323866,0.0000058347905,0.19584197,0.00016020115,0.01058079,0.00040516545],"about_ca_topic_score_codex":0.0005683302,"about_ca_topic_score_gemma":0.0013612332,"teacher_disagreement_score":0.21996374,"about_ca_system_score_codex":0.00010397039,"about_ca_system_score_gemma":0.00011345002,"threshold_uncertainty_score":0.7750091},"labels":[],"label_agreement":null},{"id":"W2009282612","doi":"10.3851/imp1418","title":"Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Simon Fraser University; St. Paul's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Discontinuation; Hazard ratio; Dosing; Nevirapine; Cohort; Logistic regression; Proportional hazards model; Odds ratio; Cohort study; Viral load; Confidence interval; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy","score_opus":0.022198433971798034,"score_gpt":0.30640844060340283,"score_spread":0.2842100066316048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009282612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952467,0.0006979484,0.000020030224,0.0014205008,0.00003537471,0.0008774142,0.0000018459637,0.000049059174,0.0016511056],"genre_scores_gemma":[0.9945893,0.001004615,0.0006843271,0.00018370993,0.000048282393,0.000004473322,0.000011801815,0.0000134269285,0.0034600303],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989989,0.000048651877,0.00029471877,0.00025120442,0.00021661041,0.00018990785],"domain_scores_gemma":[0.9995527,0.000049528182,0.00007267751,0.00022143491,0.00004272623,0.000060891132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017290938,0.00018354508,0.00042452017,0.00009436966,0.0000673409,0.000011144063,0.00005359778,0.000043922493,0.00002916204],"category_scores_gemma":[0.00001553824,0.00013042045,0.00007300959,0.00019420302,0.000057468253,0.000072789306,0.000012543078,0.0000891743,0.000013587028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029709467,0.0041741035,0.4778872,0.000008431583,0.00042850678,0.00012573438,0.0037872652,3.6288714e-7,0.01711107,0.00009376376,0.0001936658,0.49321893],"study_design_scores_gemma":[0.016190529,0.00209784,0.967194,0.000071414404,0.000084166204,0.0000105610425,0.00023552934,0.000045228473,0.009394214,0.00001766657,0.0045008324,0.0001579934],"about_ca_topic_score_codex":0.000013983147,"about_ca_topic_score_gemma":0.0000024537983,"teacher_disagreement_score":0.49306095,"about_ca_system_score_codex":0.000021420969,"about_ca_system_score_gemma":0.000038832546,"threshold_uncertainty_score":0.5318392},"labels":[],"label_agreement":null},{"id":"W2014281142","doi":"10.3851/imp1462","title":"Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Cart; Hazard ratio; Internal medicine; Incidence (geometry); Confidence interval; Viral load; Lymphoma; Prospective cohort study; Non-Hodgkin's lymphoma; Immunology; Gastroenterology; Human immunodeficiency virus (HIV)","score_opus":0.012030129115145559,"score_gpt":0.27215869634274165,"score_spread":0.2601285672275961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014281142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972725,0.0007408983,0.000007731301,0.00015451193,0.000046495068,0.0009169404,0.0000089089845,0.000023051116,0.00082899275],"genre_scores_gemma":[0.9963985,0.003348172,0.000016197699,0.00015935853,0.000012007529,0.0000040476375,0.000013693915,0.000019435147,0.000028558181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983199,0.0004184575,0.0004381228,0.00025140788,0.00035918265,0.00021291949],"domain_scores_gemma":[0.99921453,0.00008400719,0.00032316626,0.00027285772,0.00007688457,0.000028579474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007558892,0.00020494877,0.00044479658,0.0001253171,0.00007566803,0.00001699397,0.00016783489,0.00007297265,0.000007746502],"category_scores_gemma":[0.000048282567,0.00013442551,0.00010850266,0.0004896468,0.00013002218,0.00015721723,0.000013896858,0.0002230812,0.0000015940939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004949112,0.00158458,0.87125343,0.0000039538727,0.000101385405,0.000014255928,0.008864442,0.0000023885102,0.006425456,0.000020176358,0.000028181203,0.11120684],"study_design_scores_gemma":[0.011703685,0.006196499,0.9762696,0.000060598475,0.000039497118,0.0000014320937,0.0029751826,0.00025522243,0.0022324664,0.00011937982,0.000014200067,0.00013222954],"about_ca_topic_score_codex":0.0011149042,"about_ca_topic_score_gemma":0.00002478652,"teacher_disagreement_score":0.11107461,"about_ca_system_score_codex":0.000030645322,"about_ca_system_score_gemma":0.00004608623,"threshold_uncertainty_score":0.54817134},"labels":[],"label_agreement":null},{"id":"W2015222119","doi":"10.3851/imp2851","title":"Antiviral Therapy for Human Rabies","year":2014,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Rabies epidemiology and control","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Rabies; Favipiravir; Rabies virus; Amantadine; Medicine; Ribavirin; Immunology; Virology; Lyssavirus; Pharmacotherapy; Intensive care medicine; Rabies vaccine; Disease; Virus; Rhabdoviridae; Internal medicine; Infectious disease (medical specialty); Hepatitis C virus; Coronavirus disease 2019 (COVID-19)","score_opus":0.07060817184077141,"score_gpt":0.3716293609952929,"score_spread":0.30102118915452153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015222119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00057538395,0.9926295,0.00022394951,0.00013384051,0.0017224825,0.0024098642,0.00015262015,0.00024099764,0.0019113424],"genre_scores_gemma":[0.0045268442,0.98346305,0.000032738393,0.00070234586,0.0005877326,0.0008118166,0.0010966967,0.00015023719,0.0086285295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948608,0.0018491441,0.0011801441,0.0010136226,0.000048022725,0.0010482522],"domain_scores_gemma":[0.99664307,0.0014789533,0.0008470726,0.00091579906,0.00008988121,0.000025216652],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013447182,0.0010580455,0.004315624,0.00026341743,0.00069112214,0.00004225832,0.000988944,0.0018244089,0.00023649879],"category_scores_gemma":[0.0000996606,0.0007398592,0.0020120502,0.00018291347,0.00073394127,0.00013349655,0.00006726182,0.0009551705,0.00092016853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022173367,0.00015137832,0.000069969064,0.00055436324,0.0015180188,0.0000023690843,0.00004907736,2.7711271e-8,0.0009395567,0.005544405,0.012219432,0.97872967],"study_design_scores_gemma":[0.0029934882,0.0010543027,0.000043483804,0.00092173513,0.00019956884,0.000019582632,0.000009876064,2.9084208e-7,0.00037419327,0.0017349562,0.9918218,0.000826671],"about_ca_topic_score_codex":0.000033654367,"about_ca_topic_score_gemma":0.000008509837,"teacher_disagreement_score":0.9796024,"about_ca_system_score_codex":0.000037276095,"about_ca_system_score_gemma":0.00013209059,"threshold_uncertainty_score":0.9998577},"labels":[],"label_agreement":null},{"id":"W2021523247","doi":"10.3851/imp1565","title":"Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; Gilead Sciences","keywords":"Foscarnet; Recombinant DNA; Biology; Molecular biology; DNA polymerase; Virology; Polymerase; Ganciclovir; Aphidicolin; Human cytomegalovirus; Mutant; Virus; Enzyme; Wild type; Gene; Biochemistry","score_opus":0.027512844795580433,"score_gpt":0.34544414407019064,"score_spread":0.3179312992746102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021523247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943478,0.00018831331,0.000016188262,0.0007112461,0.00009066285,0.00086400344,0.000118983524,0.00006745862,0.0035953093],"genre_scores_gemma":[0.9987691,0.00023017183,0.000088972076,0.00027100064,0.00016572535,0.000058874546,0.000017359818,0.00004462371,0.00035414743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820197,0.00022035804,0.00026060088,0.0005123263,0.00040735165,0.00039738408],"domain_scores_gemma":[0.9983771,0.0004888776,0.00014598275,0.00066346454,0.00009292138,0.00023165057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051843945,0.00030562663,0.00058905076,0.00029432742,0.00021109633,0.000043898362,0.0001351798,0.00014522625,0.00013568104],"category_scores_gemma":[0.000106440144,0.00023134571,0.00019160192,0.00040615955,0.00052861945,0.00020762916,0.00004548629,0.00070249813,0.000054620104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030348906,0.0003649699,0.030462628,0.000031405747,0.00013322104,0.000024730056,0.00024329929,8.71457e-8,0.83795524,0.0005070883,0.000050302217,0.12719212],"study_design_scores_gemma":[0.004696223,0.002600929,0.069529355,0.000039366067,0.000039082304,0.000030706433,0.000008124438,0.00006834756,0.9217422,0.00007586015,0.0009712265,0.00019858187],"about_ca_topic_score_codex":0.0014231271,"about_ca_topic_score_gemma":0.00012258466,"teacher_disagreement_score":0.12699355,"about_ca_system_score_codex":0.000030755567,"about_ca_system_score_gemma":0.00009294475,"threshold_uncertainty_score":0.9434004},"labels":[],"label_agreement":null},{"id":"W2022895457","doi":"10.3851/imp1953","title":"A Case of a Potential Drug Interaction between Clobazam and Etravirine-Based Antiretroviral Therapy","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Maple Leaf Medical Clinic; St. Michael's Hospital","funders":"","keywords":"Etravirine; Clobazam; Pharmacology; CYP3A4; CYP2C19; Metabolite; Reverse-transcriptase inhibitor; Drug; Active metabolite; Drug interaction; Pharmacokinetics; Cytochrome P450; Medicine; Internal medicine; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Metabolism; Virology; Epilepsy","score_opus":0.043888118196605555,"score_gpt":0.2934531332387544,"score_spread":0.24956501504214884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022895457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747205,0.00037574445,0.00012768427,0.00026469486,0.00010739589,0.00046625477,0.000014371384,0.00006269669,0.0011090982],"genre_scores_gemma":[0.9972072,0.0004954256,0.0012005161,0.00012582367,0.000103739534,0.000015049602,0.000037043792,0.000030483721,0.00078468927],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989042,0.000080957434,0.00031457574,0.00028931716,0.00017230397,0.0002385939],"domain_scores_gemma":[0.9994602,0.000036645917,0.00013467557,0.000219738,0.000067944435,0.0000807572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017472185,0.00024024976,0.00040698663,0.00019562859,0.000079881465,0.000015212941,0.000058731544,0.00008033028,0.000108555585],"category_scores_gemma":[0.000005340902,0.00018029923,0.00014735844,0.00019146096,0.00012744083,0.0001578854,0.000016185972,0.00015370015,0.000016324193],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002402545,0.0008966563,0.73197824,0.00003528755,0.00053827476,0.0018348772,0.0028880537,1.0423269e-7,0.013855738,0.0000805427,0.0003327578,0.24515694],"study_design_scores_gemma":[0.022806605,0.0040361895,0.39543906,0.00023344511,0.0002501171,0.00086432416,0.0009491984,0.00020700449,0.5708918,0.00029702854,0.003296294,0.00072895247],"about_ca_topic_score_codex":0.0002841426,"about_ca_topic_score_gemma":0.000009852297,"teacher_disagreement_score":0.55703604,"about_ca_system_score_codex":0.000024639676,"about_ca_system_score_gemma":0.00006461488,"threshold_uncertainty_score":0.73523897},"labels":[],"label_agreement":null},{"id":"W2039639216","doi":"10.3851/imp2821","title":"Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; National Institute on Drug Abuse; National Medical Research Council; National Health and Medical Research Council; National Institutes of Health; Bristol-Myers Squibb; National Health Research Institutes; Australian Government; Gilead Sciences","keywords":"Viral quasispecies; NS5A; Sofosbuvir; Virology; Drug resistance; NS5B; Genotype; Hepatitis C virus; Pyrosequencing; Biology; Hepatitis C; Resistance mutation; Genetics; Hepacivirus; Medicine; Gene; Ribavirin; Polymerase chain reaction; Virus; Reverse transcriptase","score_opus":0.02077903399981855,"score_gpt":0.3186742726906186,"score_spread":0.29789523869080003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039639216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872685,0.00059081684,0.000113452734,0.002550969,0.000105652034,0.00067594036,0.00001767249,0.000029038063,0.0071896245],"genre_scores_gemma":[0.9964231,0.0012014974,0.00093406497,0.0009800835,0.00008812709,0.000047745263,0.000028974493,0.0000257431,0.00027066813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977347,0.00050862035,0.00048063192,0.00028080723,0.0005883025,0.00040693683],"domain_scores_gemma":[0.9986946,0.00046681022,0.00016422154,0.00045730468,0.00016849091,0.000048571645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013640095,0.00017360377,0.00035942695,0.00019315223,0.00012475096,0.000039624298,0.00031377975,0.00007370661,0.000035612677],"category_scores_gemma":[0.0004653807,0.00012302893,0.00011336915,0.0006552303,0.0001569774,0.00021825128,0.00003468669,0.00028107635,0.000026141235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043054204,0.00031454454,0.8533405,0.00012529273,0.0000684876,0.000069722264,0.00751701,0.0000039058164,0.047788247,0.0016243102,0.0023596692,0.08635775],"study_design_scores_gemma":[0.0053068926,0.00036466654,0.87125754,0.00091243774,0.000025238724,0.000010607208,0.0005314731,0.0011097491,0.060903378,0.0015908377,0.05757174,0.00041544018],"about_ca_topic_score_codex":0.00082310755,"about_ca_topic_score_gemma":0.002281688,"teacher_disagreement_score":0.08594231,"about_ca_system_score_codex":0.00006509006,"about_ca_system_score_gemma":0.00010989519,"threshold_uncertainty_score":0.5016974},"labels":[],"label_agreement":null},{"id":"W2040200721","doi":"10.3851/imp1959","title":"Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Janssen Canada","keywords":"Rilpivirine; Efavirenz; Pharmacokinetics; Medicine; Pharmacology; Ex vivo; Internal medicine; In vivo; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Biology","score_opus":0.057001649691341326,"score_gpt":0.32261737048495226,"score_spread":0.26561572079361095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040200721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615514,0.00035921708,0.000018118095,0.00025247282,0.000104487335,0.00043300737,0.0000027185965,0.000019307989,0.0026555397],"genre_scores_gemma":[0.99672014,0.0005881375,0.0021509733,0.000090746005,0.000014971123,0.000018985298,0.000017973925,0.000016505022,0.00038159222],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989504,0.00006340445,0.00039930816,0.00018702219,0.00020072286,0.00019914772],"domain_scores_gemma":[0.99958354,0.000045391254,0.0001398355,0.00015622436,0.000028169088,0.0000468452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001885935,0.00014877267,0.00038461105,0.00016526842,0.000017662085,0.0000023906211,0.00006404276,0.000049085567,0.00004266402],"category_scores_gemma":[0.000011078155,0.00012190649,0.00012494858,0.00028000728,0.000053526892,0.00008780703,0.000009271748,0.00008464765,0.000009546223],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009206576,0.0024080803,0.80102354,0.0001219736,0.00043683036,0.0002577838,0.0054952777,5.8969005e-7,0.0667819,0.00010986956,0.00013126212,0.11402634],"study_design_scores_gemma":[0.009986343,0.0025102862,0.29801878,0.00021425288,0.00006540417,0.0000073349065,0.0001794083,0.000055648587,0.68837154,0.0001031119,0.00030990594,0.00017801128],"about_ca_topic_score_codex":0.00009786394,"about_ca_topic_score_gemma":0.000029462339,"teacher_disagreement_score":0.6215896,"about_ca_system_score_codex":0.00002884005,"about_ca_system_score_gemma":0.00012145559,"threshold_uncertainty_score":0.4971202},"labels":[],"label_agreement":null},{"id":"W2051094729","doi":"10.3851/imp2670","title":"CD4 <sup>+</sup> T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: A prospective cohort analysis","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of Ottawa; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cohort; Antiretroviral therapy; Internal medicine; T cell; Immunology; Cohort study; Gastroenterology; Viral load; Human immunodeficiency virus (HIV); Immune system","score_opus":0.014171368955396378,"score_gpt":0.2852360725111386,"score_spread":0.2710647035557422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051094729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865134,0.0005211142,0.00018740821,0.00038625216,0.0000102200165,0.0014875846,0.000039761424,0.00004759835,0.010806687],"genre_scores_gemma":[0.9934178,0.0010716964,0.00024222805,0.00033746441,0.00008016198,0.00028784553,0.00015964774,0.00003687953,0.004366258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769825,0.00034602356,0.0005843897,0.00043627337,0.00047845236,0.0004566292],"domain_scores_gemma":[0.99889773,0.00011663019,0.00017250191,0.00044107225,0.000274056,0.00009801474],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005239635,0.00024250746,0.000606802,0.0010002706,0.000058574544,0.00005839089,0.00015062891,0.00014809736,0.0012445785],"category_scores_gemma":[0.000099479155,0.00019576045,0.00056124764,0.0017690498,0.00014845387,0.0004203511,0.000033320597,0.00036927813,0.00010502829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017425739,0.001046466,0.93852067,0.000029303743,0.00079448335,0.000023004277,0.0010541123,0.000010112342,0.014998327,0.0000113753995,0.0026500172,0.039119553],"study_design_scores_gemma":[0.003915535,0.008895136,0.95916635,0.00013626346,0.00009460632,0.0000027074036,0.0005023238,0.0044282004,0.021615893,0.00018204894,0.0008219174,0.00023899661],"about_ca_topic_score_codex":0.00067643326,"about_ca_topic_score_gemma":0.000029744891,"teacher_disagreement_score":0.038880557,"about_ca_system_score_codex":0.00009441391,"about_ca_system_score_gemma":0.00008525486,"threshold_uncertainty_score":0.9996684},"labels":[],"label_agreement":null},{"id":"W2051548413","doi":"10.3851/imp1839","title":"Next-Generation Sequencing of Dried Blood Spot Specimens: A Novel Approach to HIV Drug-Resistance Surveillance","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Sanger sequencing; Dried blood spot; Pyrosequencing; Genotyping; Multiplex; DNA sequencing; Dried blood; Human immunodeficiency virus (HIV); Drug resistance; Medicine; HIV drug resistance; Genotype; Virology; Biology; Genetics; Viral load; DNA; Gene; Antiretroviral therapy; Chemistry","score_opus":0.10091096437737697,"score_gpt":0.2592985268608887,"score_spread":0.15838756248351177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051548413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97458845,0.00041688836,0.0013914587,0.0004635701,0.000080278434,0.0006387351,0.000012053426,0.00005925753,0.022349276],"genre_scores_gemma":[0.9492801,0.00020606031,0.03161063,0.00018047502,0.00012884669,0.000038814767,0.000064332206,0.00003079357,0.018459935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987266,0.000042723925,0.00032915839,0.00036150022,0.00026902035,0.0002709988],"domain_scores_gemma":[0.99936664,0.000022419697,0.00011356496,0.00031974842,0.00010233095,0.000075282056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024787872,0.00021875899,0.0003929557,0.000118458585,0.00006735184,0.000015118656,0.00010599292,0.000054594162,0.000044351593],"category_scores_gemma":[0.000014284279,0.00017906068,0.00009606733,0.00031942612,0.000051709994,0.00011938048,0.000018480927,0.00008307152,0.00003961313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006897809,0.0014628222,0.036133863,0.00004899175,0.0004519441,0.000031403324,0.00945102,0.0000016998474,0.94464904,0.002449856,0.0026611206,0.0019684383],"study_design_scores_gemma":[0.005470967,0.00013236063,0.025724022,0.000118112024,0.00005789055,0.000012245639,0.0004257895,0.00015210698,0.9618413,0.00007255159,0.0055788066,0.0004138369],"about_ca_topic_score_codex":0.000027275644,"about_ca_topic_score_gemma":0.000047861904,"teacher_disagreement_score":0.030219173,"about_ca_system_score_codex":0.000057346315,"about_ca_system_score_gemma":0.000104356295,"threshold_uncertainty_score":0.7301882},"labels":[],"label_agreement":null},{"id":"W2052762873","doi":"10.3851/imp2597","title":"Distribution of Viral Hepatitis in Indigenous Populations of North America and the Circumpolar Arctic","year":2005,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"Public Health Agency","keywords":"Circumpolar star; Indigenous; Epidemiology; Arctic; Incidence (geometry); Hepatitis B; Outbreak; Virology; Hepatitis C; Viral hepatitis; Hepatitis A; Demography; Immunology; Medicine; Biology; Hepatitis; Ecology; Internal medicine","score_opus":0.06085193099193643,"score_gpt":0.37598066186094153,"score_spread":0.3151287308690051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052762873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.090819135,0.90696824,0.000035451914,0.000059491897,0.0000348252,0.0016558337,0.00035123443,0.0000096415815,0.00006612207],"genre_scores_gemma":[0.25430202,0.74491304,0.000036302503,0.000020980951,0.000058780173,0.0000545713,0.0005697318,0.000024622774,0.000019954221],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792266,0.00046085243,0.0007402345,0.00023583963,0.00036941326,0.0002710194],"domain_scores_gemma":[0.9989152,0.00018894256,0.0003706295,0.00038369565,0.00009696133,0.00004457056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002630974,0.00023531233,0.0015387828,0.00021378548,0.000057507714,0.0000104769915,0.00016330692,0.00013305254,0.000021697382],"category_scores_gemma":[0.00012523343,0.00015335566,0.00029632178,0.00064555876,0.00049041153,0.00007697572,0.000041995325,0.0004543405,0.0000095161],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056624925,0.00012377392,0.08172534,0.0011884773,0.00010375366,0.000009110357,0.00032047767,1.9330692e-7,0.000001170802,0.00006998946,0.00001121974,0.9163899],"study_design_scores_gemma":[0.0025269096,0.0006168434,0.27351907,0.004480915,0.00028367233,0.000019752333,0.000010602627,0.000030906984,0.000007164325,0.00009848687,0.7181102,0.00029546302],"about_ca_topic_score_codex":0.004866614,"about_ca_topic_score_gemma":0.0006699181,"teacher_disagreement_score":0.9160944,"about_ca_system_score_codex":0.00011745692,"about_ca_system_score_gemma":0.0002754554,"threshold_uncertainty_score":0.7356897},"labels":[],"label_agreement":null},{"id":"W2054957721","doi":"10.3851/imp2715","title":"Amiodarone and Concurrent Antiretroviral Therapy: A Case Report and Review of the Literature","year":2013,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; St. Michael's Hospital","funders":"","keywords":"Antiretroviral therapy; Medicine; Reverse-transcriptase inhibitor; Amiodarone; Human immunodeficiency virus (HIV); Internal medicine; Intensive care medicine; Viral load; Virology; Atrial fibrillation","score_opus":0.06310276160165854,"score_gpt":0.3746321253345754,"score_spread":0.31152936373291684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054957721","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005200061,0.99087834,9.007848e-7,0.00009484432,0.0002926542,0.0017024763,0.000066032866,0.000028998562,0.0017356592],"genre_scores_gemma":[0.0033059858,0.995318,0.000019984756,0.00026245872,0.00022631783,0.000043311153,0.00004101051,0.00003848056,0.00074445404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982038,0.00024887058,0.0006805029,0.00041319165,0.00026422643,0.00018941361],"domain_scores_gemma":[0.99850214,0.00013787879,0.00059229584,0.00054026395,0.00017056543,0.000056861227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003804933,0.00042797878,0.0026203995,0.00008915566,0.00011411937,0.000040878058,0.000029526629,0.00017957298,0.000006728347],"category_scores_gemma":[0.00008619046,0.00021363309,0.0006447127,0.00038786876,0.0002849726,0.00006898571,0.00007711448,0.00034274437,0.00000308065],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000083753175,0.000020829757,0.00040944119,0.02618919,0.0004363319,0.00081914256,0.00014132273,4.1837825e-10,0.0000048175903,0.000023304117,0.0032577543,0.9686895],"study_design_scores_gemma":[0.00045271602,0.00019903017,0.00015217603,0.08863819,0.0003577032,0.065680355,0.00001405111,9.666984e-8,0.0000075977564,0.0000049003283,0.8442974,0.00019577413],"about_ca_topic_score_codex":0.000028834389,"about_ca_topic_score_gemma":3.6199975e-7,"teacher_disagreement_score":0.9684937,"about_ca_system_score_codex":0.000018689632,"about_ca_system_score_gemma":0.00011042649,"threshold_uncertainty_score":0.87117046},"labels":[],"label_agreement":null},{"id":"W2060458916","doi":"10.3851/imp2742","title":"A Systematic Review of the Use of Atazanavir in Women Infected with HIV-1","year":2013,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Gilead Sciences","keywords":"Atazanavir; Medicine; Ritonavir; Discontinuation; Tolerability; Regimen; Systematic review; Human immunodeficiency virus (HIV); MEDLINE; Clinical trial; Adverse effect; Family medicine; Antiretroviral therapy; Intensive care medicine; Viral load; Internal medicine","score_opus":0.053926122615212825,"score_gpt":0.3084194161421629,"score_spread":0.25449329352695005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060458916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013718844,0.99233055,0.0000011605117,0.00008752034,0.000023248338,0.006031757,0.000022100192,0.00001348806,0.00011826607],"genre_scores_gemma":[0.00007597536,0.9950813,0.00011765412,0.00011912756,0.000009742036,0.0007212031,0.000053732037,0.000043023687,0.0037782618],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99775696,0.00041066765,0.0010491429,0.00022712725,0.00033194487,0.0002241659],"domain_scores_gemma":[0.9981279,0.00019191948,0.00084860594,0.00069568655,0.00009898436,0.000036953483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002830403,0.0003830378,0.0036548807,0.00016567479,0.00001618634,0.000008136554,0.000184519,0.00011199636,0.00006106776],"category_scores_gemma":[0.00007543166,0.00016022037,0.00036538942,0.0008104467,0.00008493723,0.00008091364,0.000036956382,0.0002019332,0.000044510427],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002151335,0.00026233797,0.00052482006,0.9364487,0.0011484517,0.000013969771,0.00021373936,8.32103e-9,0.0000012528745,0.000014917196,0.0004982128,0.06085211],"study_design_scores_gemma":[0.0006951253,0.00011829488,0.000100420584,0.8531123,0.00076074334,0.000017173716,0.00000852255,3.5305513e-7,0.00000965391,0.0000013655269,0.14502792,0.00014814801],"about_ca_topic_score_codex":0.000018989762,"about_ca_topic_score_gemma":0.0000027672636,"teacher_disagreement_score":0.14452972,"about_ca_system_score_codex":0.00011681666,"about_ca_system_score_gemma":0.00032743756,"threshold_uncertainty_score":0.6533597},"labels":[],"label_agreement":null},{"id":"W2070371941","doi":"10.3851/imp1769","title":"Mutations in Gp41 are Correlated with Coreceptor Tropism but Do Not Improve Prediction Methods Substantially","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"Canadian Institutes of Health Research; GlaxoSmithKline; Pfizer","keywords":"Maraviroc; Tropism; Gp41; Receiver operating characteristic; Mutation; Biology; Virology; Computational biology; Genetics; Statistics; Human immunodeficiency virus (HIV); Virus; Mathematics; Gene","score_opus":0.017756729943312004,"score_gpt":0.3033436694869285,"score_spread":0.28558693954361647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070371941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651957,0.00037421007,0.000744204,0.00021815705,0.00067388185,0.0004996939,0.000285126,0.000077987715,0.0006071527],"genre_scores_gemma":[0.9963534,0.0002903713,0.0010740944,0.00004526721,0.000033083594,0.00007685953,0.0002913262,0.000021469374,0.0018141617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879783,0.00028765708,0.00020294906,0.00030020048,0.00005002216,0.00036135374],"domain_scores_gemma":[0.9994218,0.00014576525,0.000093719296,0.0002303097,0.00008255714,0.000025853056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023465179,0.00017430921,0.00023300735,0.0001348308,0.0001543524,0.00002679726,0.0001297637,0.00023413806,0.00045956258],"category_scores_gemma":[0.000031402895,0.0001230017,0.00006060021,0.0001931274,0.0002561865,0.00013335308,0.00001539117,0.00057812984,0.00035833934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010823618,0.00028494067,0.041369084,0.0000021823894,0.00018247783,0.00002218042,0.00040625545,9.0240457e-7,0.87946063,0.00017066105,0.00009450426,0.07692384],"study_design_scores_gemma":[0.0075376765,0.001400957,0.19641893,0.000021820792,0.000022068767,0.00002999556,0.0002922329,0.000025460247,0.78666914,0.00012328563,0.00724218,0.00021624188],"about_ca_topic_score_codex":0.00021640252,"about_ca_topic_score_gemma":0.00033435365,"teacher_disagreement_score":0.15504985,"about_ca_system_score_codex":0.000025544807,"about_ca_system_score_gemma":0.00008762164,"threshold_uncertainty_score":0.5031888},"labels":[],"label_agreement":null},{"id":"W2071800230","doi":"10.3851/imp2709","title":"The Cost of Antiretroviral Drug Resistance in HIV-Positive Patients","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"Alberta Health Services","keywords":"Medicine; HIV drug resistance; Drug resistance; Dosing; Internal medicine; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Biology","score_opus":0.007901470614739147,"score_gpt":0.2416222029467469,"score_spread":0.23372073233200777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071800230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877337,0.0004974033,0.000006392148,0.002375196,0.00006852277,0.0008901473,0.0000075159646,0.000015891908,0.008405182],"genre_scores_gemma":[0.97409374,0.00064409216,0.0002935141,0.0001324298,0.000021334245,0.00005477602,0.000036583715,0.000014819518,0.024708698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903923,0.00006649041,0.00025526385,0.00016936283,0.00022717367,0.00024248578],"domain_scores_gemma":[0.99949205,0.00009512036,0.000088853245,0.000192164,0.00009810101,0.000033702538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116898416,0.00013847061,0.00023129204,0.00006347973,0.00007932379,0.00001823726,0.00009216315,0.000034659293,0.000031350995],"category_scores_gemma":[0.000016015081,0.00008270728,0.00007010043,0.00021144199,0.00011482372,0.00012180329,0.000017904013,0.0001002489,0.000118224074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003912913,0.0004061432,0.9535871,0.000007831969,0.00007629144,0.0000093766885,0.001355512,3.4140523e-8,0.0008212476,0.0005241049,0.009693367,0.033127688],"study_design_scores_gemma":[0.0041550454,0.0001367384,0.9643893,0.00013361186,0.000009261115,3.0967635e-7,0.0001642131,0.000010399513,0.02063623,0.00030559467,0.009930321,0.00012897205],"about_ca_topic_score_codex":0.0000491631,"about_ca_topic_score_gemma":0.000048817725,"teacher_disagreement_score":0.032998715,"about_ca_system_score_codex":0.000051519597,"about_ca_system_score_gemma":0.00004253438,"threshold_uncertainty_score":0.3372705},"labels":[],"label_agreement":null},{"id":"W2073567614","doi":"10.3851/imp2434","title":"Changes in Metabolic, Inflammatory and Coagulation Biomarkers after HIV Seroconversion – the Health in Men (Him) Biomarker Substudy","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Australian Government","keywords":"Medicine; Seroconversion; Internal medicine; Immunology; Fibrinogen; Population; Vitamin D and neurology; Biomarker; C-reactive protein; Gastroenterology; Inflammation; Human immunodeficiency virus (HIV); Biology","score_opus":0.028104985822752757,"score_gpt":0.3167124335622282,"score_spread":0.28860744773947544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073567614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98078835,0.008344586,0.0000046382816,0.0093779685,0.00004853142,0.001098293,0.0000052873525,0.000021576394,0.0003107654],"genre_scores_gemma":[0.992643,0.0061678425,0.000054854543,0.00083788135,0.00003157431,0.00012306818,0.000028886134,0.000016003685,0.00009686519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989801,0.00018483517,0.00023000188,0.00017453326,0.00011327777,0.00031725355],"domain_scores_gemma":[0.9995566,0.000051064977,0.00008330426,0.00020847263,0.000020158403,0.00008038269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005372336,0.00013566556,0.00023470138,0.00021607666,0.000088640256,0.000008909464,0.000040944502,0.00007079912,0.000028864375],"category_scores_gemma":[0.0000043824243,0.00008979869,0.000027132559,0.00032700974,0.000055336426,0.00014398592,0.000019244942,0.00011134966,0.000031257783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047086398,0.0002197026,0.9596737,0.000015678426,0.000051444546,0.0000025904073,0.0023287297,5.836267e-8,0.0005618201,0.000059049373,0.0002099709,0.036406405],"study_design_scores_gemma":[0.002677886,0.00009554353,0.98974794,0.000071466086,0.000010436068,0.000004795334,0.00034904826,0.00015437313,0.00025560087,0.000025550593,0.0065300255,0.000077323566],"about_ca_topic_score_codex":0.0002806925,"about_ca_topic_score_gemma":0.00026873665,"teacher_disagreement_score":0.036329083,"about_ca_system_score_codex":0.000065826986,"about_ca_system_score_gemma":0.00003992129,"threshold_uncertainty_score":0.36618844},"labels":[],"label_agreement":null},{"id":"W2088637525","doi":"10.3851/imp2484","title":"Who Needs Direct-Acting Antivirals for HCV? Challenges Faced in Advancing HCV Therapy for HIV–HCV-Coinfected Individuals","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's & Women's Health Centre of British Columbia; University of Ottawa; AIDS Vancouver; University of British Columbia; Toronto General Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Telaprevir; Boceprevir; Hepatitis C; Internal medicine; Coinfection; Simeprevir; Cohort; Hepatitis C virus; Ribavirin; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.09838915629328554,"score_gpt":0.3840883664835276,"score_spread":0.2856992101902421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088637525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96214676,0.0110349255,0.00079814816,0.0028834683,0.00035302673,0.005070886,0.00014107561,0.00027342327,0.01729831],"genre_scores_gemma":[0.9735039,0.02138186,0.00161308,0.00081255776,0.000763604,0.00078824954,0.00010578829,0.00019376026,0.0008371994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608094,0.00036096707,0.00069720775,0.00056362007,0.00056389655,0.0017333785],"domain_scores_gemma":[0.9974591,0.0012624088,0.0002544526,0.0005565023,0.00023535478,0.0002321605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023457457,0.0005331411,0.0011516094,0.0007569852,0.0002485696,0.00007799407,0.00027922724,0.00033132354,0.00008242127],"category_scores_gemma":[0.0006185286,0.00045870902,0.00035560207,0.00071070244,0.00012122843,0.00087640306,0.000060529375,0.00044725032,0.000046045458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010190358,0.0005517396,0.263824,0.00013837364,0.0002495604,0.000004912038,0.0055335267,0.0000015207295,0.039261494,0.00022705088,0.0012927573,0.6878961],"study_design_scores_gemma":[0.017908221,0.0025045027,0.09701784,0.0005677683,0.00003652149,0.0000028120598,0.0015065676,0.00047456825,0.15742853,0.00025091408,0.7212745,0.0010272594],"about_ca_topic_score_codex":0.0000840892,"about_ca_topic_score_gemma":0.000053454092,"teacher_disagreement_score":0.71998173,"about_ca_system_score_codex":0.00015080666,"about_ca_system_score_gemma":0.00016553093,"threshold_uncertainty_score":0.99978644},"labels":[],"label_agreement":null},{"id":"W2091650571","doi":"10.3851/imp1887","title":"Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Pegylated interferon; Medicine; Immunology; Hepatitis B; Antigen; Virology; Chronic hepatitis; Hepatitis B virus; Interferon; Ribavirin; Virus","score_opus":0.020816713282991006,"score_gpt":0.25945547526346485,"score_spread":0.23863876198047385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091650571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544847,0.0009978759,0.00025593012,0.0003859477,0.00012587567,0.0018822311,0.00013759575,0.00016943114,0.00059663836],"genre_scores_gemma":[0.97742206,0.019669386,0.0016335541,0.0005539422,0.000054745244,0.00005576661,0.00014115279,0.0001218575,0.00034755756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967872,0.0004689724,0.00072028686,0.00082177913,0.00046007874,0.0007416707],"domain_scores_gemma":[0.9984586,0.00017092729,0.00023754263,0.00048055942,0.00044532004,0.00020700278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039739817,0.0005611462,0.00087219244,0.0003763318,0.00024916395,0.00005072552,0.0001643387,0.00022746646,0.00018650545],"category_scores_gemma":[0.00013354524,0.0004864947,0.00009168664,0.00092446856,0.00022699905,0.00047587877,0.0001225494,0.0003513154,0.00013942915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008712202,0.00043715886,0.9676544,0.0000234279,0.00025520872,0.00034058988,0.0038051633,0.000004453636,0.011192878,0.000013741843,0.00019097351,0.0073698224],"study_design_scores_gemma":[0.0045078117,0.00917147,0.9619628,0.0005493275,0.00003901605,0.000019573923,0.000019824654,0.00025958687,0.022379935,0.000032186355,0.000516221,0.00054220896],"about_ca_topic_score_codex":0.081219524,"about_ca_topic_score_gemma":0.046196863,"teacher_disagreement_score":0.03502266,"about_ca_system_score_codex":0.0004175337,"about_ca_system_score_gemma":0.00017768038,"threshold_uncertainty_score":0.99975866},"labels":[],"label_agreement":null},{"id":"W2111047626","doi":"10.1177/135965350701200708","title":"External Quality Assessment of <i>HLA-B*5701</i> Reporting: An International Multicentre Survey","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Royal Victoria Hospital; Health Sciences Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; University of Calgary","funders":"","keywords":"Abacavir; HLA-B; Medicine; Typing; Human leukocyte antigen; Biology; Genetics; Human immunodeficiency virus (HIV); Family medicine; Viral load; Immunology","score_opus":0.1739402511964074,"score_gpt":0.4780670647630059,"score_spread":0.30412681356659854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111047626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96703786,0.000020517493,0.0018690348,0.00011773384,0.000594294,0.00025569575,0.000020122101,0.000059498256,0.030025275],"genre_scores_gemma":[0.99564505,0.00012654396,0.0030314827,0.00024402836,0.0002053451,0.0000026480884,0.00008625855,0.000023215736,0.00063542783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780947,0.00014079358,0.0009801537,0.00029438894,0.0005249632,0.00025021867],"domain_scores_gemma":[0.9980491,0.00017900082,0.00095765875,0.00041392233,0.0002924894,0.00010787279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028717753,0.00015039532,0.00034300663,0.00011708667,0.00004967178,0.000017312792,0.00013293621,0.000083821506,0.000044407323],"category_scores_gemma":[0.00030154563,0.00013003884,0.0001487848,0.00017215905,0.00006935139,0.000288003,0.000025037225,0.00024320449,0.000011346076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095070216,0.00071448926,0.6943421,0.0000055192822,0.00008865504,0.000045748926,0.00011990628,0.0000015821623,0.222226,0.00018441485,0.000010820202,0.08216573],"study_design_scores_gemma":[0.0016638198,0.00007031267,0.95583797,0.000043604152,0.000011876129,0.000028617644,0.00020528708,0.00009391744,0.038602278,0.000031952113,0.0032891764,0.0001211782],"about_ca_topic_score_codex":0.0009480259,"about_ca_topic_score_gemma":0.00025715155,"teacher_disagreement_score":0.26149592,"about_ca_system_score_codex":0.00010065977,"about_ca_system_score_gemma":0.0001295757,"threshold_uncertainty_score":0.530283},"labels":[],"label_agreement":null},{"id":"W2116758166","doi":"10.1177/135965350801302s07","title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Antiretroviral therapy; Population; Public health; Human immunodeficiency virus (HIV); Environmental health; Viral load; Family medicine; Internal medicine; Pathology","score_opus":0.028690203976617243,"score_gpt":0.29083398245131176,"score_spread":0.2621437784746945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116758166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953158,0.00047597862,0.000032443168,0.0031953785,0.000050438306,0.0006643461,0.000012153015,0.00008464031,0.00016885852],"genre_scores_gemma":[0.9244279,0.00191344,0.00030950818,0.00008627431,0.00003463744,0.000011421276,0.00036038223,0.00003266231,0.07282372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998631,0.00023033236,0.00031026517,0.00032727048,0.00021126315,0.00028986958],"domain_scores_gemma":[0.99952215,0.000059147187,0.00011552972,0.00014123187,0.00006408341,0.00009784386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025609852,0.0002368175,0.00041185104,0.00026452585,0.0001745467,0.000020702875,0.000038466922,0.000043278204,0.000025991632],"category_scores_gemma":[0.00003251983,0.00018877967,0.000052851006,0.0006105425,0.00003288029,0.0001271844,0.000013501344,0.00007043961,0.00002455652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007658993,0.00055104186,0.99135673,0.000007738001,0.00008935252,0.000035103847,0.0028153763,2.453491e-7,0.0016132147,0.000011885567,0.0008923723,0.0025503254],"study_design_scores_gemma":[0.002959675,0.00016058114,0.98045087,0.00010186232,0.000011045602,0.0000013444829,0.00010834236,0.0000070195542,0.015198061,0.000014900198,0.0008185226,0.00016776151],"about_ca_topic_score_codex":0.00010555171,"about_ca_topic_score_gemma":0.001006495,"teacher_disagreement_score":0.072654866,"about_ca_system_score_codex":0.00027984413,"about_ca_system_score_gemma":0.00008543134,"threshold_uncertainty_score":0.7698211},"labels":[],"label_agreement":null},{"id":"W2137554174","doi":"10.1177/135965350801302s05","title":"World Health Organization/HIVResNet Drug Resistance Laboratory Strategy","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Accreditation; Quality assurance; Medicine; Human immunodeficiency virus (HIV); Developing country; Population; External quality assessment; Operations research; Environmental health; Antiretroviral therapy; Viral load; Virology; Engineering; Economic growth; Medical education; Pathology","score_opus":0.021361288121692214,"score_gpt":0.2737638945577415,"score_spread":0.25240260643604934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137554174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96544695,0.0043111583,0.000061422725,0.018109342,0.0001483947,0.00056427816,0.000016301301,0.00025144318,0.011090706],"genre_scores_gemma":[0.83519584,0.0037651202,0.0011244218,0.0015810902,0.000121202385,0.000009315126,0.00010787829,0.00003825609,0.1580569],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891436,0.000072035036,0.00024099146,0.00025672445,0.00024304923,0.00027282818],"domain_scores_gemma":[0.99945194,0.000030275862,0.00008708786,0.00024014471,0.00009158734,0.000098985554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121280005,0.00017708793,0.0002886194,0.00012402091,0.00023871557,0.000015035688,0.000072428236,0.000030249326,0.00020138931],"category_scores_gemma":[0.000009810067,0.0001425963,0.000038893373,0.0008635736,0.000073567986,0.000112826645,0.00000975564,0.0001158625,0.0002419913],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033401023,0.0009144234,0.46516198,0.000041146435,0.00027894677,0.0003671166,0.004460489,6.9819123e-7,0.0018969872,0.0018941842,0.5184875,0.006162532],"study_design_scores_gemma":[0.0057507735,0.00015444317,0.21487358,0.00016008253,0.00001745939,0.000018182143,0.00024470524,0.000005678783,0.03515647,0.00021080533,0.7429396,0.0004682459],"about_ca_topic_score_codex":0.000016037056,"about_ca_topic_score_gemma":0.00015152058,"teacher_disagreement_score":0.2502884,"about_ca_system_score_codex":0.00008454024,"about_ca_system_score_gemma":0.0004923051,"threshold_uncertainty_score":0.5814908},"labels":[],"label_agreement":null},{"id":"W2151298956","doi":"10.1177/135965350300800601","title":"Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Medicine; Viral load; Internal medicine; Odds ratio; Population; Logistic regression; Immunology; Lentivirus; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.02188071117907574,"score_gpt":0.26681899492091177,"score_spread":0.24493828374183602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151298956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978572,0.00021974072,0.000007209629,0.00013225393,0.000045271478,0.0013225739,0.0000051010193,0.00008432039,0.00032629672],"genre_scores_gemma":[0.9936268,0.00048803032,0.0004886558,0.00005891451,0.000022349926,0.00026567728,0.00008051683,0.000023004031,0.0049461056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983408,0.00025892808,0.000305987,0.00045790637,0.00021710781,0.00041928238],"domain_scores_gemma":[0.99945456,0.000119963,0.0000926744,0.00016992046,0.000022219272,0.00014068987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002759945,0.0003027197,0.00046246802,0.00018825439,0.000127844,0.00007472835,0.00003476698,0.00010789418,0.00003552037],"category_scores_gemma":[0.000041360112,0.00020336077,0.00005919921,0.00023469131,0.000104577724,0.00024087328,0.000013430336,0.00013726634,0.000002965495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009450599,0.0006973975,0.976878,0.000012359385,0.00007417147,0.000107800355,0.0024101594,0.000002314853,0.00065512274,0.00002141307,0.000052688276,0.018143523],"study_design_scores_gemma":[0.011947133,0.0016922508,0.98206186,0.00008562623,0.000028018234,0.00000882192,0.00037836467,0.0005262631,0.00243989,0.00013270025,0.00047422163,0.00022482895],"about_ca_topic_score_codex":0.00062640646,"about_ca_topic_score_gemma":0.000114137816,"teacher_disagreement_score":0.017918695,"about_ca_system_score_codex":0.00018242362,"about_ca_system_score_gemma":0.00005976792,"threshold_uncertainty_score":0.8292812},"labels":[],"label_agreement":null},{"id":"W2166415870","doi":"10.1177/135965350100600103","title":"Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"HIV drug resistance; Drug resistance; Medicine; Drug; Intensive care medicine; Human immunodeficiency virus (HIV); Quality assurance; Antiretroviral therapy; Viral load; Pharmacology; External quality assessment; Immunology; Pathology; Biology; Genetics","score_opus":0.08782025257169648,"score_gpt":0.3617538820014005,"score_spread":0.273933629429704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166415870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570472,0.0012877872,0.00012292023,0.040298864,0.00013853092,0.000859715,0.000017390741,0.000025764808,0.00020181868],"genre_scores_gemma":[0.9517164,0.0032773563,0.012073696,0.0015744084,0.00009989137,0.00013046886,0.000024546076,0.000032953136,0.031070258],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989866,0.00005393363,0.00035185117,0.00018761336,0.0002192677,0.00020072774],"domain_scores_gemma":[0.9988499,0.0004530224,0.000105607076,0.00024995793,0.0003091064,0.00003239082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024474115,0.00014119862,0.0002479231,0.000064094915,0.00005451659,0.000013894253,0.00005298617,0.000042410804,0.000019419387],"category_scores_gemma":[0.0003374921,0.00008331902,0.000082979604,0.0002754109,0.00005858255,0.00013769111,0.000012691621,0.00008044196,0.000011537284],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067777825,0.0014923621,0.45208672,0.000048145812,0.0004495222,0.00028659412,0.0035115904,0.0000035329856,0.0065516364,0.0010206206,0.49104354,0.036727957],"study_design_scores_gemma":[0.005498766,0.00012460997,0.02766389,0.00019334986,0.00004715774,0.0000049813875,0.0003556657,0.00012107153,0.016153073,0.00013108806,0.94953096,0.00017538974],"about_ca_topic_score_codex":0.000012986968,"about_ca_topic_score_gemma":0.0001889691,"teacher_disagreement_score":0.45848742,"about_ca_system_score_codex":0.000035437934,"about_ca_system_score_gemma":0.00014283079,"threshold_uncertainty_score":0.3397651},"labels":[],"label_agreement":null},{"id":"W2170104292","doi":"10.1177/135965350400900512","title":"Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nevirapine; Efavirenz; Medicine; Internal medicine; Stavudine; Adverse effect; Lamivudine; Quality of life (healthcare); Health related quality of life; Viral load; Antiretroviral therapy; Human immunodeficiency virus (HIV); Virology; Disease","score_opus":0.03863834630585736,"score_gpt":0.29900894697576225,"score_spread":0.2603706006699049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170104292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973674,0.00072142057,0.000024246814,0.0007158281,0.000024507925,0.00078485475,0.000012286342,0.000054216176,0.00029526357],"genre_scores_gemma":[0.99551684,0.0030748518,0.0004703553,0.00033326037,0.000034051198,0.000027719,0.000087030596,0.000036078538,0.00041983827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984115,0.00007561374,0.0005339384,0.0003476838,0.0003162374,0.00031506224],"domain_scores_gemma":[0.99930423,0.00007875209,0.0001973466,0.00023748203,0.000088706576,0.000093479706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022026671,0.0003104748,0.00076517643,0.00018480678,0.000070706184,0.000014997995,0.0000733203,0.00009457731,0.00003478713],"category_scores_gemma":[0.00003601922,0.00018873592,0.000080615115,0.0004192916,0.00014155029,0.00016823228,0.000017018705,0.00013690075,0.0000061274695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013517107,0.0013861193,0.95286864,0.00003137977,0.00023650186,0.00003049202,0.0009004275,0.0000018959885,0.00056621135,0.00007849358,0.000013458482,0.030369287],"study_design_scores_gemma":[0.046217546,0.0071715224,0.93909895,0.00025992823,0.000014799196,0.0000018772064,0.00008889655,0.000006124084,0.006541605,0.000033316122,0.0003169811,0.00024846583],"about_ca_topic_score_codex":0.0004628617,"about_ca_topic_score_gemma":0.0002014611,"teacher_disagreement_score":0.03270044,"about_ca_system_score_codex":0.00006472887,"about_ca_system_score_gemma":0.00016354556,"threshold_uncertainty_score":0.7696428},"labels":[],"label_agreement":null},{"id":"W2182593161","doi":"10.1177/135965350701200112","title":"The Development of Artificial Neural Networks to Predict Virological response to Combination HIV Therapy","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Viral load; Regimen; Medicine; Combination therapy; Artificial neural network; Machine learning; Internal medicine; Artificial intelligence; Human immunodeficiency virus (HIV); Statistics; Immunology; Computer science; Mathematics","score_opus":0.030144911094992646,"score_gpt":0.3029147908529278,"score_spread":0.27276987975793515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2182593161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304426,0.00062659587,0.0039024015,0.0012990446,0.00024165146,0.00067786523,0.000009935622,0.000039453014,0.00015877328],"genre_scores_gemma":[0.9988274,0.00008974304,0.0001560921,0.0002659797,0.00003266252,0.00004767662,0.00004125318,0.000011406016,0.00052776973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984175,0.00041087074,0.0003405294,0.00022965547,0.000088512126,0.000512952],"domain_scores_gemma":[0.99907434,0.00052663445,0.000058592712,0.00022244664,0.00007291842,0.000045043507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015684672,0.00015304788,0.00018561349,0.00009804473,0.00039203878,0.000020113719,0.0002560947,0.00012707336,0.000063553314],"category_scores_gemma":[0.000059048554,0.00009064338,0.0000695935,0.00023852987,0.00014040752,0.00003775541,0.000052024014,0.00017889676,0.00029354222],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024822025,0.00043030243,0.007958649,4.3004056e-7,0.00013924668,0.0000072325893,0.0010476607,0.00001710702,0.4007272,0.00015907607,0.00093796133,0.56375307],"study_design_scores_gemma":[0.0025098475,0.0035830976,0.5588851,0.000008200712,0.0000030720037,0.000004389821,0.00020243776,0.000031847798,0.3559084,0.00007721977,0.078596786,0.00018961258],"about_ca_topic_score_codex":0.0000068459794,"about_ca_topic_score_gemma":0.000040742652,"teacher_disagreement_score":0.56356347,"about_ca_system_score_codex":0.000037796814,"about_ca_system_score_gemma":0.00004891312,"threshold_uncertainty_score":0.37729895},"labels":[],"label_agreement":null},{"id":"W2214017990","doi":"10.1177/135965350901400104","title":"Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Gastroenterology; Medicine; Internal medicine; Hepatitis C virus; Adverse effect; Placebo; Population; Pharmacokinetics; Hepatitis C; Viral load; Pharmacology; Immunology; Virology; Virus; Pathology","score_opus":0.02176250953072437,"score_gpt":0.33295685861030033,"score_spread":0.31119434907957594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214017990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389654,0.0025665688,0.00008867459,0.00059270015,0.00013768642,0.0011404016,0.00022061716,0.00013753118,0.0012192603],"genre_scores_gemma":[0.9766931,0.021732667,0.0003342557,0.0005424471,0.00026124693,0.000041173837,0.000038540253,0.00008525734,0.0002713171],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763304,0.00023606015,0.00048586229,0.000496736,0.00055624114,0.00059204735],"domain_scores_gemma":[0.9990479,0.00015109098,0.00011329608,0.0004139566,0.00008360676,0.00019015837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032250737,0.00045134203,0.00084713957,0.00028419963,0.00009185514,0.000042529562,0.0001167769,0.00015595419,0.00007873706],"category_scores_gemma":[0.00003608363,0.00033258792,0.00023205654,0.00040595126,0.00026620727,0.00021576918,0.00004480974,0.00025430022,0.00003259588],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038868245,0.00061167375,0.14749952,0.000027281087,0.00015512606,0.0002093318,0.00021624935,1.9536266e-7,0.43146628,0.000013962556,0.00014216051,0.41577142],"study_design_scores_gemma":[0.013206614,0.012317422,0.12603633,0.00013970946,0.00010081254,0.000018711457,0.00000391223,0.0003940292,0.8411798,0.000014484368,0.006263429,0.00032473926],"about_ca_topic_score_codex":0.0016422375,"about_ca_topic_score_gemma":0.00012031036,"teacher_disagreement_score":0.41544667,"about_ca_system_score_codex":0.00010288652,"about_ca_system_score_gemma":0.00009941933,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2313239396","doi":"10.3851/imp2536","title":"Article Commentary: Long-Term Adherence to Antiretroviral Therapy in Resource-Limited Settings: A Bitter Pill to Swallow","year":2013,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Pill; Medicine; Psychological intervention; Intensive care medicine; Antiretroviral therapy; Medication adherence; Pharmacotherapy; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Family medicine; Psychiatry; Pharmacology","score_opus":0.03994279566461841,"score_gpt":0.3342235241138344,"score_spread":0.294280728449216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313239396","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6120339,0.00029622935,0.000038939666,0.38477713,0.000100119185,0.0016461466,0.00006599044,0.000092232665,0.000949307],"genre_scores_gemma":[0.17718019,0.00047587615,0.00025880212,0.7890914,0.0016411645,0.00042371062,0.0005331155,0.00015993477,0.030235779],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561864,0.00047230045,0.00075740303,0.000931681,0.0008508576,0.0013691295],"domain_scores_gemma":[0.998193,0.00015343972,0.00014792578,0.0010188747,0.00017508074,0.00031166288],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00043393156,0.0006347313,0.000938375,0.0009300908,0.00013453298,0.00023208855,0.0006653455,0.00048145084,0.0018531769],"category_scores_gemma":[0.00008132334,0.0005139101,0.0004959488,0.0009963785,0.00014873533,0.00026990921,0.00016499935,0.0020376744,0.0019398818],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059283857,0.00035510614,0.06756371,0.00006273949,0.00017611038,0.00049592793,0.00063022814,1.068352e-7,0.020824807,7.1731824e-7,0.7779989,0.13129877],"study_design_scores_gemma":[0.0048244298,0.03574447,0.04766512,0.0019496459,0.000023587716,0.000024084775,0.000104604056,0.00005007182,0.00959421,0.000020849855,0.89914316,0.00085574435],"about_ca_topic_score_codex":0.0009407027,"about_ca_topic_score_gemma":0.0000818255,"teacher_disagreement_score":0.43485373,"about_ca_system_score_codex":0.00019313363,"about_ca_system_score_gemma":0.00007260919,"threshold_uncertainty_score":0.99973124},"labels":[],"label_agreement":null},{"id":"W2314467161","doi":"10.3851/imp2711","title":"Presence of Anti-Interferon Antibodies is Not Associated with Non-Response to Pegylated Interferon Treatment in Chronic Hepatitis B","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Bristol-Myers Squibb","keywords":"Medicine; Antibody; Pegylated interferon; HBsAg; Immunology; HBeAg; Interferon; Internal medicine; Gastroenterology; Hepatitis B; Chronic hepatitis; Hepatitis B virus; Virology; Virus; Ribavirin","score_opus":0.03615289961723678,"score_gpt":0.33223118749327124,"score_spread":0.29607828787603446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314467161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958316,0.00015328029,0.000039237453,0.0015247752,0.000050009752,0.0018743224,0.000046643745,0.00005115007,0.00042896287],"genre_scores_gemma":[0.99585783,0.0017531293,0.0000799438,0.00024538586,0.000034175227,0.00014367921,0.000023214261,0.000055970173,0.0018066943],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99771494,0.0003055385,0.00044303492,0.00046012137,0.0004771696,0.00059918733],"domain_scores_gemma":[0.9987551,0.00025271103,0.00011773812,0.00048046932,0.0002624707,0.00013152798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031471884,0.0003203365,0.0007248329,0.0004152182,0.000050799623,0.00004347752,0.00020545209,0.00013545257,0.00045812802],"category_scores_gemma":[0.00011563655,0.00023272133,0.000108406115,0.00059684506,0.00018261581,0.00025962197,0.00006173455,0.00021864261,0.00022127369],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003891907,0.00042931724,0.42851582,0.000021520536,0.00021693471,0.00007883314,0.002335512,0.000005239076,0.5334212,0.000001267218,0.00041105255,0.030671388],"study_design_scores_gemma":[0.0033409314,0.012541826,0.59400487,0.0005445139,0.000010657806,0.0000020361977,0.000042437758,0.001113391,0.3878699,0.000003254697,0.000350293,0.00017590013],"about_ca_topic_score_codex":0.013073095,"about_ca_topic_score_gemma":0.0021202087,"teacher_disagreement_score":0.16548903,"about_ca_system_score_codex":0.00059834437,"about_ca_system_score_gemma":0.0003295556,"threshold_uncertainty_score":0.9934989},"labels":[],"label_agreement":null},{"id":"W2315153666","doi":"10.3851/imp2066","title":"Current research on respiratory viral infections: XIIth International Symposium","year":2012,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Respiratory viral infections research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Pandemic; Epidemiology; Coronavirus disease 2019 (COVID-19); Virology; Infectious disease (medical specialty); Medicine; Disease; Pathology","score_opus":0.19864885518442296,"score_gpt":0.49266053730887477,"score_spread":0.29401168212445183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315153666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95805293,0.0020111378,0.00005690086,0.00082911755,0.001671547,0.00078638096,0.000011039939,0.0001453231,0.036435638],"genre_scores_gemma":[0.9936148,0.0018908179,0.000028428974,0.00076239574,0.0025059741,0.00019207639,0.000019394407,0.00005712457,0.0009289675],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966611,0.00057832815,0.00036140738,0.00040017857,0.0011851606,0.0008137871],"domain_scores_gemma":[0.99843085,0.00021415575,0.00006702399,0.0006024365,0.00044259013,0.00024295562],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020366032,0.00023689671,0.00026488738,0.00075028586,0.00038153015,0.0001020759,0.00024433222,0.00015001763,0.00044686534],"category_scores_gemma":[0.00018335273,0.00019186818,0.00017997964,0.0008358878,0.00032126938,0.00060940976,0.000102617065,0.001259586,0.0020008825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012222935,0.0045774295,0.62964535,0.000037055222,0.00022960312,0.000022384711,0.0003386577,0.00000587894,0.107703745,0.0075511667,0.021956254,0.22671016],"study_design_scores_gemma":[0.0018779598,0.0023979214,0.11233687,0.000104092665,0.0000075926505,0.00001544579,0.000050820134,0.000024167879,0.053787675,0.00013722859,0.82903636,0.00022386243],"about_ca_topic_score_codex":0.00003885709,"about_ca_topic_score_gemma":0.0000028300633,"teacher_disagreement_score":0.8070801,"about_ca_system_score_codex":0.00035726826,"about_ca_system_score_gemma":0.00015793553,"threshold_uncertainty_score":0.9987762},"labels":[],"label_agreement":null},{"id":"W2318573097","doi":"10.3851/imp2685","title":"Significant Interaction between Activated Charcoal and Antiretroviral Therapy Leading to Subtherapeutic Drug Concentrations, Virological Breakthrough and Development of Resistance","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Poisoning and overdose treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Toronto General Hospital; University of Toronto","funders":"","keywords":"Antiretroviral therapy; Drug resistance; Drug; Charcoal; Medicine; Antiretroviral drug; Human immunodeficiency virus (HIV); Internal medicine; Pharmacology; Virology; Viral load; Intensive care medicine; Biology; Chemistry; Microbiology","score_opus":0.05142089867741031,"score_gpt":0.3157021093530544,"score_spread":0.26428121067564414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318573097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976344,0.00071164774,0.00013143134,0.0006053946,0.000044726945,0.00064753677,0.000005787512,0.000051838168,0.00016725002],"genre_scores_gemma":[0.9973542,0.00078230706,0.0011114614,0.0003402259,0.000051123014,0.0000327511,0.000024600611,0.000020317055,0.00028302846],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988457,0.00008733254,0.00030622227,0.00032028422,0.00017643062,0.00026403271],"domain_scores_gemma":[0.9994893,0.000107244494,0.000112863985,0.00014000712,0.000056185967,0.00009436429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012964683,0.00021078296,0.00039333958,0.00008004587,0.00014095103,0.000041214862,0.0000559559,0.000075190575,0.000028411905],"category_scores_gemma":[0.000010489606,0.00015476087,0.000037099333,0.00013722247,0.0001188722,0.00023454786,0.000017844113,0.00014078441,0.000016173257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052040163,0.00014639812,0.38579577,0.000013477895,0.00018019619,0.0000028285463,0.0026068098,1.2070393e-7,0.48941374,0.000033787703,0.00006633061,0.12122016],"study_design_scores_gemma":[0.0021717388,0.0006266038,0.63516897,0.00011007948,0.000012770103,0.0000031397822,0.00034750666,0.0000073520227,0.35975498,0.00003426297,0.001603666,0.00015893696],"about_ca_topic_score_codex":0.00008351362,"about_ca_topic_score_gemma":0.0000047482126,"teacher_disagreement_score":0.2493732,"about_ca_system_score_codex":0.00004927931,"about_ca_system_score_gemma":0.000048052923,"threshold_uncertainty_score":0.63109654},"labels":[],"label_agreement":null},{"id":"W2319508451","doi":"10.3851/imp2612","title":"Targeting Human Papillomavirus Genome Replication for Antiviral Drug Discovery","year":2013,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Biology; Drug discovery; Viral replication; Virology; Helicase; Genome; DNA replication; Computational biology; Virus; DNA; Bioinformatics; Genetics; Gene","score_opus":0.1264365398765943,"score_gpt":0.43935097641415943,"score_spread":0.3129144365375651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319508451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035513038,0.9889506,0.00010732175,0.0001358504,0.00015667622,0.0036913848,0.00017371723,0.000106417865,0.006322865],"genre_scores_gemma":[0.0010562461,0.97993547,0.00018092197,0.00021940348,0.0016159072,0.000870326,0.0020323202,0.00017238798,0.013917016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968937,0.000189415,0.00078180246,0.0010361712,0.00043663225,0.0006622988],"domain_scores_gemma":[0.99803734,0.00019579139,0.00032722633,0.0010724424,0.00025656045,0.00011063104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005977786,0.00053645665,0.0019529968,0.00019160745,0.00026764092,0.00018301884,0.00034560263,0.00030237524,0.0004475144],"category_scores_gemma":[0.000077956,0.00038771925,0.0010053087,0.00038051992,0.00013680439,0.00030486108,0.000106326566,0.0006155976,0.00027125893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008175167,0.00015967301,0.000037412196,0.006041388,0.0002474576,0.000011429265,0.00003679009,1.2748262e-8,0.0011269744,0.0003640169,0.0030065335,0.98888654],"study_design_scores_gemma":[0.001129384,0.0002958286,0.00025435566,0.0007376911,0.00021289165,0.000007098688,0.000012952996,0.0000032996052,0.00035541557,0.0003961502,0.9961496,0.00044530455],"about_ca_topic_score_codex":0.00007568039,"about_ca_topic_score_gemma":0.0000043507225,"teacher_disagreement_score":0.9931431,"about_ca_system_score_codex":0.00017978194,"about_ca_system_score_gemma":0.00035618467,"threshold_uncertainty_score":0.9998575},"labels":[],"label_agreement":null},{"id":"W2322898079","doi":"10.3851/imp2724","title":"Risk of Cardiovascular Disease Associated with HCV and HBV Coinfection among Antiretroviral-Treated HIV-Infected Individuals","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Public Health Ontario; St. Michael's Hospital; Ontario HIV Treatment Network; McMaster University; St. Paul's Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Coinfection; Medicine; Internal medicine; Hepatitis C; Myocardial infarction; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.011094386408624332,"score_gpt":0.24713375567505994,"score_spread":0.2360393692664356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322898079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964749,0.0011226467,0.00008222039,0.00008146765,0.000020982396,0.0012491546,0.000069864596,0.00012967833,0.00076907536],"genre_scores_gemma":[0.9969974,0.0022370971,0.00006426847,0.000033948792,0.000022132108,0.000092126866,0.00024930856,0.00003588349,0.00026782823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986544,0.00020364241,0.0002781117,0.00032195987,0.00027594407,0.00026592216],"domain_scores_gemma":[0.9989103,0.00008148794,0.00020568052,0.00041251976,0.00022646495,0.0001635521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017744536,0.00021915762,0.00047632083,0.00016384138,0.0001799596,0.000025015877,0.00004364245,0.00011516374,0.000049701],"category_scores_gemma":[0.0000572302,0.00015616661,0.00016161852,0.0004699223,0.00016507864,0.00020151534,0.000014367851,0.00018604817,0.000040013012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008397895,0.00041845225,0.98583394,0.00001693648,0.0016008238,0.000010279447,0.00010490225,0.000009569955,0.00014095158,0.000014896719,0.00011187478,0.011653389],"study_design_scores_gemma":[0.004041164,0.00093823625,0.9927228,0.00017324406,0.0006741677,0.0000028101347,0.000015744194,0.00043962474,0.0005256983,0.0000583027,0.0002583148,0.00014986326],"about_ca_topic_score_codex":0.0015624741,"about_ca_topic_score_gemma":0.0000071639033,"teacher_disagreement_score":0.011503526,"about_ca_system_score_codex":0.00004880953,"about_ca_system_score_gemma":0.00005599805,"threshold_uncertainty_score":0.63682896},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2323648016","doi":"10.3851/imp2747","title":"Genome-Wide Association Study to Characterize Serum Bilirubin Elevations in Patients with HCV Treated with Gs-9256, An HCV Ns3 Serine Protease Inhibitor","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Heme Oxygenase-1 and Carbon Monoxide","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Gilead Sciences","keywords":"Bilirubin; Genotyping; Genotype; Biology; Genome-wide association study; Internal medicine; Single-nucleotide polymorphism; Population; Medicine; Gastroenterology; Genetics; Gene","score_opus":0.0071952887360460125,"score_gpt":0.21473513563083216,"score_spread":0.20753984689478613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323648016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731886,0.0000086951695,0.000015159754,0.00022083169,0.000022263834,0.002258896,0.00004440491,0.000029128925,0.00008173889],"genre_scores_gemma":[0.9978738,0.0000148358295,0.00010329742,0.0005111244,0.00009512623,0.00034852987,0.00035942512,0.000047496083,0.000646374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985608,0.00016221667,0.00024973578,0.00045451126,0.00022341647,0.00034931037],"domain_scores_gemma":[0.9991844,0.000009265505,0.00013065856,0.00036873115,0.00019844294,0.00010849155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017150815,0.00025198332,0.00022442931,0.000091464084,0.00007279213,0.00006687516,0.00013957625,0.00009049577,0.000031885345],"category_scores_gemma":[0.000027217207,0.00018897268,0.000035698133,0.0003022648,0.000018540626,0.000042020296,0.00003183653,0.00010315197,0.000023492388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004733467,0.0009594765,0.80930054,0.0000026688388,0.00006276417,0.0000025313523,0.0001667439,0.000004192981,0.18748567,3.239206e-7,0.000031127358,0.0015106022],"study_design_scores_gemma":[0.0028862637,0.004245454,0.9335004,0.000010324689,0.000007970818,1.0011042e-7,0.00013237045,0.0000040274904,0.057945214,0.0000020643374,0.0009809219,0.00028488887],"about_ca_topic_score_codex":0.00028432955,"about_ca_topic_score_gemma":0.0003684767,"teacher_disagreement_score":0.12954044,"about_ca_system_score_codex":0.000055056138,"about_ca_system_score_gemma":0.000059515773,"threshold_uncertainty_score":0.77060825},"labels":[],"label_agreement":null},{"id":"W2326321318","doi":"10.3851/imp1786","title":"Lopinavir Up-Regulates Expression of the Antiviral Protein Ribonuclease L in Human Papillomavirus-Positive Cervical Carcinoma Cells","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Thunder Bay Regional Research Institute","funders":"National Science Council; Cancer Prevention Research Trust; Humane Research Trust","keywords":"Lopinavir; Biology; Molecular biology; Western blot; Transfection; Proteasome inhibitor; Cell culture; Virology; Cancer research; Virus; Viral load; Gene; Biochemistry","score_opus":0.021040166907169103,"score_gpt":0.31189104919005645,"score_spread":0.29085088228288736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326321318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915926,0.00015511131,0.0000022531133,0.00062620384,0.0001707854,0.00092291826,0.000034145847,0.00002816506,0.006467803],"genre_scores_gemma":[0.9980523,0.0000481742,0.000058340025,0.0002171356,0.0001925468,0.000034188728,0.000015563854,0.000041933992,0.0013398324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998034,0.00020349454,0.0003712678,0.00041273297,0.0005350404,0.0004434704],"domain_scores_gemma":[0.9989537,0.000058825146,0.00010291196,0.0006056696,0.00018035344,0.0000985409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022139955,0.00023968,0.00044184618,0.00010582216,0.0001459268,0.00002776403,0.00029836412,0.0002071961,0.00056124723],"category_scores_gemma":[0.000029306315,0.00015585095,0.00024123616,0.00043619177,0.00042696318,0.00013644753,0.00016277019,0.0008343234,0.000025881931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010391845,0.00089160044,0.03684819,0.000065555105,0.000014026438,0.000039057944,0.00031352986,6.073091e-8,0.9435993,0.00048910186,0.00009897321,0.016601423],"study_design_scores_gemma":[0.003923938,0.0002740542,0.38854247,0.000060275535,0.0000062303834,0.000002810469,0.00003707225,0.000014058853,0.6060408,0.0005323109,0.000452985,0.00011297715],"about_ca_topic_score_codex":0.00043629075,"about_ca_topic_score_gemma":0.0001736294,"teacher_disagreement_score":0.3516943,"about_ca_system_score_codex":0.00003874472,"about_ca_system_score_gemma":0.00014781603,"threshold_uncertainty_score":0.63554174},"labels":[],"label_agreement":null},{"id":"W2326748359","doi":"10.3851/imp1794","title":"Reduced Airborne Transmission of Oseltamivir-Resistant Pandemic A/H1N1 Virus in Ferrets","year":2010,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Virology; Oseltamivir; Virus; Neuraminidase; Biology; Transmission (telecommunications); Influenza A virus; Microbiology; Mutant; Medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.07152097901518477,"score_gpt":0.3829970275423331,"score_spread":0.31147604852714833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326748359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946676,0.0014834794,0.000015927508,0.00040561176,0.000108120556,0.0005569705,0.000013723143,0.000060753013,0.0026877953],"genre_scores_gemma":[0.9953769,0.0034935654,0.00035356949,0.00023843744,0.00009048513,0.000026045644,0.000007463604,0.00003363642,0.00037993529],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982397,0.00010092199,0.00042456065,0.0003175963,0.00047725553,0.0004399801],"domain_scores_gemma":[0.9992107,0.00012184326,0.00008806624,0.00037571174,0.00011576038,0.00008789997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059538375,0.00021851461,0.0005140223,0.00024424834,0.0000706788,0.000010074375,0.00017097185,0.00016736206,0.00014837558],"category_scores_gemma":[0.00010854859,0.0001614165,0.00014491891,0.00035021984,0.00025990888,0.00011981277,0.000030084253,0.0006498382,0.000027905302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024104787,0.0003023021,0.013126659,0.000038947892,0.000056377707,0.00004733139,0.000651245,2.5947583e-7,0.87653047,0.00011161922,0.00016551053,0.106558785],"study_design_scores_gemma":[0.0042332313,0.00077051134,0.3681044,0.00015076427,0.000011748299,0.000007414397,0.000055628556,0.000060853858,0.6132378,0.00030740362,0.012873484,0.0001867675],"about_ca_topic_score_codex":0.00039503872,"about_ca_topic_score_gemma":0.000112194466,"teacher_disagreement_score":0.35497776,"about_ca_system_score_codex":0.000034971086,"about_ca_system_score_gemma":0.00014602876,"threshold_uncertainty_score":0.65823734},"labels":[],"label_agreement":null},{"id":"W2327325395","doi":"10.3851/imp2956","title":"An Economic Evaluation of Conception Strategies for Heterosexual Serodiscordant Couples where the Male Partner is HIV-Positive","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Serodiscordant; Demography; Psychological intervention; Population; Cost-effectiveness analysis; Medicine; Gynecology; Family planning; Fertility; Sperm washing; Cost–benefit analysis; Unintended pregnancy; Cost effectiveness; Family medicine; Human immunodeficiency virus (HIV); Environmental health; Viral load; Antiretroviral therapy; Political science; Sociology","score_opus":0.06836961604135396,"score_gpt":0.40499909276457785,"score_spread":0.3366294767232239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327325395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206364,0.0003085724,0.0038145597,0.0008015395,0.0000369267,0.00081554893,0.00013143114,0.000013164203,0.0020145865],"genre_scores_gemma":[0.99756616,0.0002321526,0.00009032197,0.000096269636,0.00020535925,0.00010320092,0.00014093675,0.000014095357,0.0015514881],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99900156,0.00022417794,0.00020740429,0.00018091452,0.00021171547,0.00017423161],"domain_scores_gemma":[0.99936986,0.00006826056,0.000089720925,0.00024005125,0.00019463114,0.000037483784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007749461,0.000100992394,0.00017993762,0.000040196857,0.000105012536,0.000051638905,0.00009868471,0.000039883358,0.0005294057],"category_scores_gemma":[0.000013874671,0.00006503507,0.0001284203,0.00003664286,0.00017813663,0.00030173917,0.000008054343,0.00007452782,0.00003674058],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021990056,0.0008854559,0.032326296,0.000114875766,0.0005340786,9.346624e-7,0.005295366,0.00020061746,0.47376838,0.012565472,0.044187017,0.42792252],"study_design_scores_gemma":[0.018287705,0.043888506,0.11576642,0.00048235914,0.00028867397,0.00002495532,0.01829435,0.5538262,0.21617135,0.009629775,0.022648105,0.00069157814],"about_ca_topic_score_codex":0.000097379736,"about_ca_topic_score_gemma":0.00018157443,"teacher_disagreement_score":0.5536256,"about_ca_system_score_codex":0.00003261298,"about_ca_system_score_gemma":0.000110388384,"threshold_uncertainty_score":0.57966214},"labels":[],"label_agreement":null},{"id":"W2330500715","doi":"10.3851/imp2567","title":"Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results","year":2013,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Ribavirin; Medicine; Genotype; Sofosbuvir; Internal medicine; Virology; Hepatitis C virus; Biology; Virus","score_opus":0.1219904933411081,"score_gpt":0.3699764390028687,"score_spread":0.24798594566176058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330500715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840836,0.004468197,0.00024040285,0.002792507,0.00016276017,0.0039716214,0.0001956515,0.00014075862,0.0039444873],"genre_scores_gemma":[0.9598158,0.027990498,0.0020812242,0.0010870233,0.00048399242,0.00058568525,0.00023157662,0.00011773934,0.0076064556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692225,0.00025621906,0.0005730431,0.0008096479,0.00048144208,0.00095737947],"domain_scores_gemma":[0.99817604,0.00034696076,0.00015687094,0.0007064682,0.00033154475,0.00028210663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046953,0.000529298,0.00080865884,0.00022589766,0.00030689416,0.00017846456,0.00024961145,0.00027447072,0.00037442622],"category_scores_gemma":[0.000108925706,0.00038651662,0.00027648575,0.00030165658,0.00032924284,0.00047779584,0.00005075487,0.00025918285,0.00058685476],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006138063,0.0007617707,0.061270803,0.000032113378,0.00052409165,0.0000494847,0.00084386155,0.0000011391808,0.02327492,0.00020645217,0.018671006,0.8882263],"study_design_scores_gemma":[0.051781747,0.020369178,0.21848415,0.00014903079,0.00009685559,0.00003862693,0.0002067324,0.0015699553,0.034400698,0.0032722845,0.6683403,0.0012903906],"about_ca_topic_score_codex":0.0026313504,"about_ca_topic_score_gemma":0.0002348302,"teacher_disagreement_score":0.8869359,"about_ca_system_score_codex":0.00014866589,"about_ca_system_score_gemma":0.00022360687,"threshold_uncertainty_score":0.9998587},"labels":[],"label_agreement":null},{"id":"W2331891559","doi":"10.3851/imp1912","title":"Telbivudine Exerts no Antiviral Activity against HIV-1 <i>In Vitro</i> and in Humans","year":2011,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Telbivudine; Virology; In vivo; In vitro; Drug resistance; Antiviral drug; Human immunodeficiency virus (HIV); Biology; Drug; Genotype; Virus; Medicine; Hepatitis B virus; Pharmacology; Lamivudine; Microbiology; Genetics; Gene","score_opus":0.027933703811589442,"score_gpt":0.26063006942563127,"score_spread":0.23269636561404183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331891559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97158086,0.00027809793,0.000008262184,0.00048219526,0.00008878627,0.0005189908,0.000008193065,0.000056012304,0.026978584],"genre_scores_gemma":[0.9918296,0.0017274058,0.00065427134,0.00030456856,0.00006384056,0.00003688066,0.000032186686,0.00003431247,0.00531695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863845,0.000076283715,0.00025672078,0.00042305858,0.00018317104,0.0004223356],"domain_scores_gemma":[0.9995683,0.000035156223,0.00006569282,0.00023955152,0.000027742033,0.000063554195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022357801,0.00029038725,0.00049758214,0.00024900312,0.0000561453,0.000015987469,0.00007836098,0.000107878324,0.000045906392],"category_scores_gemma":[0.00001087,0.00023289843,0.00007993929,0.00027127122,0.00010639254,0.00024797246,0.000038116672,0.00022292932,0.0001271365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003002777,0.0015859685,0.73230904,0.000029441226,0.00008941864,0.0006331104,0.002477317,3.9550798e-8,0.18602782,0.000032776064,0.00065112335,0.07316116],"study_design_scores_gemma":[0.009333874,0.00026733853,0.6373514,0.0001801244,0.000018695577,0.0000064393676,0.00009925807,0.00006137206,0.34555504,0.000099171906,0.0065793237,0.0004479511],"about_ca_topic_score_codex":0.00006169758,"about_ca_topic_score_gemma":0.00006330009,"teacher_disagreement_score":0.15952721,"about_ca_system_score_codex":0.0000621589,"about_ca_system_score_gemma":0.000052218184,"threshold_uncertainty_score":0.94973224},"labels":[],"label_agreement":null},{"id":"W2334045336","doi":"10.3851/imp2973","title":"Description and Consequences of Prescribing Off-Label Antiretrovirals in the Madrid Cohort of HIV-Infected Children over a Quarter of a Century (1988–2012)","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fundación Para La Innovación Y La Prospectiva En Salud En España","keywords":"Human immunodeficiency virus (HIV); Medicine; Quarter (Canadian coin); Cohort; Antiretroviral therapy; Antiretroviral treatment; Cohort study; Virology; Viral load; Pediatrics; Internal medicine; History","score_opus":0.07465229108370537,"score_gpt":0.3437738206433544,"score_spread":0.269121529559649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334045336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038583,0.007319593,0.0000077956165,0.0005946755,0.000055340253,0.00052936183,0.0000257088,0.000007871786,0.0010738123],"genre_scores_gemma":[0.991978,0.007643118,0.00007523709,0.00023144309,0.00003484816,0.00000590097,0.000009213514,0.000007098953,0.000015179516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884886,0.00022012404,0.00033746517,0.00014942516,0.0002799794,0.00016416358],"domain_scores_gemma":[0.9993557,0.00014689704,0.00022818575,0.00014719475,0.00008721913,0.000034851382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062094454,0.00011994931,0.0003865897,0.000066433415,0.00002486851,0.000009741022,0.000082394545,0.000055744586,0.000022043198],"category_scores_gemma":[0.00007952151,0.000073385556,0.000050991053,0.00021015968,0.00033587255,0.00025891396,0.00002328407,0.00014329315,9.763475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089824334,0.00036293737,0.8990836,0.00003456259,0.00016537061,0.0000041115586,0.0012200242,1.3381626e-7,0.08932648,0.00015607062,0.00052144274,0.008226995],"study_design_scores_gemma":[0.003802916,0.001251066,0.971231,0.0001451542,0.00009920785,0.000017288847,0.0005000678,0.00007108254,0.021471059,0.00015580957,0.0011563515,0.00009901433],"about_ca_topic_score_codex":0.0004971809,"about_ca_topic_score_gemma":0.0000136622075,"teacher_disagreement_score":0.07214735,"about_ca_system_score_codex":0.00001027504,"about_ca_system_score_gemma":0.000039346054,"threshold_uncertainty_score":0.2992576},"labels":[],"label_agreement":null},{"id":"W2338781044","doi":"10.1177/135965350601100310","title":"Association of Apolipoproteins C3 and E with Metabolic Changes in HIV-Infected Adults Treated with a Protease-Inhibitor-Containing Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Protease inhibitor (pharmacology); Antiretroviral therapy; Lentivirus; Medicine; Human immunodeficiency virus (HIV); Virology; Sida; Internal medicine; Viral load; Immunology; Pharmacology; Viral disease","score_opus":0.01028567247314771,"score_gpt":0.2554069928589985,"score_spread":0.24512132038585077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338781044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954864,0.0011202638,0.000017638395,0.00069770275,0.000008540195,0.0019713657,0.00002521596,0.00008105454,0.00059185066],"genre_scores_gemma":[0.9977178,0.00095097884,0.00040817904,0.00008140971,0.000075646574,0.0002237545,0.000105826344,0.00003992642,0.0003964641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869114,0.00010931395,0.00027871062,0.00032069688,0.00025752274,0.00034259981],"domain_scores_gemma":[0.999241,0.00004366543,0.00028831643,0.00021814585,0.00015497614,0.000053881486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014917996,0.0002448344,0.0005036688,0.00025646557,0.00009578052,0.000017255947,0.000042101503,0.0001276396,0.000010491284],"category_scores_gemma":[0.000007861735,0.00016131127,0.000038888676,0.00059642637,0.00006000318,0.0001178614,0.0000062889935,0.00018321446,0.0000039191023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003461342,0.0006552887,0.96366787,0.000025640264,0.00016574931,0.000021675452,0.00039687962,8.268337e-7,0.0072823674,0.00011362739,0.000016478718,0.024192257],"study_design_scores_gemma":[0.016985744,0.005860067,0.943635,0.00043956673,0.000051901057,0.000014918925,0.00007189325,0.00011911552,0.032128766,0.000024997655,0.00047720375,0.00019086889],"about_ca_topic_score_codex":0.0045958124,"about_ca_topic_score_gemma":0.0009000723,"teacher_disagreement_score":0.0248464,"about_ca_system_score_codex":0.000077806384,"about_ca_system_score_gemma":0.00008728181,"threshold_uncertainty_score":0.69475245},"labels":[],"label_agreement":null},{"id":"W2340099473","doi":"10.1177/135965350701200315","title":"Five-Year Follow up of Once-Daily Therapy with Emtricitabine, Didanosine and Efavirenz (Montana ANRS 091 Trial)","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Emtricitabine; Efavirenz; Didanosine; Tolerability; Medicine; Regimen; Internal medicine; Adverse effect; Lipodystrophy; Gastroenterology; Immunology; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.018782236023382425,"score_gpt":0.27160611842065696,"score_spread":0.25282388239727455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340099473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187696,0.0019210575,0.00007749742,0.0008631575,0.00018540885,0.0011244735,0.000008274528,0.000067215406,0.003875951],"genre_scores_gemma":[0.9796045,0.0034484018,0.001218691,0.0002064803,0.00015856358,0.000022536746,0.00003655333,0.00004924836,0.015255068],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983472,0.000052095602,0.00040692821,0.00037861484,0.00042179253,0.00039333067],"domain_scores_gemma":[0.9991697,0.0001228236,0.00016969616,0.00031181096,0.00011023218,0.000115717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003645845,0.0003328834,0.0006385164,0.00022100535,0.00009824172,0.000021558053,0.00009992677,0.000112506066,0.000059797534],"category_scores_gemma":[0.000014218518,0.00021434583,0.00013447514,0.00049709494,0.00015648169,0.00014541844,0.000016766015,0.00014777733,0.000015322468],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19929855,0.0022314894,0.47696862,0.000042125466,0.0016816993,0.0003884494,0.0060159713,3.1602815e-7,0.020382227,0.00051331124,0.0035539102,0.28892332],"study_design_scores_gemma":[0.42047173,0.012698491,0.36508644,0.00034871406,0.0002106896,0.000048432823,0.0011874426,0.000022324255,0.16152097,0.00021391983,0.0372576,0.00093325495],"about_ca_topic_score_codex":0.00008014316,"about_ca_topic_score_gemma":0.000058467293,"teacher_disagreement_score":0.28799006,"about_ca_system_score_codex":0.000057177418,"about_ca_system_score_gemma":0.00014093937,"threshold_uncertainty_score":0.8740769},"labels":[],"label_agreement":null},{"id":"W2345024104","doi":"10.3851/imp3042","title":"Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Regimen; Hepacivirus; TaqMan; Antigen; Internal medicine; Hepatitis C; Gastroenterology; Chronic hepatitis; Virology; Immunology; Hepatitis C virus; Biology; Real-time polymerase chain reaction; Virus","score_opus":0.12082622205251256,"score_gpt":0.39204449028015853,"score_spread":0.27121826822764594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345024104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806756,0.00028354037,0.00022642598,0.000318401,0.000028109773,0.00091589015,0.00001979234,0.000009963299,0.00013028953],"genre_scores_gemma":[0.96261734,0.037065607,0.00018732743,0.0000352425,0.00001598076,0.000046183788,0.000009071637,0.000013346181,0.0000098831015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985936,0.0002949386,0.00036620616,0.00028622235,0.0002957171,0.00016329084],"domain_scores_gemma":[0.99906117,0.00017203447,0.0001455814,0.00048945897,0.00009395656,0.00003781684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009696429,0.000107237196,0.00026534783,0.00008743743,0.000034162204,0.000010972652,0.00014115669,0.00006672224,0.000017506842],"category_scores_gemma":[0.000054204644,0.000060021917,0.000030335572,0.00016355664,0.00031077155,0.00019511083,0.000051328756,0.00010626754,9.70217e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004618702,0.00019724724,0.5718549,0.00004448636,0.00004882822,0.0000018602626,0.00014008515,8.332684e-9,0.00050590193,0.00001595722,0.000023817165,0.42670506],"study_design_scores_gemma":[0.0028185297,0.0029291902,0.98925024,0.0003515013,0.000017109505,2.9188442e-7,0.000033613996,0.00010407401,0.0035902918,0.00007684869,0.0007584514,0.00006983602],"about_ca_topic_score_codex":0.00075717963,"about_ca_topic_score_gemma":0.0018754315,"teacher_disagreement_score":0.4266352,"about_ca_system_score_codex":0.000026477004,"about_ca_system_score_gemma":0.000020715208,"threshold_uncertainty_score":0.24476229},"labels":[],"label_agreement":null},{"id":"W2395716928","doi":"10.1177/135965350501000210","title":"Dynamic Changes in Clinical Features and Cytokine/Chemokine Responses in Sars Patients Treated with Interferon Alfacon-1 plus Corticosteroids","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; North York General Hospital; Toronto General Hospital; University of Toronto","funders":"","keywords":"CXCL10; Viral load; Cytokine; Immunology; Medicine; Interferon; Chemokine; CCL5; Tumor necrosis factor alpha; Inflammation; Virus; Immune system; T cell","score_opus":0.04254191401554771,"score_gpt":0.37323302649172185,"score_spread":0.33069111247617416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395716928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748623,0.00059774675,0.0000025553272,0.0009883314,0.00003196838,0.00062933395,0.000011476928,0.00003769195,0.00021463522],"genre_scores_gemma":[0.9890018,0.00042115228,0.000056587214,0.010281016,0.000049518672,0.00003347119,0.000013730677,0.00003490177,0.00010780544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998397,0.00019113158,0.0003459592,0.00041995646,0.0002643303,0.0003816562],"domain_scores_gemma":[0.9994047,0.00016910625,0.00007309515,0.00025951088,0.00006059257,0.000032985146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034241215,0.00023131687,0.0004850928,0.0003490391,0.000027837743,0.00003097875,0.00011197632,0.00016082452,0.000004760454],"category_scores_gemma":[0.00007138854,0.00016385541,0.0000480632,0.0003431413,0.00019960759,0.00011973628,0.000045634533,0.00042337962,0.00000870402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01835833,0.00044311592,0.82191825,0.000015119352,0.000041103387,0.00009941304,0.0003442034,9.5555144e-8,0.04291159,0.0000016591974,0.000047650425,0.115819484],"study_design_scores_gemma":[0.01304718,0.0044703474,0.91226685,0.00019290559,0.000010161963,0.00001718126,0.000060565137,0.0002720265,0.06667271,0.000005662956,0.0028024851,0.00018193208],"about_ca_topic_score_codex":0.0002498286,"about_ca_topic_score_gemma":0.0023670292,"teacher_disagreement_score":0.115637556,"about_ca_system_score_codex":0.00013471468,"about_ca_system_score_gemma":0.00008147621,"threshold_uncertainty_score":0.66818297},"labels":[],"label_agreement":null},{"id":"W2397692736","doi":"10.3851/imp3010","title":"Efficacy and Safety of a Switch to Rilpivirine-Based Regimens in Treatment-Experienced HIV-1-Infected Patients: A Cohort Study","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rilpivirine; Medicine; Human immunodeficiency virus (HIV); Cohort; Internal medicine; Cohort study; Antiretroviral therapy; Viral load; Oncology; Virology","score_opus":0.024745624430365838,"score_gpt":0.3018561189093522,"score_spread":0.2771104944789864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397692736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956043,0.0000565915,0.000016367325,0.0004843037,0.00004245557,0.0031034292,0.000007470746,0.00004763154,0.00063744554],"genre_scores_gemma":[0.9979781,0.000045319153,0.00033597054,0.00008988233,0.000016835542,0.00017405713,0.000059356145,0.000023723263,0.0012767783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986194,0.000102148275,0.00035229215,0.00037544215,0.00029442782,0.0002563098],"domain_scores_gemma":[0.9992993,0.00006683644,0.000079963094,0.0002953752,0.000110656794,0.00014787725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018216294,0.00025351456,0.00055052934,0.00022500572,0.000037503956,0.000010774739,0.000056556728,0.00004957878,0.000019080539],"category_scores_gemma":[0.000046499765,0.0001797715,0.000050677867,0.00046659223,0.000050415056,0.00007050291,0.000021566479,0.00005748886,0.000026282434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040241103,0.005200139,0.9756896,0.0000035285009,0.00018408145,0.00004027319,0.0062924908,0.000001846021,0.00061558286,0.000005168895,0.00013047818,0.007812737],"study_design_scores_gemma":[0.03933084,0.0045531085,0.94829303,0.000060168295,0.00004654374,0.0000010183209,0.0004791149,0.000022922588,0.00554642,0.0000025224597,0.0014916039,0.00017272387],"about_ca_topic_score_codex":0.00011642964,"about_ca_topic_score_gemma":0.000055698314,"teacher_disagreement_score":0.035306733,"about_ca_system_score_codex":0.00016539678,"about_ca_system_score_gemma":0.00014177512,"threshold_uncertainty_score":0.7330869},"labels":[],"label_agreement":null},{"id":"W2398926585","doi":"10.1177/135965350100600108","title":"Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Antiretroviral drug; Drug resistance; Human immunodeficiency virus (HIV); Medicine; Drug-naïve; Internal medicine; Drug; Antiretroviral therapy; HIV drug resistance; Didanosine; Viral load; Efavirenz; Pharmacology; Virology; Biology; Genetics","score_opus":0.011982501845383724,"score_gpt":0.26320116213799166,"score_spread":0.2512186602926079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398926585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906464,0.000272747,0.000005318613,0.0026751517,0.00010924679,0.0009787729,0.000010759469,0.000047179143,0.0052544246],"genre_scores_gemma":[0.9627319,0.0008326002,0.0008290984,0.0003920041,0.00005728498,0.00008097497,0.00009388032,0.000031717,0.03495056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832106,0.000076540826,0.00037187446,0.00042107922,0.00032368978,0.00048577954],"domain_scores_gemma":[0.99952596,0.000030075358,0.000067718414,0.0002395022,0.000053091568,0.000083641804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001877571,0.00025505843,0.00039785993,0.00036212624,0.000050839095,0.000020771553,0.00011635904,0.0000631376,0.00007085739],"category_scores_gemma":[0.000020963203,0.0002120843,0.00008261819,0.0007644518,0.000041070147,0.00015797825,0.000031845422,0.00015835912,0.00036701912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009698813,0.00080077955,0.97882915,0.000013449693,0.000027739978,0.00013337214,0.0027598876,2.2240476e-7,0.00031601137,0.00012127649,0.0049715242,0.011056714],"study_design_scores_gemma":[0.0067054154,0.00018437128,0.9548524,0.00030258455,0.0000073891824,0.0000011007472,0.00032937716,0.000007850063,0.00629017,0.000120554185,0.030898094,0.00030069883],"about_ca_topic_score_codex":0.000053769036,"about_ca_topic_score_gemma":0.00018760879,"teacher_disagreement_score":0.029696139,"about_ca_system_score_codex":0.00015316001,"about_ca_system_score_gemma":0.00006459336,"threshold_uncertainty_score":0.86485463},"labels":[],"label_agreement":null},{"id":"W2400934244","doi":"10.1177/135965350400900215","title":"Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Amprenavir; Univariate analysis; Medicine; Regimen; Lentivirus; Multivariate analysis; Virology; Internal medicine; Protease; Biology; Molecular biology; Gastroenterology; Human immunodeficiency virus (HIV); HIV-1 protease; Viral disease","score_opus":0.04791851658269943,"score_gpt":0.33075501861853995,"score_spread":0.28283650203584054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400934244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95845985,0.00005131414,0.000035006837,0.039949365,0.000017978491,0.00061417976,0.0000047870403,0.00001974304,0.0008477805],"genre_scores_gemma":[0.9973125,0.00015266036,0.00007166921,0.0015338127,0.00003052009,0.000058061745,0.000009566825,0.000010023554,0.00082120823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901474,0.00023872312,0.00018206626,0.00016666758,0.00020234198,0.00019548854],"domain_scores_gemma":[0.9993373,0.00023677619,0.000043062348,0.00032742452,0.000021962025,0.00003344629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004013871,0.0001433798,0.00019260295,0.00010764548,0.00007647647,0.000011248738,0.00014017985,0.000057223617,0.00002822848],"category_scores_gemma":[0.0000625163,0.000059060814,0.0001481566,0.0003888305,0.00007573752,0.000036630674,0.000013750309,0.00016198424,0.00014807242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07087354,0.010254696,0.64637434,0.000011825187,0.00080368633,0.0009881043,0.045912653,0.00021966085,0.15648176,0.0071474398,0.01711805,0.043814242],"study_design_scores_gemma":[0.0028410708,0.0022251606,0.98382574,0.00007847755,0.000011692619,0.000018828112,0.00020017165,0.0000037061382,0.0054974006,0.0005235034,0.0046789744,0.00009524446],"about_ca_topic_score_codex":0.000043986274,"about_ca_topic_score_gemma":0.000011013967,"teacher_disagreement_score":0.33745143,"about_ca_system_score_codex":0.00008374703,"about_ca_system_score_gemma":0.0000865167,"threshold_uncertainty_score":0.240843},"labels":[],"label_agreement":null},{"id":"W2401749080","doi":"10.1177/135965350901400304","title":"Predictive value of immune parameters before treatment interruption (TI) for CD4 <sup>+</sup> T-cell count change during TI in HIV infection","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; McGill University Health Centre","funders":"","keywords":"CD8; Peripheral blood mononuclear cell; T cell; Immunology; Cart; Viral load; Immune system; Medicine; Surrogate endpoint; Internal medicine; CD28; Gastroenterology; Biology; Human immunodeficiency virus (HIV); In vitro","score_opus":0.04319101484268174,"score_gpt":0.2893590897591211,"score_spread":0.24616807491643938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401749080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967324,0.0012712025,0.000121093726,0.00009254409,0.00010103413,0.0013004497,0.00019044364,0.000038010352,0.00015281547],"genre_scores_gemma":[0.99457127,0.0037132178,0.00005983043,0.000014708522,0.000029842007,0.00049229455,0.0004570755,0.000020984928,0.0006407524],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988449,0.00016595842,0.0002856537,0.0002764248,0.000047698424,0.00037935542],"domain_scores_gemma":[0.99955964,0.00006849789,0.00010782867,0.00019717329,0.00004933124,0.000017530938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011871112,0.00021045333,0.0003341449,0.00019929805,0.00014209122,0.000005403621,0.00008118624,0.000157375,0.000039378127],"category_scores_gemma":[0.000009513055,0.00016272343,0.0001906383,0.00012682995,0.00017027777,0.00016329948,0.000021053524,0.00012680738,0.00009413844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010112614,0.0050771814,0.5916806,0.000101318416,0.0014793891,0.000056817214,0.02615241,0.00019316608,0.31218758,0.00013528143,0.0001833882,0.05264029],"study_design_scores_gemma":[0.015117602,0.008715143,0.40060994,0.00010540619,0.000034725883,0.00003406859,0.0002861697,0.00025473576,0.5726671,0.00009612719,0.001846875,0.00023209014],"about_ca_topic_score_codex":0.0010745788,"about_ca_topic_score_gemma":0.000062930056,"teacher_disagreement_score":0.26047954,"about_ca_system_score_codex":0.00022309089,"about_ca_system_score_gemma":0.00004232106,"threshold_uncertainty_score":0.6635669},"labels":[],"label_agreement":null},{"id":"W2405604868","doi":"10.1177/135965350300800202","title":"Prevalence and clinical implications of insertions in the HIV-1 p6 <sup>Gag</sup> N-terminal region in drug-naive individuals initiating antiretroviral therapy","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Virology; Lentivirus; Drug resistance; Zidovudine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Proportional hazards model; Medicine; Viral load; Biology; Hazard ratio; Internal medicine; Immunology; Confidence interval; Viral disease; Genetics","score_opus":0.05621731728574788,"score_gpt":0.3470232791541528,"score_spread":0.29080596186840496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405604868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352866,0.0042350907,0.00001584685,0.00074504927,0.00002950635,0.00064696843,0.00007761102,0.000013714237,0.0007075368],"genre_scores_gemma":[0.9857853,0.013601128,0.00006163651,0.00026486916,0.000014602112,0.0000878523,0.000065879954,0.000011337248,0.0001073622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970863,0.0016502423,0.0005015524,0.00032542477,0.00006307071,0.00037342616],"domain_scores_gemma":[0.9988092,0.00065226073,0.0001477767,0.00032889776,0.000043004962,0.000018831863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095820584,0.00017464759,0.0002995323,0.00017216774,0.00016702223,0.00002131184,0.00026009182,0.00014635781,0.000038272257],"category_scores_gemma":[0.000114957395,0.00012032005,0.000097987446,0.00033595107,0.00045641587,0.00017693077,0.000028955492,0.00043580314,0.00006191306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114219365,0.00069836003,0.96586597,0.000008275986,0.00006915675,0.00001786735,0.0021790592,5.9485575e-7,0.0012282365,0.0011787667,0.00025784978,0.02838163],"study_design_scores_gemma":[0.0036486625,0.0007988447,0.9899775,0.00006788209,0.0000095206815,0.00006688777,0.00052301213,0.0000025606455,0.0020207951,0.0007667042,0.0019783473,0.00013931288],"about_ca_topic_score_codex":0.00011570742,"about_ca_topic_score_gemma":0.000029228777,"teacher_disagreement_score":0.028242318,"about_ca_system_score_codex":0.000020326746,"about_ca_system_score_gemma":0.00009979661,"threshold_uncertainty_score":0.49065095},"labels":[],"label_agreement":null},{"id":"W2406362442","doi":"10.3851/imp2908","title":"Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada","year":2014,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Nevirapine; Tolerability; Medicine; Internal medicine; Adverse effect; Population; Pharmacology; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy; Environmental health","score_opus":0.0043824124745371,"score_gpt":0.22208401534603697,"score_spread":0.21770160287149987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406362442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984434,0.00019999278,0.000012076315,0.0002731518,0.0000292094,0.00092149695,0.0000069470652,0.00002283611,0.00009088031],"genre_scores_gemma":[0.99901557,0.000045447774,0.00021490155,0.00032969596,0.0000144073465,0.00015149187,0.00005073102,0.000018797726,0.00015897072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985003,0.00031767978,0.00026962772,0.00040407848,0.00023743387,0.00027087014],"domain_scores_gemma":[0.99933773,0.00028188562,0.000063501844,0.00018307981,0.00006257177,0.00007122146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006155334,0.00014001862,0.0004220926,0.00005135835,0.00008207229,0.000052475916,0.000046572884,0.000047514717,0.000032087544],"category_scores_gemma":[0.00015039252,0.00015888746,0.000023187975,0.00028439722,0.00005454889,0.00008840012,0.000010259811,0.00012167089,4.2207776e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058387057,0.0002220012,0.9621829,0.000050998624,0.000021194379,0.00013521298,0.00010202438,0.000003949589,0.0005408295,9.3780636e-7,0.000008736239,0.036147356],"study_design_scores_gemma":[0.0047447057,0.00017839532,0.993443,0.00048446772,0.000007727143,0.000011218625,0.00008279838,0.00042047835,0.00030320036,0.000009740302,0.000127335,0.00018692783],"about_ca_topic_score_codex":0.7839292,"about_ca_topic_score_gemma":0.9308117,"teacher_disagreement_score":0.14688247,"about_ca_system_score_codex":0.0002311788,"about_ca_system_score_gemma":0.0002922048,"threshold_uncertainty_score":0.64792424},"labels":[],"label_agreement":null},{"id":"W2409673291","doi":"10.1177/135965350901400408","title":"Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Abbott Laboratories","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Medicine; Tolerability; Regimen; Pharmacokinetics; Gastroenterology; Internal medicine; Area under the curve; Interquartile range; Pharmacology; Viral load; Human immunodeficiency virus (HIV); Adverse effect; Antiretroviral therapy; Immunology","score_opus":0.0372966081615957,"score_gpt":0.30808345389957575,"score_spread":0.27078684573798006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409673291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625397,0.00086237665,0.0000047438884,0.0006986964,0.000080696824,0.0007514984,0.000021049034,0.00004745693,0.0012795114],"genre_scores_gemma":[0.9917006,0.006358009,0.00054836593,0.000047821577,0.00006819276,0.000031991414,0.000094060284,0.000021766527,0.0011292049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878854,0.000074208365,0.00034108947,0.00033139295,0.00020054073,0.00026425198],"domain_scores_gemma":[0.9994835,0.000081551974,0.00008271143,0.00023001363,0.000046507867,0.00007569428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000075585966,0.00026234883,0.00051111844,0.00012047645,0.00005987614,0.000005777208,0.000057588484,0.00008017221,0.00004711788],"category_scores_gemma":[0.000009582619,0.00020096602,0.0000990882,0.00026496203,0.00018114057,0.00006997981,0.000020393052,0.000110615394,0.000020059173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023374709,0.0014605512,0.93336064,0.000010613522,0.0002724715,0.00008683425,0.0014072075,8.8649784e-7,0.004830212,0.000021434706,0.00010934102,0.056102347],"study_design_scores_gemma":[0.021853477,0.0014234215,0.91801494,0.000051953357,0.000059581456,0.000029642842,0.000035479585,0.000046003624,0.05474895,0.000014552407,0.0035131501,0.00020885716],"about_ca_topic_score_codex":0.00016725858,"about_ca_topic_score_gemma":0.000027793296,"teacher_disagreement_score":0.05589349,"about_ca_system_score_codex":0.00012256793,"about_ca_system_score_gemma":0.00011611208,"threshold_uncertainty_score":0.81951565},"labels":[],"label_agreement":null},{"id":"W2410585105","doi":"10.3851/imp3028","title":"Artesunate Demonstrates <i>in vitro</i> Synergism with Several Antiviral Agents against Human Cytomegalovirus","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Foscarnet; Ganciclovir; Human cytomegalovirus; Cidofovir; Artesunate; Pharmacology; Virology; In vitro; Biology; Virus; Immunology; Biochemistry","score_opus":0.05600981701911194,"score_gpt":0.32991627976030635,"score_spread":0.2739064627411944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410585105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95605946,0.00052182924,0.000036386602,0.00055158045,0.000108540466,0.0007904149,0.000030668685,0.00015815796,0.04174296],"genre_scores_gemma":[0.995033,0.0007054677,0.0003970271,0.0013847767,0.00027161304,0.000051300507,0.000110950146,0.000107030115,0.0019387976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99662256,0.000194186,0.00052463776,0.00070781854,0.0008989692,0.0010518242],"domain_scores_gemma":[0.9986946,0.00005347484,0.00013655327,0.00056972646,0.00019298308,0.0003526381],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067388,0.00050812226,0.00081152783,0.00047560653,0.00017877278,0.00015522893,0.00030596417,0.0002236551,0.000041330408],"category_scores_gemma":[0.00002281182,0.00038829658,0.00019682846,0.0008586495,0.00036708062,0.0005173019,0.00007587711,0.0007440642,0.00029212056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010003804,0.001803942,0.17041463,0.00005425145,0.00042095577,0.0032154953,0.0011230168,0.000029866587,0.7236483,0.00046906326,0.003875069,0.084941596],"study_design_scores_gemma":[0.04459259,0.0047006817,0.14569412,0.0004891912,0.00006834921,0.00019197965,0.00077797443,0.0026756357,0.7110218,0.0010924854,0.08647229,0.0022229257],"about_ca_topic_score_codex":0.00053367903,"about_ca_topic_score_gemma":0.00015996941,"teacher_disagreement_score":0.08271867,"about_ca_system_score_codex":0.00018865964,"about_ca_system_score_gemma":0.0003683571,"threshold_uncertainty_score":0.9998569},"labels":[],"label_agreement":null},{"id":"W2411572535","doi":"10.1177/135965350701200417","title":"Recent Advances in the Search for Antiviral Agents against Human Papillomaviruses","year":2007,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Genital warts; Medicine; HPV vaccines; Sex organ; HPV infection; Cervical cancer; Immunology; Virology; Papillomaviridae; Anal cancer; Human papillomavirus; Cancer; Bioinformatics; Biology; Internal medicine; Genetics","score_opus":0.301906594557629,"score_gpt":0.5257281152180348,"score_spread":0.22382152066040573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411572535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025491777,0.9558715,0.000013615385,0.00015563298,0.00019018282,0.002832587,0.000071702154,0.00003713468,0.040572684],"genre_scores_gemma":[0.0006746797,0.99594605,0.00003456475,0.0011796313,0.0008195319,0.00025807574,0.00041233381,0.000097396245,0.0005777545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965114,0.00042111866,0.0007029427,0.0006551599,0.0008417985,0.00086756604],"domain_scores_gemma":[0.9984287,0.0004928316,0.0001335976,0.00064485776,0.00021304429,0.000086957465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014563816,0.00049178663,0.001587695,0.0003354626,0.00021308822,0.00008212208,0.00053298904,0.0003245866,0.00024058887],"category_scores_gemma":[0.000048817335,0.0002895322,0.00071340066,0.0009909521,0.00021847447,0.00015132435,0.00007384042,0.0010003429,0.00008682768],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024113046,0.00036642037,0.0002556257,0.0032938288,0.00009549435,0.00012561498,0.00010303924,2.7330495e-8,0.000008836307,0.00023198703,0.0009023154,0.9943757],"study_design_scores_gemma":[0.0017513793,0.0005722517,0.00077220757,0.0014232137,0.000060661925,0.00000874644,0.000060560265,0.0000010210023,0.0001327954,0.0001251997,0.99477744,0.0003145414],"about_ca_topic_score_codex":0.0000128483625,"about_ca_topic_score_gemma":0.00008545665,"teacher_disagreement_score":0.9940611,"about_ca_system_score_codex":0.00016951693,"about_ca_system_score_gemma":0.00040107995,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W2412571829","doi":"10.1177/135965350400900407","title":"Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Amprenavir; Lopinavir; Ritonavir; Lopinavir/ritonavir; Medicine; Virology; Reverse-transcriptase inhibitor; Viral load; Internal medicine; Gastroenterology; Biology; Virus; Antiretroviral therapy; Protease; HIV-1 protease; Enzyme","score_opus":0.01476171776978681,"score_gpt":0.25943529803548254,"score_spread":0.24467358026569574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412571829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543625,0.00049889006,0.00001821086,0.002214723,0.000042427615,0.0012200604,0.000013625165,0.000092912094,0.0004629056],"genre_scores_gemma":[0.99397117,0.0032317294,0.0010681025,0.0006378827,0.000051409894,0.00010004506,0.00015021939,0.000048367856,0.00074109435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804276,0.00011528541,0.00038927607,0.00057683076,0.0003346114,0.0005412212],"domain_scores_gemma":[0.99940956,0.00006853237,0.0000912677,0.00027363756,0.00004788094,0.00010910243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014715592,0.00044313943,0.00061965914,0.0002574588,0.00007876626,0.000038324673,0.000115509276,0.00022045289,0.000114040195],"category_scores_gemma":[0.00001357183,0.00026504122,0.00006928642,0.00061589293,0.00017452831,0.00023765041,0.00003248768,0.000388827,0.0000583067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004609797,0.0023412216,0.96725166,0.000013556615,0.00010612819,0.000577042,0.0012533673,0.0000023993225,0.002334945,0.00009344692,0.00013824848,0.021278184],"study_design_scores_gemma":[0.037387293,0.0023644827,0.94878596,0.00029757406,0.000013794348,0.000025272326,0.000104801205,0.00000772242,0.004791543,0.0002437503,0.005554404,0.00042339033],"about_ca_topic_score_codex":0.00015125384,"about_ca_topic_score_gemma":0.0005362298,"teacher_disagreement_score":0.032777496,"about_ca_system_score_codex":0.00015034659,"about_ca_system_score_gemma":0.00014364462,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W2413643247","doi":"10.1177/135965350801301s03","title":"Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Hepatitis C virus; Medicine; Internal medicine; Viral load; Genotype; Hepatitis C; Hepacivirus; Chronic hepatitis; Gastroenterology; Virus; Immunology; Biology; Gene","score_opus":0.04796626981172269,"score_gpt":0.3164073012733263,"score_spread":0.2684410314616036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413643247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966709,0.00009765408,0.000048082387,0.00017519553,0.000051691044,0.0006101572,0.000015304131,0.00005732193,0.0022737035],"genre_scores_gemma":[0.99331355,0.0028907408,0.0018655782,0.0006043981,0.00003772102,0.000028187229,0.000024813775,0.000047377634,0.0011876215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985176,0.00007453422,0.00023050181,0.000270113,0.0005044336,0.00040286712],"domain_scores_gemma":[0.9994003,0.00006288733,0.00004639872,0.00030166286,0.000104523504,0.00008420115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010301053,0.00018184785,0.00039865403,0.00019385987,0.00009273794,0.000014099083,0.00011213333,0.000078408615,0.00033316787],"category_scores_gemma":[0.00005010669,0.00011513304,0.000057306683,0.0003708739,0.00012035837,0.00018843607,0.000027682527,0.0002433548,0.00015185663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014973427,0.00042694216,0.97221166,0.0000063642046,0.0000636431,0.00030386247,0.00046268394,0.0000013455474,0.0005200267,0.0000066718458,0.00017342351,0.024326034],"study_design_scores_gemma":[0.0053715627,0.0016274822,0.9866398,0.000038744893,0.0000039405018,0.0000029865116,0.0000056112963,0.000035451994,0.0030336531,0.0000046705454,0.0030706918,0.00016538888],"about_ca_topic_score_codex":0.0017832057,"about_ca_topic_score_gemma":0.0008444894,"teacher_disagreement_score":0.024160646,"about_ca_system_score_codex":0.0000774052,"about_ca_system_score_gemma":0.00014687673,"threshold_uncertainty_score":0.46949893},"labels":[],"label_agreement":null},{"id":"W2415009490","doi":"10.1177/135965350501000801","title":"TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals <i>in Vitro</i>","year":2005,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pharmacology; Drug; Protease inhibitor (pharmacology); CCR5 receptor antagonist; In vitro; Medicine; Human immunodeficiency virus (HIV); Chemistry; Internal medicine; Antiretroviral therapy; Virology; Viral load; Inflammation; Chemokine receptor; Biochemistry","score_opus":0.030810820858888907,"score_gpt":0.2673798028364486,"score_spread":0.23656898197755966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415009490","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10591438,0.0020907284,0.000146117,0.86593413,0.00071174384,0.0026475703,0.00023089713,0.00038411687,0.021940317],"genre_scores_gemma":[0.15070838,0.0014344377,0.007045964,0.43093717,0.005887589,0.0003775571,0.0013282673,0.0005217868,0.40175885],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679846,0.00010567541,0.0006401012,0.0008946872,0.0006758728,0.0008852182],"domain_scores_gemma":[0.99870485,0.00013278701,0.0003178984,0.0006528814,0.00010336058,0.00008820571],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019868721,0.00088091666,0.0012418799,0.00061603385,0.00018563902,0.00016093941,0.00024201308,0.0003610063,0.00031876558],"category_scores_gemma":[0.000009238672,0.00063478365,0.00033631478,0.00055441196,0.00021212905,0.0003767439,0.000038858107,0.0018090656,0.00044578803],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001407986,0.0014756446,0.010007663,0.00009317315,0.0010514212,0.0010897461,0.001172533,7.163567e-7,0.03397018,0.000009365153,0.93452245,0.015199119],"study_design_scores_gemma":[0.0067760814,0.00018588097,0.00034475786,0.0006726192,0.00011371232,0.000095842785,0.000069773494,0.000013339101,0.042435642,0.0000099598965,0.948589,0.0006933679],"about_ca_topic_score_codex":0.00029798286,"about_ca_topic_score_gemma":0.00011005674,"teacher_disagreement_score":0.43499696,"about_ca_system_score_codex":0.0003186268,"about_ca_system_score_gemma":0.00037011542,"threshold_uncertainty_score":0.99961036},"labels":[],"label_agreement":null},{"id":"W2415049193","doi":"10.1177/135965350400900414","title":"Predictive Value of HIV-1 Protease Genotype and Virtual Phenotype on the Virological Response to Lopinavir/Ritonavir-Containing Salvage Regimens","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver; University Health Network; McGill University; University of Toronto; Montreal General Hospital","funders":"","keywords":"Lopinavir; Lopinavir/ritonavir; Ritonavir; Internal medicine; Virology; Viral load; Regimen; Odds ratio; Population; Univariate analysis; Genotype; Salvage therapy; Biology; Medicine; Oncology; Immunology; Multivariate analysis; Human immunodeficiency virus (HIV); Genetics; Antiretroviral therapy; Chemotherapy","score_opus":0.021165686277663992,"score_gpt":0.2760755676495867,"score_spread":0.2549098813719227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415049193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850572,0.00019594344,0.0002592134,0.0122366985,0.00005073451,0.0013878137,0.00002155543,0.00006004455,0.0007308003],"genre_scores_gemma":[0.9960331,0.00011263099,0.00081635185,0.0015126353,0.00008364849,0.00008874658,0.000015108229,0.000029274395,0.0013085353],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985087,0.00022917932,0.0002583066,0.00037843356,0.0003258966,0.00029951724],"domain_scores_gemma":[0.99917585,0.00025103719,0.00008698899,0.0003167394,0.000058593407,0.00011082367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052298285,0.0002571314,0.00036269796,0.00010534463,0.00015130555,0.000016652686,0.00011300435,0.00010439064,0.000031206466],"category_scores_gemma":[0.00013436911,0.00015371591,0.00008552917,0.0002248174,0.00018305871,0.00006688826,0.000050738152,0.00022934364,0.00009141113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2424036,0.0040920135,0.08000262,0.000045567613,0.0017338942,0.0011663518,0.03350299,0.00016939845,0.54591835,0.045108724,0.0015359956,0.044320483],"study_design_scores_gemma":[0.018134004,0.029717185,0.73755103,0.0007196058,0.00018069767,0.00005115192,0.0017772467,0.00008492078,0.19648692,0.0027370816,0.0117821,0.00077805464],"about_ca_topic_score_codex":0.00001807171,"about_ca_topic_score_gemma":0.0000013451967,"teacher_disagreement_score":0.6575484,"about_ca_system_score_codex":0.00009371269,"about_ca_system_score_gemma":0.00015300565,"threshold_uncertainty_score":0.6268353},"labels":[],"label_agreement":null},{"id":"W2416661311","doi":"10.1177/135965350501000119","title":"Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; McGill University; Jewish General Hospital","funders":"","keywords":"Tolerability; Clinical trial; Drug resistance; Nucleoside Reverse Transcriptase Inhibitor; Reverse transcriptase; Drug development; Clinical study design; Medicine; Pharmacodynamics; Pharmacology; Reverse-transcriptase inhibitor; Intensive care medicine; Biology; Drug; Human immunodeficiency virus (HIV); Bioinformatics; Pharmacokinetics; Virology; Antiretroviral therapy; Viral load; Adverse effect; Genetics; RNA","score_opus":0.12900661530849614,"score_gpt":0.3734704503012295,"score_spread":0.24446383499273336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416661311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416032,0.004147348,0.006196114,0.043276303,0.0005670795,0.003380524,0.000014953478,0.000099524645,0.0007149688],"genre_scores_gemma":[0.9464714,0.0088125905,0.034548,0.0005993014,0.0008716859,0.00019870044,0.000052986044,0.00004612374,0.008399236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998909,0.00002745253,0.00047759057,0.00023441242,0.00014433985,0.00020719423],"domain_scores_gemma":[0.9993978,0.0001820896,0.00011109501,0.0001763642,0.00006819396,0.000064457294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050742354,0.00016714302,0.00031373487,0.00006118303,0.000120288925,0.000007496494,0.00005938091,0.000091344584,0.000022140694],"category_scores_gemma":[0.00003238699,0.0001051139,0.0002666517,0.00007329424,0.00005002764,0.00008945834,0.000007021413,0.000079999045,0.000019524225],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011471285,0.00055496814,0.010095448,0.00003994677,0.00043611965,9.034492e-7,0.0032055448,6.7785226e-7,0.001505574,0.00021284002,0.02604888,0.95675194],"study_design_scores_gemma":[0.0073872115,0.00035814606,0.028248895,0.0000877754,0.000096768556,0.000002197534,0.00017730726,0.000050449784,0.057992157,0.00008818261,0.90537256,0.00013833951],"about_ca_topic_score_codex":0.0000056401054,"about_ca_topic_score_gemma":0.00005957838,"teacher_disagreement_score":0.9566136,"about_ca_system_score_codex":0.000038845938,"about_ca_system_score_gemma":0.00020800183,"threshold_uncertainty_score":0.42864203},"labels":[],"label_agreement":null},{"id":"W2417874692","doi":"10.1177/135965350801300104","title":"The Prophylactic Administration of a Monoclonal Antibody against Human Metapneumovirus Attenuates viral Disease and Airways Hyperresponsiveness in Mice","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Respiratory viral infections research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Human metapneumovirus; Monoclonal antibody; Immunology; Respiratory disease; Respiratory tract; Respiratory system; Lung; Antibody; Respiratory tract infections; Internal medicine","score_opus":0.05465177580044545,"score_gpt":0.37142260249998305,"score_spread":0.3167708266995376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417874692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968315,0.0015882029,0.000009468029,0.00045058315,0.000042315154,0.0007139962,0.0000087982135,0.00002563452,0.0003295287],"genre_scores_gemma":[0.9977173,0.001766223,0.00002653052,0.00013686361,0.00006935058,0.000056173565,0.000017040576,0.00002445081,0.0001860751],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983964,0.00032193577,0.00036536148,0.00028794195,0.00034986035,0.00027852744],"domain_scores_gemma":[0.9991948,0.00017911042,0.00011144359,0.000282038,0.00013610898,0.00009650033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040053457,0.00018154128,0.00029450137,0.00020484532,0.0003478891,0.00003313559,0.00011671429,0.00006240707,0.0000069298117],"category_scores_gemma":[0.00013461437,0.00012472738,0.00009766917,0.00035975088,0.0005456164,0.00024627658,0.000034952398,0.00026354636,0.000009943034],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036312551,0.00038745784,0.18517733,0.000030176703,0.00005275641,0.00031337552,0.00012398485,0.000003147102,0.8023542,0.00022279074,0.000012481482,0.007691038],"study_design_scores_gemma":[0.0019108062,0.0014999585,0.81475604,0.0000457395,0.000015818809,0.000044266966,0.00006690297,0.00021967189,0.18021771,0.00018697318,0.000872267,0.00016383544],"about_ca_topic_score_codex":0.00009069827,"about_ca_topic_score_gemma":0.000025692245,"teacher_disagreement_score":0.6295787,"about_ca_system_score_codex":0.0000383354,"about_ca_system_score_gemma":0.00030242113,"threshold_uncertainty_score":0.5086235},"labels":[],"label_agreement":null},{"id":"W2418527354","doi":"10.1177/135965350100600105","title":"Predictors of Virological Response in HIV-Infected Patients to Salvage Antiretroviral Therapy that Includes Nelfinavir","year":2001,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of Toronto; University Health Network","funders":"","keywords":"Nelfinavir; Salvage therapy; Medicine; Reverse transcriptase; Internal medicine; Protease inhibitor (pharmacology); Reverse-transcriptase inhibitor; Viral load; Virology; Indinavir; Zidovudine; Sida; Population; Lentivirus; Cohort; Human immunodeficiency virus (HIV); Gastroenterology; Biology; Viral disease; Antiretroviral therapy; Chemotherapy; RNA","score_opus":0.025609689694692822,"score_gpt":0.28316745155591944,"score_spread":0.2575577618612266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418527354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638504,0.00018885841,0.000027274722,0.0014215924,0.00012196355,0.0010189692,0.000018001643,0.00010289424,0.00071538554],"genre_scores_gemma":[0.99597585,0.0012564752,0.00028687515,0.00072445004,0.00005464763,0.00004638434,0.00007849164,0.000039329087,0.00153752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978646,0.00030507616,0.0004307188,0.0004249835,0.00046363266,0.0005109571],"domain_scores_gemma":[0.99913895,0.00016959068,0.000117062555,0.00034032733,0.00007206805,0.00016200414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044878357,0.00034011248,0.0006016015,0.00040938167,0.00007149591,0.00001739886,0.00016969464,0.0001700015,0.0001166111],"category_scores_gemma":[0.000111740774,0.00024071145,0.00016213059,0.0007095106,0.0001150148,0.00016016954,0.00005913458,0.0002002511,0.00007712145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019199602,0.0016963445,0.9419588,0.000004194957,0.000115330084,0.00013825983,0.0013138268,0.0000010254337,0.022774307,0.000010769771,0.00066765654,0.012119913],"study_design_scores_gemma":[0.008443745,0.0040445602,0.9476951,0.00007296753,0.000011536115,0.000004509722,0.00005471119,0.0000114701525,0.030943656,0.000026340502,0.008467173,0.00022427567],"about_ca_topic_score_codex":0.00003025903,"about_ca_topic_score_gemma":0.000006416192,"teacher_disagreement_score":0.011895636,"about_ca_system_score_codex":0.00011015873,"about_ca_system_score_gemma":0.000107176646,"threshold_uncertainty_score":0.9815928},"labels":[],"label_agreement":null},{"id":"W2419179490","doi":"10.1177/135965350300800511","title":"HIV Lipodystrophy Case Definition using Artificial Neural Network Modelling","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Toronto Western Hospital; St. Paul's Hospital; Montreal General Hospital","funders":"","keywords":"Logistic regression; Lipodystrophy; Artificial neural network; Regression analysis; Regression; Statistics; Artificial intelligence; Machine learning; Computer science; Medicine; Human immunodeficiency virus (HIV); Mathematics; Antiretroviral therapy","score_opus":0.11529193465511006,"score_gpt":0.33139837626358815,"score_spread":0.21610644160847808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419179490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97868496,0.0007912948,0.017338816,0.0001919755,0.00014281282,0.00034344252,0.0000065089976,0.000063696156,0.0024364756],"genre_scores_gemma":[0.9874137,0.00018420457,0.01178982,0.00027908836,0.00020257084,0.000013473055,0.0000319209,0.000027652843,0.00005753988],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990296,0.000083656014,0.0002517317,0.00021939691,0.00010622364,0.00030939418],"domain_scores_gemma":[0.9995359,0.000034109078,0.000075308,0.00021645213,0.000059462407,0.0000787489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010292834,0.00014115583,0.00019660583,0.00005969979,0.000349947,0.00002116755,0.000024939594,0.00008364156,0.000042563555],"category_scores_gemma":[0.0000042898128,0.00012277739,0.000086195345,0.0002573953,0.000034267567,0.00008257744,0.000003993323,0.00016985461,0.00007752323],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048196753,0.008645131,0.1910964,0.0002572229,0.0017045836,0.019183885,0.0034356106,0.16535293,0.03086235,0.357617,0.002510013,0.21451522],"study_design_scores_gemma":[0.010709988,0.0027766265,0.0027189848,0.00053738547,0.0005041445,0.011221903,0.00040867392,0.9046672,0.0065320404,0.048392214,0.01017499,0.0013558525],"about_ca_topic_score_codex":0.0000644584,"about_ca_topic_score_gemma":0.0000022519037,"teacher_disagreement_score":0.73931426,"about_ca_system_score_codex":0.00004488821,"about_ca_system_score_gemma":0.00005655418,"threshold_uncertainty_score":0.5006717},"labels":[],"label_agreement":null},{"id":"W2419820409","doi":"10.1177/135965350601100315","title":"Oligonucleotide-Based Therapeutic Options against Hepatitis C Virus Infection","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Ribozyme; Hepatitis C virus; Virology; Oligonucleotide; Biology; Computational biology; Hepatitis C; Virus; RNA; DNA; Genetics; Gene","score_opus":0.034396012841801465,"score_gpt":0.31922700220882977,"score_spread":0.28483098936702833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419820409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785484,0.00059097214,0.0015421367,0.00080208306,0.00016479584,0.00062482274,0.000025522093,0.0002739067,0.017427327],"genre_scores_gemma":[0.98947716,0.0072582704,0.00037887986,0.0015351495,0.00033014984,0.000071540344,0.00011773466,0.00006459832,0.00076653616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983194,0.00017184185,0.00030291497,0.0003232655,0.00043642023,0.0004461488],"domain_scores_gemma":[0.99922764,0.00007298222,0.00006968102,0.00039806773,0.00014893779,0.00008269983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002449534,0.00022162293,0.0002955478,0.00027278578,0.00020535766,0.00007043214,0.00009303813,0.0001321786,0.0002709555],"category_scores_gemma":[0.000021438867,0.00019600386,0.00020435655,0.00051218073,0.00015817655,0.00018606057,0.000016254267,0.00029702348,0.0004757249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016075179,0.0005091372,0.6877476,0.000016665184,0.00006301033,0.00005965697,0.000024486244,0.000049619004,0.14475328,0.00063989224,0.0016446966,0.16433121],"study_design_scores_gemma":[0.00252455,0.00063342554,0.7948622,0.00006125798,0.000020194893,0.000004382844,0.000002211745,0.0022504881,0.10928711,0.00047328655,0.089596435,0.00028441913],"about_ca_topic_score_codex":0.009894849,"about_ca_topic_score_gemma":0.0016865198,"teacher_disagreement_score":0.1640468,"about_ca_system_score_codex":0.00012288714,"about_ca_system_score_gemma":0.00015122897,"threshold_uncertainty_score":0.9966983},"labels":[],"label_agreement":null},{"id":"W2423411180","doi":"10.1177/135965350400900308","title":"The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Nelfinavir; Amprenavir; Saquinavir; Lopinavir; Indinavir; Ritonavir; Protease; Biology; Drug resistance; Virology; Protease inhibitor (pharmacology); Resistance mutation; Atazanavir; Lentivirus; Darunavir; Genetics; HIV-1 protease; Virus; Viral load; Gene; Viral disease; Reverse transcriptase; Antiretroviral therapy; Enzyme","score_opus":0.011686820211874805,"score_gpt":0.25909179243735847,"score_spread":0.24740497222548366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2423411180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715006,0.00020560996,0.0000012491045,0.0007216158,0.00002481236,0.0015325391,0.000010047385,0.000017958522,0.0003361193],"genre_scores_gemma":[0.99643016,0.001557271,0.00020586903,0.00004102969,0.000024102957,0.0001519189,0.000016850234,0.000015970161,0.0015568389],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990019,0.0000625327,0.00030525163,0.0001990243,0.00024770852,0.00018359043],"domain_scores_gemma":[0.9994626,0.000052091058,0.00016613811,0.00017316797,0.00011871433,0.000027294502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000956189,0.00017471626,0.00026018292,0.00010075104,0.000072452036,0.0000064758115,0.000060646762,0.000052543946,0.0000046235496],"category_scores_gemma":[0.000021301255,0.00009886174,0.00007675182,0.000304748,0.000100346486,0.00008378307,0.0000051054053,0.000072078554,0.000008950216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006314498,0.0031045033,0.934372,0.000022650607,0.00019148478,0.000009906734,0.0023966385,0.000021148287,0.02752015,0.0003979062,0.00009798012,0.025551135],"study_design_scores_gemma":[0.00888419,0.0018952846,0.4709013,0.00026261722,0.000007375754,3.3019384e-7,0.000060532144,0.000001244845,0.5164027,0.00024361008,0.0012484734,0.00009230097],"about_ca_topic_score_codex":0.000042201784,"about_ca_topic_score_gemma":0.000035260815,"teacher_disagreement_score":0.48888257,"about_ca_system_score_codex":0.00014738747,"about_ca_system_score_gemma":0.00015303734,"threshold_uncertainty_score":0.40314648},"labels":[],"label_agreement":null},{"id":"W24266920","doi":"10.1177/135965350801300306","title":"Distinct Signature Type I Interferon Responses are Determined by the Infecting virus and the Target Cell","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Biology; Interferon; Sendai virus; Virus; Virology; Gene; Gene expression; Interferon-stimulated gene; Immunology; Immune system; Innate immune system; Genetics","score_opus":0.016249503477538205,"score_gpt":0.2440967339733823,"score_spread":0.2278472304958441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W24266920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732081,0.02442125,0.00002637854,0.0005859257,0.00046869402,0.0002786857,0.000022269463,0.000056288998,0.0009323485],"genre_scores_gemma":[0.98706657,0.0021472839,0.000006423621,0.0007965101,0.00003674115,0.000014792685,0.000017535374,0.000022821036,0.009891312],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819225,0.0010242913,0.00021693975,0.00022838653,0.000036586986,0.0003015288],"domain_scores_gemma":[0.9985899,0.0009069178,0.00014655215,0.00029546296,0.000051698484,0.000009509376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038574537,0.00022846126,0.00028001596,0.000043260294,0.0006402906,0.000032411375,0.000287187,0.00017132264,0.00015864022],"category_scores_gemma":[0.00014725831,0.000112072135,0.000102393846,0.00011578196,0.0008276541,0.000085207896,0.0000890096,0.0004974745,0.00011814631],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015575137,0.00010125738,0.006783461,0.0000045768156,0.00012138178,0.000011306883,0.001982654,9.683351e-8,0.95704025,0.000048499092,0.014392162,0.003939224],"study_design_scores_gemma":[0.0035618537,0.0008771417,0.019846018,0.000027239344,0.00001558496,0.00013165733,0.00040360112,0.000005276399,0.8484985,0.000052843174,0.12633611,0.0002441363],"about_ca_topic_score_codex":0.00012285341,"about_ca_topic_score_gemma":0.000012637123,"teacher_disagreement_score":0.111943945,"about_ca_system_score_codex":0.000012212237,"about_ca_system_score_gemma":0.00003632244,"threshold_uncertainty_score":0.49246624},"labels":[],"label_agreement":null},{"id":"W2427378135","doi":"10.1177/135965350601100516","title":"The Xivth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug resistance; HIV drug resistance; Human immunodeficiency virus (HIV); Resistance (ecology); Epidemiology; Medicine; Transmission (telecommunications); Antiretroviral therapy; Virology; Biology; Viral load; Pathology","score_opus":0.013942685347122959,"score_gpt":0.29621805326961176,"score_spread":0.2822753679224888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2427378135","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39828774,0.00703681,0.00081529457,0.40026954,0.00086469046,0.00078920403,0.000104429135,0.00011875716,0.19171353],"genre_scores_gemma":[0.36714086,0.0006199111,0.00005852957,0.00024182932,0.00033083564,0.00001528885,0.000051409428,0.000011904315,0.6315294],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985949,0.00007484003,0.0002477623,0.00019538085,0.0005057133,0.00038143113],"domain_scores_gemma":[0.9993374,0.00011894717,0.000061982995,0.00028474213,0.00012421169,0.000072763854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028122278,0.00012364442,0.00014806436,0.00005766268,0.00024709495,0.00008994343,0.00027547733,0.000034202218,0.00047381443],"category_scores_gemma":[0.000053379383,0.000082220075,0.00013421664,0.00016196408,0.00014129646,0.00011831796,0.00003449592,0.0002498164,0.000044169286],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023512599,0.000102651196,0.003656165,0.0000035457654,0.00006885565,0.000032281318,0.000028736771,3.9321327e-7,0.0010753076,0.002379663,0.98597044,0.006446839],"study_design_scores_gemma":[0.00087665365,0.000017625622,0.010640664,0.00008424417,0.000004637299,0.0000030050028,0.000114562994,0.0000975649,0.0032284171,0.0003971821,0.9844396,0.00009584512],"about_ca_topic_score_codex":0.21097106,"about_ca_topic_score_gemma":0.9863711,"teacher_disagreement_score":0.77540004,"about_ca_system_score_codex":0.00017896506,"about_ca_system_score_gemma":0.00038592616,"threshold_uncertainty_score":0.79428315},"labels":[],"label_agreement":null},{"id":"W2461594029","doi":"10.3851/imp3059","title":"A Case of a Probable drug Interaction between Lurasidone and Atazanavir-Based Antiretroviral Therapy","year":2015,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Atazanavir; Lurasidone; CYP3A4; Pharmacology; Ritonavir; Drug; Paliperidone; Protease inhibitor (pharmacology); Drug interaction; Therapeutic drug monitoring; Antipsychotic drug; Medicine; Antipsychotic; Cytochrome P450; Antiretroviral therapy; Internal medicine; Metabolism; Human immunodeficiency virus (HIV); Virology; Viral load","score_opus":0.062016771864384465,"score_gpt":0.3203811694096541,"score_spread":0.25836439754526963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461594029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657065,0.00074407354,0.00006291509,0.0010436713,0.000074665535,0.00063329603,0.000011490012,0.00006419853,0.0007950705],"genre_scores_gemma":[0.9962901,0.00029662868,0.0011851683,0.00012624382,0.00009326985,0.00002545616,0.00007066182,0.000029891246,0.0018826014],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888015,0.00008800222,0.00029527035,0.0002812784,0.00021822804,0.00023707033],"domain_scores_gemma":[0.9993446,0.000061459636,0.00013417641,0.00023098094,0.00010684662,0.0001219388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002809822,0.00022747106,0.0004416862,0.0001638333,0.00006460023,0.000024589015,0.000052682015,0.00006809094,0.00001735049],"category_scores_gemma":[0.000014098247,0.00016676707,0.000092444054,0.00025009422,0.00010433443,0.0002116628,0.000016885491,0.00013501482,0.000018993229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015426282,0.0005950161,0.862732,0.000034741133,0.0003431038,0.0007703435,0.0023451732,6.560053e-7,0.004302899,0.000045513098,0.0016423769,0.12564553],"study_design_scores_gemma":[0.087009646,0.011553828,0.11211132,0.00090781495,0.00046579778,0.0017644905,0.004946313,0.00087233435,0.73284125,0.0008496458,0.044791818,0.001885741],"about_ca_topic_score_codex":0.0001947547,"about_ca_topic_score_gemma":0.000025947702,"teacher_disagreement_score":0.7506207,"about_ca_system_score_codex":0.000052563417,"about_ca_system_score_gemma":0.00014051847,"threshold_uncertainty_score":0.6800564},"labels":[],"label_agreement":null},{"id":"W2465570878","doi":"10.1177/135965350200700104","title":"Prevalence and Response to Antiretroviral Therapy of Non-B Subtypes of HIV in Antiretroviral-Naive Individuals in British Columbia","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"Canadian Foundation for AIDS Research","keywords":"Virology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral load; Biology; Lentivirus; Reverse-transcriptase inhibitor; Reverse transcriptase; Medicine; Viral disease; Immunology; Internal medicine; Polymerase chain reaction; Genetics","score_opus":0.01652190095736021,"score_gpt":0.2631948752469902,"score_spread":0.24667297428962998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465570878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913846,0.007326471,0.0000017072773,0.00007403371,0.00005142434,0.00069194596,0.00028595896,0.000013208427,0.00017063036],"genre_scores_gemma":[0.9872608,0.010852003,0.00005802936,0.000048768332,0.0000068350564,0.00003288617,0.000019129711,0.000018283175,0.0017032437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806696,0.00056574756,0.00042839785,0.00038066224,0.00009681424,0.0004614373],"domain_scores_gemma":[0.999286,0.00024730313,0.00012142248,0.00026447093,0.000051413244,0.000029369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057842385,0.00015683696,0.0004991075,0.00024490865,0.000058006317,0.00003396122,0.00024826397,0.00017493257,0.00042784956],"category_scores_gemma":[0.00007642887,0.00018917541,0.00007572356,0.0004564103,0.0003656262,0.00016596228,0.00006169244,0.0002195589,0.000067309105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008731846,0.00048685435,0.7439741,0.000016057626,0.00005925741,0.000032684344,0.0010162952,2.774992e-7,0.20866157,0.0000011700146,0.00050360925,0.044374954],"study_design_scores_gemma":[0.00490118,0.0041022724,0.9438005,0.00016482708,0.000002812564,0.000009885084,0.00011412601,0.0000027596623,0.04634259,0.000022320026,0.00037135888,0.00016538554],"about_ca_topic_score_codex":0.005346705,"about_ca_topic_score_gemma":0.0011384903,"teacher_disagreement_score":0.19982639,"about_ca_system_score_codex":0.00003009122,"about_ca_system_score_gemma":0.000045242377,"threshold_uncertainty_score":0.80826545},"labels":[],"label_agreement":null},{"id":"W2470502126","doi":"10.1177/135965350601100114","title":"Risks of Non-Accidental Mortality by Baseline CD4 <sup>+</sup> T-Cell Strata in Hepatitis-C-Positive and -Negative Individuals Initiating Highly Active Antiretroviral Therapy","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Medicine; Hepatitis C virus; Hepatitis C; Hazard ratio; Internal medicine; Immunology; Proportional hazards model; Confidence interval; Hepacivirus; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Virus","score_opus":0.04707390294040986,"score_gpt":0.35880998018133814,"score_spread":0.3117360772409283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470502126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924188,0.0007232321,0.00011262059,0.0001213047,0.000035814097,0.0014778803,0.001348248,0.000045123175,0.003716962],"genre_scores_gemma":[0.993694,0.004559669,0.0005253861,0.00026871078,0.00016273456,0.00006440827,0.0005581717,0.00007707751,0.00008984263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615824,0.000690592,0.0008546687,0.00071730604,0.00088267017,0.0006964995],"domain_scores_gemma":[0.998334,0.0005429998,0.00035452028,0.00040265077,0.00023491505,0.00013094845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009258147,0.00047749002,0.00093719363,0.0003617123,0.00014447163,0.00007470021,0.00023490058,0.00026348126,0.000115912924],"category_scores_gemma":[0.00010749776,0.00043649806,0.00016571268,0.00070109504,0.00048748075,0.0006847659,0.00009398037,0.00070668984,0.000013603674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060227996,0.0008905441,0.869986,0.000033179447,0.00016455638,0.00010766786,0.0012613173,0.000005848404,0.07756075,0.000022640124,0.00032285156,0.04904235],"study_design_scores_gemma":[0.0057866606,0.0018457293,0.63395935,0.00013341595,0.00001889543,0.0000027706067,0.00042271384,0.0013388809,0.35599592,0.00013846149,0.000059385024,0.00029782837],"about_ca_topic_score_codex":0.03769329,"about_ca_topic_score_gemma":0.000635325,"teacher_disagreement_score":0.27843517,"about_ca_system_score_codex":0.00013169972,"about_ca_system_score_gemma":0.0002288207,"threshold_uncertainty_score":0.99980867},"labels":[],"label_agreement":null},{"id":"W2471505848","doi":"10.1177/135965350400900602","title":"Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Tolerability; Lamivudine; Regimen; Didanosine; Internal medicine; Efavirenz; Nelfinavir; Medicine; Stavudine; Zidovudine; Gastroenterology; Adverse effect; Viral load; Pharmacology; Immunology; Human immunodeficiency virus (HIV); Viral disease; Antiretroviral therapy; Virus","score_opus":0.019668753747712413,"score_gpt":0.2831689572905201,"score_spread":0.2635002035428077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471505848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961611,0.00009383811,0.0000720841,0.001839303,0.00010158508,0.0014882786,0.000016387783,0.000020918213,0.00020650159],"genre_scores_gemma":[0.9961252,0.00019522704,0.00022252956,0.000034867804,0.000035452977,0.00001801012,0.000017684244,0.000013821561,0.0033371898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902374,0.000062425665,0.00033710367,0.00022115411,0.00021831013,0.00013728828],"domain_scores_gemma":[0.9993898,0.000074902775,0.00016571382,0.00025242177,0.00009051494,0.000026621601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029252478,0.00014194107,0.00034499879,0.000051875602,0.000112790185,0.00000536519,0.000057587506,0.000036016838,0.000009384781],"category_scores_gemma":[0.000025651678,0.00008909982,0.0001239572,0.00015575999,0.00010967137,0.00006954732,0.000035867855,0.00006328054,0.000002817835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012469983,0.0018989336,0.980308,0.00002980341,0.00022110541,0.0000015390208,0.0029558968,0.000006866209,0.0060711186,0.0001336161,0.00012750752,0.0069986186],"study_design_scores_gemma":[0.011415788,0.00104567,0.8816968,0.000060680726,0.00007080192,0.0000030629,0.00013154211,0.00001718051,0.1041053,0.0001523675,0.001205447,0.00009531218],"about_ca_topic_score_codex":0.00015069365,"about_ca_topic_score_gemma":0.000064996544,"teacher_disagreement_score":0.098611146,"about_ca_system_score_codex":0.00008969613,"about_ca_system_score_gemma":0.000058323127,"threshold_uncertainty_score":0.36333853},"labels":[],"label_agreement":null},{"id":"W2473682917","doi":"10.1177/135965350701200703","title":"Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Reverse transcriptase; Genotyping; Virology; Transmission (telecommunications); Protease; Biology; Integrase; Index case; Genotype; Viral load; Human immunodeficiency virus (HIV); Gp41; Drug resistance; Genetics; Polymerase chain reaction; Enzyme; Antibody; Epitope; Gene","score_opus":0.017663606525148735,"score_gpt":0.2910289731068751,"score_spread":0.27336536658172633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473682917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961291,0.0002829366,0.0007497557,0.0009729588,0.000048419453,0.0004097543,0.000039706993,0.00005199112,0.0013153878],"genre_scores_gemma":[0.9946792,0.00010013736,0.002724123,0.00027558368,0.000073298695,0.00000616124,0.00022643761,0.000023941213,0.0018911186],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988669,0.000043082397,0.00025999505,0.0002534602,0.00032970455,0.00024683206],"domain_scores_gemma":[0.9994612,0.00005499255,0.000055509594,0.00021362885,0.00006446348,0.00015026092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019584951,0.00017831361,0.0003091496,0.00017073844,0.000051119816,0.000010083868,0.00009012087,0.000069204434,0.00016195477],"category_scores_gemma":[0.0000049933396,0.00013084798,0.0000908603,0.00027685528,0.000039076476,0.00008711506,0.000012652154,0.000088592424,0.000048246347],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045409645,0.0015849405,0.28834054,0.000021363414,0.00058821833,0.00024850352,0.04062096,6.355738e-7,0.41117597,0.00011217836,0.0035275666,0.24923816],"study_design_scores_gemma":[0.0048425505,0.00049993827,0.48128968,0.00014099063,0.00007128866,0.0000017645968,0.0005978289,0.000005367533,0.47290802,0.00006815964,0.039361473,0.0002129076],"about_ca_topic_score_codex":0.00014909197,"about_ca_topic_score_gemma":0.00005772895,"teacher_disagreement_score":0.24902526,"about_ca_system_score_codex":0.000033547432,"about_ca_system_score_gemma":0.000070498056,"threshold_uncertainty_score":0.5335826},"labels":[],"label_agreement":null},{"id":"W2523601083","doi":"10.3851/imp3089","title":"Interchangeability between First-Line Generic Antiretroviral Products Prequalified by WHO using Adjusted Indirect Comparisons","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Universiteit Utrecht; World Health Organization","keywords":"Interchangeability; Medicine; Statistics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Mathematics; Computer science; Viral load; Virology","score_opus":0.2677889492011937,"score_gpt":0.3342942277627913,"score_spread":0.06650527856159755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523601083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884913,0.0017772936,0.0023979142,0.003812721,0.0003485102,0.00042084558,0.0011170125,0.0000789543,0.0015554772],"genre_scores_gemma":[0.9961658,0.0018283908,0.00021816137,0.00070486974,0.0005017489,0.000017669418,0.000037587393,0.000053419782,0.00047233189],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780124,0.00007605472,0.000787014,0.00069205737,0.00004509464,0.00059853087],"domain_scores_gemma":[0.9988207,0.00013737437,0.00039328422,0.0004906057,0.000030384512,0.00012765422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006602314,0.00030821018,0.000796183,0.000188703,0.00015534411,0.00007641917,0.00039291574,0.00015862803,0.00019113584],"category_scores_gemma":[0.00008206438,0.00026580144,0.00016655208,0.00035019298,0.00019484473,0.0004051714,0.00010038437,0.00018476794,0.00028012792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017704887,0.00032967806,0.93459916,0.000048640373,0.00029833414,0.0000019282386,0.00042388326,0.0000044426033,0.0069095613,0.0066070785,0.008456116,0.042144116],"study_design_scores_gemma":[0.007769396,0.0014311477,0.20768407,0.00014215485,0.000043489807,0.000004457404,0.000025348947,0.0048046466,0.12277824,0.0169394,0.6359271,0.0024505577],"about_ca_topic_score_codex":0.00033692576,"about_ca_topic_score_gemma":0.000018070217,"teacher_disagreement_score":0.7269151,"about_ca_system_score_codex":0.00016111511,"about_ca_system_score_gemma":0.000030115836,"threshold_uncertainty_score":0.99997944},"labels":[],"label_agreement":null},{"id":"W2547674430","doi":"10.3851/imp3105","title":"Reporting on the Prevalence of Antiretroviral Drug Resistance in a Regional HIV Population over 20 Years: A Word of Caution","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Hip and Knee Clinic","funders":"","keywords":"Medicine; Population; Drug resistance; Prevalence; HIV drug resistance; Internal medicine; Human immunodeficiency virus (HIV); Epidemiology; Viral load; Immunology; Antiretroviral therapy; Environmental health; Biology","score_opus":0.02995695752612521,"score_gpt":0.29092920642927816,"score_spread":0.26097224890315296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547674430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965644,0.0002689892,0.000007689126,0.002498522,0.00002799322,0.0002777519,0.0000056233184,0.0000118774815,0.0003371899],"genre_scores_gemma":[0.9857686,0.00044339555,0.00022652876,0.000049978622,0.000028485136,0.000010554735,0.0000071323343,0.0000093211665,0.013455989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988418,0.000067606365,0.0005170227,0.00017247887,0.00027686986,0.0001241712],"domain_scores_gemma":[0.9991328,0.00009244878,0.0005211903,0.00020528064,0.000034729313,0.000013555372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043623414,0.000092341594,0.00021029972,0.000088606095,0.000020733165,0.0000027873366,0.00005268562,0.000034208162,0.000038537015],"category_scores_gemma":[0.000085449756,0.000050426963,0.000076116674,0.00018597212,0.00006338319,0.00008367684,0.000008930218,0.0000555423,0.00000480701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072207424,0.00015921492,0.96686566,0.000042041138,0.000039117684,0.00001848124,0.00079755555,9.5809554e-8,0.017457591,0.0010860661,0.0010685724,0.011743516],"study_design_scores_gemma":[0.0012727424,0.00005841039,0.9827285,0.0008720962,0.000010616595,0.000001231663,0.000022091013,0.0000050206454,0.013638058,0.0005054082,0.0008226528,0.000063167565],"about_ca_topic_score_codex":0.00003122291,"about_ca_topic_score_gemma":0.00003008074,"teacher_disagreement_score":0.01586283,"about_ca_system_score_codex":0.000053628333,"about_ca_system_score_gemma":0.000043640986,"threshold_uncertainty_score":0.20563519},"labels":[],"label_agreement":null},{"id":"W2560505321","doi":"10.3851/imp3114","title":"A Comparison of Virological Suppression and Rebound between Indigenous and Non-Indigenous Persons Initiating Combination Antiretroviral Therapy in a Multisite Cohort of Individuals Living with HIV in Canada","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; McGill University; McGill University Health Centre; Simon Fraser University; St. Michael's Hospital; Sunnybrook Hospital; AIDS Vancouver; Ontario HIV Treatment Network; Lakehead University; University of British Columbia; Public Health Ontario; CAAN Communities, Alliances & Network; 2-Spirited; Women's College Hospital; McMaster University; HIV Legal Network; Maple Leaf Medical Clinic; Ottawa Hospital; University Health Network; University of Toronto","funders":"Fonds de Recherche du Québec - Santé; Ministry of Health, British Columbia; Simon Fraser University; Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Medicine; Cart; Demography; Indigenous; Viral load; Incidence (geometry); Cumulative incidence; Cohort; Cohort study; Psychological intervention; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Gerontology; Biology","score_opus":0.029135764413091646,"score_gpt":0.32680175763325076,"score_spread":0.29766599322015913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560505321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821836,0.00060571526,0.000115389965,0.000077344564,0.0000070935553,0.0007994674,0.00007342357,0.00000696016,0.00009622168],"genre_scores_gemma":[0.99895936,0.000765238,0.00013983363,0.000018263514,0.000013690072,0.000021499141,0.00002015678,0.000016319756,0.0000456147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983598,0.00023489253,0.0004565186,0.00025567788,0.00035279157,0.00034034107],"domain_scores_gemma":[0.99911606,0.00039797134,0.00020642957,0.0001424128,0.00006350711,0.00007359973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049469,0.00016062903,0.0006020067,0.00029284717,0.00008106952,0.0000147953515,0.00008477476,0.00009097364,0.000017860904],"category_scores_gemma":[0.00007505822,0.00010206259,0.000039809922,0.00024899186,0.00019307274,0.00018242604,0.000040219653,0.0002271404,3.1926538e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016932626,0.00031723798,0.90589017,0.00003976295,0.0000733221,0.000011504499,0.0069885543,2.188734e-7,0.026708938,0.0000019888842,0.000012303563,0.059786674],"study_design_scores_gemma":[0.0037153782,0.0067778914,0.9756914,0.0009028042,0.000009601141,0.00000481028,0.00097561587,0.00012598016,0.011659841,0.000012535014,0.000008472334,0.000115664596],"about_ca_topic_score_codex":0.15989187,"about_ca_topic_score_gemma":0.06575117,"teacher_disagreement_score":0.09414069,"about_ca_system_score_codex":0.000097115335,"about_ca_system_score_gemma":0.000259241,"threshold_uncertainty_score":0.95129645},"labels":[],"label_agreement":null},{"id":"W2569661228","doi":"10.3851/imp3123","title":"HCV Genotype-1 Subtypes and Resistance-Associated Substitutions in Drug-Naive and in Direct-Acting Antiviral Treatment Failure Patients","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"NS5A; NS3; Medicine; Internal medicine; Genotype; Drug resistance; Virology; Biology; Hepatitis C virus; Hepacivirus; Virus; Genetics; Gene","score_opus":0.02510943689565565,"score_gpt":0.297871199646457,"score_spread":0.27276176275080133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569661228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125963,0.0006222486,0.0000023207438,0.0010022486,0.000037693975,0.0005401302,0.000045730638,0.000033558354,0.0064564357],"genre_scores_gemma":[0.9924974,0.006511389,0.000086356995,0.00006731366,0.000027672548,0.000033895634,0.00001725048,0.000023115857,0.00073563034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860364,0.00019443396,0.0002440818,0.0003557301,0.0002108458,0.00039126535],"domain_scores_gemma":[0.9994654,0.00017916397,0.00006410959,0.00015993652,0.00006626814,0.00006510581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023056398,0.00018497865,0.00036081616,0.00022764236,0.000091081296,0.00002629962,0.00004797885,0.00009650536,0.000019057345],"category_scores_gemma":[0.00014955588,0.0001259114,0.000038711885,0.0003222617,0.0001736938,0.00022865881,0.000025543788,0.00012816627,0.0000165869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004468562,0.00024416935,0.90434426,0.000008008039,0.000040841507,0.000056177927,0.0007045379,2.3022125e-8,0.0034010052,0.00006187185,0.000094552866,0.0905977],"study_design_scores_gemma":[0.0072477423,0.0002897335,0.9720907,0.00029760782,0.000008918827,2.3695496e-7,0.00007399451,0.0000073120455,0.0047983727,0.00012896162,0.014861866,0.00019450787],"about_ca_topic_score_codex":0.0007610644,"about_ca_topic_score_gemma":0.014838542,"teacher_disagreement_score":0.09040319,"about_ca_system_score_codex":0.00025150395,"about_ca_system_score_gemma":0.00008567437,"threshold_uncertainty_score":0.82802546},"labels":[],"label_agreement":null},{"id":"W2587896987","doi":"10.3851/imp3139","title":"Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Children's Hospital of Eastern Ontario; Université de Montréal; University Health Network; University of Toronto; Toronto General Hospital; McGill University Health Centre","funders":"Merck Canada; McGill University Health Centre; Gilead Sciences","keywords":"Raltegravir; Dosing; Medicine; Therapeutic drug monitoring; Drug; Gestational age; Pediatrics; Pregnancy; Drug resistance; Human immunodeficiency virus (HIV); Viral load; Pharmacology; Antiretroviral therapy; Immunology; Biology","score_opus":0.023197962399288497,"score_gpt":0.3033020600364695,"score_spread":0.28010409763718097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587896987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911307,0.0005737891,0.0040318193,0.0029047215,0.000040478466,0.00116552,0.0000025842014,0.000046905934,0.00010349086],"genre_scores_gemma":[0.9900278,0.00022145148,0.006275947,0.00005162096,0.000047890764,0.000113812996,0.000005005943,0.00003875351,0.0032177267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879044,0.000065154774,0.00029560985,0.0003013916,0.00023879702,0.00030861158],"domain_scores_gemma":[0.9995214,0.000107193744,0.000049757902,0.0001809477,0.00006582486,0.00007492087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021726388,0.00021334118,0.0003535734,0.00015188621,0.00005764663,0.000015840094,0.000075350436,0.000068057794,0.00001634205],"category_scores_gemma":[0.000013610527,0.00011990664,0.00010796353,0.00021193932,0.000035963003,0.00016436611,0.000012899348,0.00005293923,0.0000039503657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004099432,0.00061758043,0.11798043,0.00012921747,0.00026048077,0.000031929045,0.0068858084,0.000001277412,0.5730477,0.00010247954,0.00007902531,0.29676464],"study_design_scores_gemma":[0.010884851,0.0011911042,0.3523631,0.007333737,0.00009602733,0.00002108047,0.00037708465,0.000101566344,0.62430197,0.0002854542,0.0026540775,0.00038992884],"about_ca_topic_score_codex":0.000006313677,"about_ca_topic_score_gemma":0.000004618402,"teacher_disagreement_score":0.2963747,"about_ca_system_score_codex":0.00008784996,"about_ca_system_score_gemma":0.00007886111,"threshold_uncertainty_score":0.4889651},"labels":[],"label_agreement":null},{"id":"W2589708348","doi":"10.3851/imp3145","title":"Increases in CD4 <sup>+</sup> T-Cell Count at Antiretroviral Therapy Initiation among HIV-Positive Illicit Drug users during a Treatment-as-Prevention Initiative in Canada","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Simon Fraser University; University of Calgary","funders":"National Institutes of Health; International AIDS Society; National Institute on Drug Abuse; Canada Research Chairs; ViiV Healthcare; Gilead Sciences; Ministry of Health, British Columbia; Leverhulme Trust; Bristol-Myers Squibb","keywords":"Hazard ratio; Medicine; Proportional hazards model; Viral load; Treatment as prevention; Internal medicine; Antiretroviral therapy; Human immunodeficiency virus (HIV); Cohort; Prospective cohort study; Cohort study; Immunology; Demography; Confidence interval","score_opus":0.013778993391863519,"score_gpt":0.24177840340967796,"score_spread":0.22799941001781443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589708348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595517,0.0015621035,0.0000028061852,0.00018424286,0.00005259175,0.000941191,0.0003711363,0.000034299937,0.0008964564],"genre_scores_gemma":[0.9906333,0.0067941383,0.000006131317,0.0001163212,0.000025647554,0.00019131068,0.0005129551,0.000036204474,0.0016839711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732494,0.00085298205,0.0004145766,0.0005302881,0.0001316881,0.00074551214],"domain_scores_gemma":[0.9991065,0.00034880015,0.00016931722,0.00026202734,0.00006301891,0.000050291408],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018117651,0.0003919097,0.00046366724,0.0002966746,0.00021248955,0.000021995378,0.0001782966,0.0001485785,0.0004493813],"category_scores_gemma":[0.00002524392,0.00027232143,0.00012707974,0.0003103941,0.00019282434,0.00046159528,0.00004703884,0.0001893112,0.00032811137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024586914,0.000741483,0.89036113,0.000004485365,0.0002302463,0.00023310786,0.0017431264,0.0000060452076,0.09120213,0.00001715271,0.00013662476,0.01286577],"study_design_scores_gemma":[0.016262954,0.0011976386,0.6381706,0.00013610163,0.000009371102,0.000009633709,0.00086183136,0.000005974627,0.34249732,0.000056078265,0.0004664924,0.00032600094],"about_ca_topic_score_codex":0.5342205,"about_ca_topic_score_gemma":0.43192637,"teacher_disagreement_score":0.25219053,"about_ca_system_score_codex":0.002064659,"about_ca_system_score_gemma":0.00067156204,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W2591603178","doi":"","title":"Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression (Antiviral Theraphy (2007) 12 (1147-1156))","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Reproductive tract infections research","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Microbicides for sexually transmitted diseases; Herpes simplex virus; Virology; DNA; Gene; Biology; Virus; Medicine; Genetics; Population","score_opus":0.02200983258415449,"score_gpt":0.27325432576940867,"score_spread":0.25124449318525416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591603178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98505336,0.012969713,0.000035606372,0.00021530823,0.00048823212,0.000542917,0.0001225999,0.00014733519,0.0004249143],"genre_scores_gemma":[0.9821805,0.015215602,0.00007367858,0.00020731162,0.0001843488,0.000041657284,0.00007595877,0.00006752515,0.0019534272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969194,0.0006684183,0.000412162,0.0009675054,0.00012992478,0.0009026],"domain_scores_gemma":[0.99890035,0.00016390468,0.0002428387,0.0005313251,0.000096730735,0.00006482042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004346471,0.00052818086,0.0005844622,0.0004493357,0.0010573968,0.00008179463,0.00027415884,0.00038324704,0.00025310018],"category_scores_gemma":[0.00003703251,0.00043955795,0.00015308938,0.00027931752,0.0014330306,0.0005006626,0.0001468447,0.00061729527,0.00012862113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008560778,0.00033328636,0.099256985,0.000013518298,0.00029021964,0.000051798717,0.00079742266,4.0519802e-7,0.8764211,0.000022704271,0.0010991497,0.020857342],"study_design_scores_gemma":[0.0024827817,0.0004894288,0.13313922,0.000049765375,0.000019647216,0.0003559242,0.00017584545,0.0000010974602,0.8340823,0.00007011085,0.02866766,0.00046622314],"about_ca_topic_score_codex":0.0006830383,"about_ca_topic_score_gemma":0.00004390737,"teacher_disagreement_score":0.0423388,"about_ca_system_score_codex":0.0000456834,"about_ca_system_score_gemma":0.000091432485,"threshold_uncertainty_score":0.9998056},"labels":[],"label_agreement":null},{"id":"W2600310501","doi":"10.3851/imp3158","title":"Peramivir Susceptibilities of Recombinant Influenza A and B Variants Selected with Various Neuraminidase Inhibitors","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Zanamivir; Neuraminidase; Neuraminidase inhibitor; Oseltamivir; Virology; Recombinant DNA; Influenzavirus B; Mutant; Influenza A virus; Hemagglutinin (influenza); Chemistry; Orthomyxoviridae; Biology; Virus; Microbiology; Medicine; Gene; Biochemistry; Coronavirus disease 2019 (COVID-19)","score_opus":0.05447669347885111,"score_gpt":0.3339081648260733,"score_spread":0.2794314713472222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600310501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974717,0.0008458876,0.00002747654,0.00039267432,0.00006870147,0.0006049358,0.000013765792,0.00007418072,0.00050070486],"genre_scores_gemma":[0.99732965,0.0012925627,0.00022005539,0.0004052977,0.000058419962,0.000028061986,0.0000015168581,0.000037916194,0.00062653475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833435,0.00013744815,0.00033351043,0.00036696382,0.00038293414,0.00044480278],"domain_scores_gemma":[0.9987614,0.00027083256,0.00014425527,0.000342626,0.00038929994,0.00009157463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029781376,0.00025171757,0.0004967304,0.00018072846,0.00011101758,0.000020692396,0.00008656387,0.00009031669,0.00004444124],"category_scores_gemma":[0.0003131039,0.00013128179,0.00005678611,0.0003276589,0.00061061577,0.00022479639,0.000057848414,0.00017193491,0.000013091985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049114255,0.00045954174,0.5661817,0.00011267687,0.00042919113,0.00009038229,0.0022515785,1.2877595e-7,0.33260483,0.0003418821,0.000428128,0.092188515],"study_design_scores_gemma":[0.012527555,0.008333722,0.8689972,0.00059062825,0.000049671937,0.0000623755,0.00032434936,0.000015072078,0.10244636,0.00035227035,0.005902776,0.00039800155],"about_ca_topic_score_codex":0.00019340831,"about_ca_topic_score_gemma":0.000026826952,"teacher_disagreement_score":0.3028155,"about_ca_system_score_codex":0.000043127064,"about_ca_system_score_gemma":0.00017141792,"threshold_uncertainty_score":0.53535163},"labels":[],"label_agreement":null},{"id":"W2601970093","doi":"10.3851/imp3162","title":"Progressive Multifocal Leukoencephalopathy due to John Cunningham (JC) virus following Allogeneic Haematopoietic Cell Transplantation","year":2016,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Progressive multifocal leukoencephalopathy; JC virus; Complication; Medicine; Transplantation; Leukoencephalopathy; Hematopoietic stem cell transplantation; Immunology; Virus; Pathology; Internal medicine; Disease","score_opus":0.033874558779755023,"score_gpt":0.3437304782448088,"score_spread":0.30985591946505375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601970093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014207527,0.98127705,0.00015570172,0.000060143437,0.00065763784,0.0024431122,0.0001488078,0.00018596524,0.00086405745],"genre_scores_gemma":[0.014080194,0.9834587,0.00025009178,0.00024299492,0.00042561907,0.00034301422,0.00020730303,0.0001758675,0.0008162197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968329,0.00025749792,0.00080870074,0.0008465909,0.00052582077,0.000728459],"domain_scores_gemma":[0.99856925,0.00014082198,0.00035105474,0.00052836846,0.00005878707,0.00035171967],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020719889,0.00081862643,0.0021800147,0.00037344443,0.00019632243,0.00006284136,0.00031662345,0.0005893058,0.00012135507],"category_scores_gemma":[0.000021980186,0.00050124974,0.0014765436,0.0004421798,0.00013468746,0.00015269603,0.0000358014,0.00044237007,0.0008672377],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024672662,0.00042768888,0.00011077173,0.0033267692,0.0005426035,0.006606808,0.00034087602,1.7497604e-7,0.0012450526,0.000012788559,0.0003016716,0.98683804],"study_design_scores_gemma":[0.004365354,0.0012938009,0.0003263839,0.060720384,0.002979259,0.001033554,0.00003318179,0.0000026822308,0.0060318517,0.000045843735,0.9215584,0.0016092961],"about_ca_topic_score_codex":0.000026264765,"about_ca_topic_score_gemma":0.0000017225458,"teacher_disagreement_score":0.9852288,"about_ca_system_score_codex":0.00011293358,"about_ca_system_score_gemma":0.00048333604,"threshold_uncertainty_score":0.9999107},"labels":[],"label_agreement":null},{"id":"W2687319114","doi":"10.3851/imp3181","title":"Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir","year":2017,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ledipasvir; NS5A; Daclatasvir; Viral quasispecies; Sofosbuvir; Medicine; Population; Internal medicine; Virology; Gastroenterology; Hepatitis C virus; Ribavirin; Hepacivirus; Virus","score_opus":0.06577570250110594,"score_gpt":0.33958179904916264,"score_spread":0.2738060965480567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2687319114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98209,0.0013506665,0.00004743236,0.00245381,0.00011414448,0.0010131464,0.00007003692,0.00005670363,0.012804066],"genre_scores_gemma":[0.9871622,0.0030076832,0.00010216239,0.0001630783,0.00017850832,0.00017243407,0.000024083256,0.000048981943,0.009140922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997774,0.00018033445,0.00031000908,0.0004483865,0.0007256799,0.0005615605],"domain_scores_gemma":[0.9979759,0.00009535555,0.0002699826,0.0012404372,0.00028857336,0.00012979019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003593444,0.00032613106,0.00055558863,0.000106533735,0.00068690773,0.00012558885,0.00036656344,0.00014892129,0.00012954175],"category_scores_gemma":[0.000078574245,0.0001896144,0.0002358149,0.00019430793,0.0012258597,0.00032920486,0.00005828363,0.00030116682,0.0000662233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002514718,0.0006484215,0.959324,0.000032583055,0.0005386946,0.00026312217,0.0013244406,2.1609397e-7,0.0064834147,0.00007319594,0.00036269045,0.028434524],"study_design_scores_gemma":[0.00584147,0.0016900753,0.9636583,0.00052754115,0.00013989667,0.000004486205,0.00012096963,0.00001705409,0.016250804,0.000022272216,0.011423689,0.00030346168],"about_ca_topic_score_codex":0.0004228883,"about_ca_topic_score_gemma":0.00480932,"teacher_disagreement_score":0.028131062,"about_ca_system_score_codex":0.00023905298,"about_ca_system_score_gemma":0.00036445566,"threshold_uncertainty_score":0.77322507},"labels":[],"label_agreement":null},{"id":"W2735274296","doi":"10.3851/imp3180","title":"<i>In vitro</i> Susceptibility of Geographically and Temporally Distinct Zika Viruses to Favipiravir and Ribavirin","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; Université Laval","funders":"","keywords":"Favipiravir; Zika virus; Ribavirin; Virology; In vitro; Meningoencephalitis; Biology; Virus; Medicine; Internal medicine; Disease; Coronavirus disease 2019 (COVID-19); Genetics","score_opus":0.014878541675537605,"score_gpt":0.28624494013483276,"score_spread":0.27136639845929517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735274296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579597,0.001066723,0.00008232198,0.0022075411,0.000038372185,0.000527168,0.00006899601,0.000025435438,0.00018747569],"genre_scores_gemma":[0.9973621,0.00054685574,0.00013096775,0.0017197058,0.00006928994,0.000022064534,0.000003094012,0.000018851106,0.00012707457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987573,0.0000748211,0.00031853083,0.00040484456,0.00018630603,0.0002582149],"domain_scores_gemma":[0.9992895,0.0001075861,0.00007067545,0.0003206017,0.000060923885,0.00015067495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026078266,0.00018641689,0.0004476105,0.00010060153,0.000033330038,0.000016050777,0.00008129828,0.00007124613,0.000041050844],"category_scores_gemma":[0.000058279766,0.000115455754,0.000100735066,0.00016888537,0.00021400143,0.00012317249,0.000046336183,0.00007262628,0.00000496427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00216369,0.00018005025,0.46841174,0.000018449815,0.000025256164,0.000015605105,0.00003827148,6.4366277e-9,0.4547548,0.00011002077,0.00006154707,0.074220546],"study_design_scores_gemma":[0.0043679215,0.000951475,0.95130914,0.000096322554,0.000026103644,0.0000042442625,0.000024393128,0.0000041607836,0.03715059,0.00061410095,0.005273597,0.00017794194],"about_ca_topic_score_codex":0.00021880044,"about_ca_topic_score_gemma":0.00009460565,"teacher_disagreement_score":0.4828974,"about_ca_system_score_codex":0.0000099794115,"about_ca_system_score_gemma":0.000036934238,"threshold_uncertainty_score":0.4708149},"labels":[],"label_agreement":null},{"id":"W2736481878","doi":"10.3851/imp3185","title":"Frailty in Men Living with HIV: A Cross-Sectional Comparison of Three Frailty Instruments","year":2017,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"ViiV Healthcare; Gilead Sciences","keywords":"Medicine; Frailty Index; Frailty syndrome; Gerontology; Quality of life (healthcare); Cross-sectional study; Life expectancy; Logistic regression; Internal medicine; Population; Environmental health","score_opus":0.09134431394667682,"score_gpt":0.4006972473596791,"score_spread":0.3093529334130023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736481878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856293,0.00012916513,0.0000949037,0.00025948038,0.000045138302,0.00041317922,0.000014647988,0.00002372301,0.013390445],"genre_scores_gemma":[0.9986773,0.00008910257,0.00058279786,0.000045622764,0.00003808177,0.000035569476,0.000020209205,0.00001750074,0.0004938301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989569,0.000024378323,0.00032198607,0.000244087,0.0002335928,0.00021903493],"domain_scores_gemma":[0.9990627,0.000041651565,0.00025533073,0.00050444785,0.00007905902,0.000056801287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013073736,0.00013718284,0.00031418292,0.0000891325,0.00031093726,0.0000381479,0.0001565798,0.00009885336,0.00008868718],"category_scores_gemma":[0.000019672454,0.00010270476,0.000053470347,0.000087669774,0.00015128247,0.0001823975,0.000033512937,0.00021316693,0.000044809116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025471207,0.0006464006,0.98312926,0.000015006304,0.00009110277,0.0000032272617,0.00026199748,0.00000246853,0.000617746,0.00020154785,0.000043544107,0.014732983],"study_design_scores_gemma":[0.00331959,0.0005278547,0.9939375,0.00020906334,0.000008373285,0.0000046680634,0.000024590434,0.00061713846,0.00069756503,0.00016879854,0.00039687642,0.00008799949],"about_ca_topic_score_codex":0.0006217909,"about_ca_topic_score_gemma":0.00019229055,"teacher_disagreement_score":0.014644983,"about_ca_system_score_codex":0.000059802063,"about_ca_system_score_gemma":0.000096621545,"threshold_uncertainty_score":0.41881785},"labels":[],"label_agreement":null},{"id":"W2769969382","doi":"10.3851/imp3211","title":"Article Commentary: Frailty: Is Thy Name…..Universal? Evolving Challenges of Managing Effectively Treated Older People Living with HIV","year":2017,"lang":"en","type":"letter","venue":"Antiviral Therapy","topic":"Frailty in Older Adults","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Frailty Index; Operationalization; Gerontology; Vulnerability (computing); Human immunodeficiency virus (HIV); Medicine; Quality of life (healthcare); Population; Construct (python library); Scale (ratio); Computer science; Family medicine; Computer security; Environmental health","score_opus":0.022389776916153847,"score_gpt":0.2676678152981051,"score_spread":0.24527803838195128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769969382","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34192657,0.0041228444,0.00009556833,0.64612466,0.00019845895,0.0013927075,0.00007065177,0.00021951774,0.005849007],"genre_scores_gemma":[0.8885962,0.003654416,0.00030428037,0.10347378,0.0010052506,0.00004087918,0.00009487153,0.00021848714,0.00261185],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99735045,0.00023263248,0.00033390542,0.0007798928,0.00062955264,0.00067356613],"domain_scores_gemma":[0.99751335,0.0005136561,0.00048281468,0.0012142694,0.00020063572,0.00007525724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023482874,0.0006501207,0.0011711979,0.0002856998,0.00023581335,0.0000759777,0.00045503376,0.00046740813,0.00029303035],"category_scores_gemma":[0.000040382183,0.0005238755,0.0002858623,0.00015321087,0.0002678669,0.0004144546,0.000115129216,0.0012624873,0.000055658795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041725213,0.00042755043,0.13895726,0.0010952783,0.0024614723,0.0010039996,0.014191767,6.9682295e-7,0.0020692307,0.000009952113,0.794757,0.04460852],"study_design_scores_gemma":[0.020164225,0.005327641,0.7645126,0.0231454,0.0013161552,0.00022801835,0.0028653543,0.0008396197,0.02386678,0.00019875159,0.15478197,0.0027534855],"about_ca_topic_score_codex":0.0009731231,"about_ca_topic_score_gemma":0.00007577277,"teacher_disagreement_score":0.6399751,"about_ca_system_score_codex":0.00015102667,"about_ca_system_score_gemma":0.000060116832,"threshold_uncertainty_score":0.9997213},"labels":[],"label_agreement":null},{"id":"W2890738265","doi":"10.3851/imp3265","title":"Substance use Patterns and HIV-1 RNA Viral Load Rebound among HIV-Positive Illicit Drug users in a Canadian Setting","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV, Drug Use, Sexual Risk","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"British Columbia Centre on Substance Use; St. Paul's Hospital; University of British Columbia; University of Alberta","funders":"National Institute on Drug Abuse","keywords":"Viral load; Medicine; Hazard ratio; Proportional hazards model; Internal medicine; Prospective cohort study; Cohort; Cohort study; Human immunodeficiency virus (HIV); Young adult; Confidence interval; Immunology","score_opus":0.024127953394166287,"score_gpt":0.29407368982739507,"score_spread":0.2699457364332288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890738265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954342,0.00016504424,0.00002908495,0.0011332222,0.0001523201,0.0006510103,0.0001478004,0.00006765584,0.002219666],"genre_scores_gemma":[0.99497324,0.00033325856,0.00018930144,0.001777076,0.00032319283,0.000017095457,0.00006247231,0.00007711186,0.002247267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762076,0.00016926345,0.00036960395,0.0005903719,0.0003504651,0.00089953287],"domain_scores_gemma":[0.9988094,0.00014974237,0.00012526626,0.00042081936,0.00015312078,0.0003416266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045717353,0.0003495775,0.00044760515,0.00027297557,0.00020718531,0.00011869275,0.00016775346,0.00014779484,0.000051650204],"category_scores_gemma":[0.00007344847,0.0003247834,0.000070131435,0.0003441105,0.00038371628,0.00060821715,0.0000262922,0.00042699854,0.00009939061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002875974,0.000058753136,0.9538348,0.000012469508,0.00006373619,0.00028845578,0.030622533,5.027078e-7,0.0050240783,0.000050451134,0.0010229625,0.008733669],"study_design_scores_gemma":[0.0030242093,0.00032536872,0.9730059,0.00046145168,0.000025892037,0.000017768756,0.0050810417,0.00042196765,0.014010839,0.00006289945,0.0030816575,0.00048099054],"about_ca_topic_score_codex":0.24136361,"about_ca_topic_score_gemma":0.6477567,"teacher_disagreement_score":0.4063931,"about_ca_system_score_codex":0.00038897246,"about_ca_system_score_gemma":0.0002789185,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W2898149304","doi":"10.3851/imp3274","title":"Optimizing Concentrations of Concomitant Antiretrovirals by Reducing Etravirine Doses: Two Case Reports of Complex Drug-drug Interactions","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Etravirine; Darunavir; Elvitegravir; Dolutegravir; Raltegravir; Drug; Pharmacology; Medicine; Concomitant; Drug interaction; Enfuvirtide; Maraviroc; Human immunodeficiency virus (HIV); Internal medicine; Antiretroviral therapy; Virology; Viral load; Immunology","score_opus":0.03408805450868194,"score_gpt":0.33665609141918984,"score_spread":0.3025680369105079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898149304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991723,0.0004199715,0.00019043364,0.00080467446,0.00024580673,0.0005576819,0.00004975475,0.000053293676,0.005955366],"genre_scores_gemma":[0.99058247,0.0003073583,0.0047602034,0.000105282175,0.000114695846,0.000014548371,0.00012437813,0.000029741856,0.0039613307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825984,0.00009230128,0.00080311875,0.00033154618,0.00024088784,0.00027229212],"domain_scores_gemma":[0.99868333,0.00012796544,0.00046294954,0.00038934767,0.00025236895,0.0000840458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027768785,0.00023378484,0.0005782189,0.00014730239,0.00016666629,0.000018676454,0.000057972153,0.000029589984,0.00023854872],"category_scores_gemma":[0.000033779816,0.00019286886,0.00016277503,0.00033017446,0.00035041297,0.00021230178,0.000028686723,0.00013901251,0.000010083353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049502205,0.0013517778,0.087508544,0.00006022387,0.0008620147,0.0022555199,0.011210001,0.0000036960766,0.8564908,0.0003475309,0.027755992,0.011658854],"study_design_scores_gemma":[0.0043468294,0.00040023177,0.0022923518,0.000390792,0.00015833894,0.001711155,0.0020374462,0.0003676952,0.9742439,0.000049147806,0.013693359,0.00030877048],"about_ca_topic_score_codex":0.0006187514,"about_ca_topic_score_gemma":0.00008928719,"teacher_disagreement_score":0.117753066,"about_ca_system_score_codex":0.00006474317,"about_ca_system_score_gemma":0.00012913765,"threshold_uncertainty_score":0.78649634},"labels":[],"label_agreement":null},{"id":"W2898792243","doi":"10.3851/imp3278","title":"Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Toronto General Hospital; University of Toronto; Regina General Hospital; University of Alberta; University of Saskatchewan; Research Canada","funders":"Daiichi Sankyo Europe; Gilead Sciences; Pfizer; Daiichi-Sankyo; Bristol-Myers Squibb","keywords":"Sofosbuvir; Daclatasvir; Ribavirin; Medicine; Internal medicine; Cirrhosis; Hepatitis C; Gastroenterology; Clinical endpoint; Adverse effect; Hepatitis C virus; Virology; Clinical trial; Virus","score_opus":0.027791113161629178,"score_gpt":0.3371077543208006,"score_spread":0.3093166411591714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898792243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418724,0.0002861626,0.00030633522,0.000117470816,0.00005732294,0.0044896547,0.00008183713,0.00012134718,0.00035262367],"genre_scores_gemma":[0.9979077,0.00052921294,0.00035954552,0.00021423017,0.00019814233,0.0004007461,0.000114667826,0.0001240134,0.00015173317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975682,0.00016481448,0.00037834924,0.0006617919,0.00054927974,0.00067758205],"domain_scores_gemma":[0.99877375,0.000099142235,0.00011802554,0.00052291516,0.00032988592,0.00015625576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035655583,0.00035886766,0.00060993555,0.00030210597,0.0001650696,0.00006927206,0.00016492786,0.00011692392,0.00008459879],"category_scores_gemma":[0.000040159786,0.00025554237,0.000050023737,0.0005799615,0.0003479637,0.0003199213,0.000058014084,0.00032422776,0.000024349703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00800852,0.0022596198,0.8679591,0.00003886129,0.00031979065,0.000066037,0.0011975674,2.5126198e-7,0.0033978766,0.000015871652,0.0002868097,0.11644973],"study_design_scores_gemma":[0.07742739,0.05281839,0.8565979,0.00023797879,0.00007370152,0.0000038945523,0.000071269504,0.00045510862,0.0042563216,0.00002687353,0.007577921,0.00045327152],"about_ca_topic_score_codex":0.0021058745,"about_ca_topic_score_gemma":0.008659254,"teacher_disagreement_score":0.11599646,"about_ca_system_score_codex":0.00020949358,"about_ca_system_score_gemma":0.0003570035,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W2900996895","doi":"10.3851/imp3250","title":"Expert Opinion on Managing Chronic HCV in Patients with Non-Hodgkin Lymphoma and other Extrahepatic Malignancies","year":2018,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Lymphoma; Internal medicine; Epidemiology; Hepatitis C virus; Risk factor; Non-Hodgkin's lymphoma; Oncology; Immunology; Gastroenterology; Virus","score_opus":0.06293111279938804,"score_gpt":0.3728573706064033,"score_spread":0.3099262578070152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900996895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015042157,0.9797524,0.000012745186,0.000032755135,0.00016182863,0.002293938,0.00002343945,0.000043260232,0.0026374261],"genre_scores_gemma":[0.0062761293,0.99236655,0.000097447504,0.00026450845,0.0003386943,0.00020476231,0.000061906714,0.00016618558,0.00022382892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974489,0.00024461333,0.0004745121,0.00066733506,0.00057691435,0.0005877153],"domain_scores_gemma":[0.9989755,0.0001022246,0.00018358654,0.00057946716,0.00006186946,0.0000973568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031250413,0.00054293225,0.0014040449,0.0004982071,0.000078759724,0.00005874802,0.00021160925,0.00025752615,0.00008826078],"category_scores_gemma":[0.0000194429,0.00036037312,0.00015780944,0.00043244715,0.00022610463,0.00012078362,0.000058382855,0.00026678178,0.00015130681],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019828067,0.00022346829,0.012601195,0.0017055315,0.00013384249,0.00003053267,0.00017754156,1.1937277e-8,0.0000014808492,0.000014683645,0.0003267667,0.98458666],"study_design_scores_gemma":[0.0035372523,0.0029024116,0.0071994583,0.031047955,0.000018114904,0.000003194927,0.000006750539,0.000019659836,0.000016005188,0.000008634031,0.9548172,0.00042338],"about_ca_topic_score_codex":0.0002631197,"about_ca_topic_score_gemma":0.000061020295,"teacher_disagreement_score":0.9841633,"about_ca_system_score_codex":0.00036361918,"about_ca_system_score_gemma":0.00032471475,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W2909866007","doi":"10.3851/imp3287","title":"Impact of three Decades of Antiretroviral Therapy in a Longitudinal Population Cohort Study","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pill; Regimen; Population; Efavirenz; Viral load; Cohort study; Mortality rate; Internal medicine; Cohort; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Pharmacology; Environmental health","score_opus":0.03908051172415777,"score_gpt":0.3525158055405722,"score_spread":0.31343529381641444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909866007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825305,0.00020292206,0.000013888953,0.00003841035,0.000048807753,0.0010845069,0.0000047908075,0.000021344702,0.00033230457],"genre_scores_gemma":[0.9992294,0.00020127362,0.00020178157,0.000007894491,0.00006606448,0.000017974986,0.000023521843,0.000020877374,0.0002312497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987407,0.000063688436,0.00040469875,0.0002532174,0.00032000896,0.00021772587],"domain_scores_gemma":[0.99940175,0.000032254735,0.00016110016,0.00026427183,0.000107103166,0.000033506712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030443363,0.00019778078,0.0005432957,0.00026657066,0.00003586416,0.000006972537,0.00008533959,0.0000643156,0.00009859763],"category_scores_gemma":[0.000011986309,0.0001328511,0.0001632864,0.00045676916,0.00010793819,0.00012571512,0.000015177629,0.00008275339,0.000009186603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015645298,0.0017862964,0.96026576,0.000004927366,0.00051396375,0.000015649459,0.0007782237,2.5464834e-7,0.0056318706,0.00002002989,0.000032216936,0.029386252],"study_design_scores_gemma":[0.005040024,0.0067112944,0.9802989,0.000052691135,0.00002616827,0.0000029959217,0.000053158856,0.000033499462,0.007581927,0.00007873783,0.00000743781,0.00011316628],"about_ca_topic_score_codex":0.0012462437,"about_ca_topic_score_gemma":0.00022041646,"teacher_disagreement_score":0.029273087,"about_ca_system_score_codex":0.00006361253,"about_ca_system_score_gemma":0.00007093923,"threshold_uncertainty_score":0.541751},"labels":[],"label_agreement":null},{"id":"W2921597040","doi":"10.3851/imp3302","title":"Tenofovir and Emtricitabine Resistance among Antiretroviral-Naive Patients in the Canadian Observational Cohort Collaboration: Implications for PrEP","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University Health Network; Ottawa Hospital; Institute for Clinical Evaluative Sciences; Simon Fraser University; McGill University Health Centre; AIDS Vancouver; St. Michael's Hospital; University of British Columbia; Public Health Ontario; University of Toronto; HIV Legal Network; Maple Leaf Medical Clinic; Women's College Hospital","funders":"Canadian Institutes of Health Research; Ministry of Health, British Columbia; National Institute on Drug Abuse; McGill University","keywords":"Emtricitabine; Medicine; Internal medicine; Cumulative incidence; Drug resistance; Hazard ratio; Incidence (geometry); Cohort; Regimen; Cohort study; Viral load; Antiretroviral therapy; Virology; Human immunodeficiency virus (HIV); Confidence interval; Biology; Genetics","score_opus":0.04002693143752805,"score_gpt":0.3465619635941738,"score_spread":0.30653503215664574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921597040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799174,0.0001594983,0.000107212545,0.008000905,0.000032026546,0.001720804,0.00023965511,0.000014288453,0.009808194],"genre_scores_gemma":[0.9911927,0.00013383021,0.000259121,0.00064187625,0.00015221533,0.00027719096,0.0003201754,0.000013405591,0.007009497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897885,0.00007898062,0.00023700432,0.00023444011,0.00019296817,0.00027776344],"domain_scores_gemma":[0.9989148,0.00009337659,0.0000626821,0.00024578377,0.0005961767,0.00008720212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003631497,0.00010422659,0.00015171058,0.00016832874,0.0004146861,0.0000847561,0.00012922629,0.00006392688,0.000033766704],"category_scores_gemma":[0.00023255647,0.000075842305,0.000055409902,0.0006375756,0.00025879807,0.00026281635,0.000010328449,0.00010737815,0.00000842839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012055569,0.00010631407,0.95412177,0.000009341346,0.000030052455,8.0839203e-7,0.0003411196,3.0419795e-8,0.00031347337,0.0027667042,0.039238714,0.0029511484],"study_design_scores_gemma":[0.0012733462,0.0016087315,0.979009,0.000041026036,0.000009450242,6.239568e-7,0.00007237092,0.00008951471,0.00018881376,0.0009346138,0.0166914,0.00008115631],"about_ca_topic_score_codex":0.008188736,"about_ca_topic_score_gemma":0.15568173,"teacher_disagreement_score":0.14749299,"about_ca_system_score_codex":0.00012195126,"about_ca_system_score_gemma":0.0003557227,"threshold_uncertainty_score":0.9984158},"labels":[],"label_agreement":null},{"id":"W2921686214","doi":"10.3851/imp3304","title":"Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data","year":2018,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"American Association for the Study of Liver Diseases","keywords":"Medicine; Meta-analysis; Chronic hepatitis; Internal medicine; Ribavirin; Gastroenterology; Virology; Virus","score_opus":0.4278429051974251,"score_gpt":0.44766296908937825,"score_spread":0.01982006389195312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921686214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023472797,0.99441093,0.000009971387,0.0001394851,0.00004050407,0.003772674,0.0013088083,0.00003169959,0.000051205778],"genre_scores_gemma":[0.0024821844,0.9955001,0.000102873106,0.00033673627,0.00006470302,0.00053429086,0.000761401,0.00007175319,0.00014597656],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945433,0.0011968507,0.002253902,0.0009238172,0.0005784257,0.00050370884],"domain_scores_gemma":[0.9960725,0.0004538936,0.0012803879,0.0019877658,0.00012319676,0.00008228465],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0024927645,0.00073451875,0.01581987,0.00068130647,0.00006846719,0.000046581546,0.00073122454,0.00020810627,0.00020368428],"category_scores_gemma":[0.0003615187,0.0004632512,0.0015316362,0.0010606609,0.00028388263,0.00020273293,0.00048607067,0.00037346146,0.00004929894],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008369961,0.00009745239,0.00014694316,0.6428046,0.34323624,0.00003896572,0.00033241126,2.4751573e-8,6.333501e-7,0.00002209882,0.0004289932,0.01288323],"study_design_scores_gemma":[0.00024008958,0.00036215488,0.00022199849,0.12485371,0.8474377,0.000014159521,0.000010576972,0.000024177412,0.0000012760306,0.0000046404057,0.026447408,0.0003821424],"about_ca_topic_score_codex":0.0013784197,"about_ca_topic_score_gemma":0.0043199575,"teacher_disagreement_score":0.51795095,"about_ca_system_score_codex":0.00011590656,"about_ca_system_score_gemma":0.000308541,"threshold_uncertainty_score":0.9997819},"labels":[],"label_agreement":null},{"id":"W2943441727","doi":"10.3851/imp3312","title":"Lean Mass Declines Consistently over 10 Years in People living with HIV on Antiretroviral Therapy, with Patterns Differing by Sex","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Institute on Aging; National Institutes of Health; Gilead Sciences","keywords":"Medicine; Cohort; Lean body mass; Integrase inhibitor; Antiretroviral therapy; Demography; Wasting; Viral load; Human immunodeficiency virus (HIV); Dolutegravir; Efavirenz; Internal medicine; Immunology","score_opus":0.017976438236219344,"score_gpt":0.2897836045540148,"score_spread":0.27180716631779545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943441727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976901,0.0001623893,0.00010743238,0.00027802202,0.000034340712,0.0004932633,0.000019895648,0.000074577445,0.0011399724],"genre_scores_gemma":[0.9962724,0.00062967493,0.00017630865,0.00069058966,0.00009285343,0.000036910515,0.000039681767,0.000058152957,0.0020034416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987444,0.00004953596,0.00022492901,0.00037763125,0.00023506218,0.0003684391],"domain_scores_gemma":[0.9993221,0.00008600868,0.000098896664,0.00036222124,0.00005232225,0.00007842786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009178353,0.00023860944,0.00034747107,0.0001303569,0.00011912854,0.00002995805,0.00008911204,0.000081768805,0.00016691239],"category_scores_gemma":[0.0000045237744,0.00016080991,0.000050386217,0.00026548002,0.00009767528,0.00009256332,0.000011638552,0.00019113703,0.00007680718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006225108,0.00047963878,0.981934,0.0000118029,0.000104165454,0.00003104955,0.00074731704,5.7661e-7,0.0022475177,0.000019560657,0.00022905988,0.0135728195],"study_design_scores_gemma":[0.004954994,0.005118203,0.9863428,0.0004538926,0.000015278994,0.000012790609,0.00013422125,0.0001677425,0.001444207,0.000008534586,0.0011455471,0.00020181024],"about_ca_topic_score_codex":0.0002700033,"about_ca_topic_score_gemma":0.00011667515,"teacher_disagreement_score":0.013371008,"about_ca_system_score_codex":0.00006259499,"about_ca_system_score_gemma":0.000058364298,"threshold_uncertainty_score":0.6557638},"labels":[],"label_agreement":null},{"id":"W2965382341","doi":"10.3851/imp3326","title":"Antiviral drug Utilization and Annual Expenditures for Patients with Chronic HBV Infection in Guangzhou, China, in 2008–2015","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Drug; Medicine; Antiviral drug; Virology; Internal medicine; Hepatitis B virus; Environmental health; Pharmacology; Virus","score_opus":0.01799540470010741,"score_gpt":0.3100485782797768,"score_spread":0.29205317357966937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965382341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720013,0.0008961791,0.00008586062,0.00017304425,0.00017245572,0.0011045825,0.00003341115,0.00004213414,0.0002921815],"genre_scores_gemma":[0.9971148,0.0021042258,0.00011310128,0.00012617101,0.00025417184,0.00007272959,0.00006612421,0.00003303829,0.00011566868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998889,0.00006861317,0.00023137669,0.00031361973,0.00018056933,0.000316793],"domain_scores_gemma":[0.9996176,0.000034179677,0.00008369097,0.00014464324,0.00009100357,0.00002888038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017847531,0.00020037187,0.00031752445,0.00023091206,0.00009726825,0.000017819419,0.000040897023,0.000078679186,0.000014792372],"category_scores_gemma":[0.000034890527,0.00015576508,0.000032962344,0.00022258947,0.0001775712,0.00036073232,0.000023924275,0.00012100859,0.000007920103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000750091,0.00028685413,0.9594194,0.000028717726,0.000027843755,0.0000038800003,0.0023275502,3.449999e-7,0.00020582134,0.0000320818,0.0014006665,0.035516705],"study_design_scores_gemma":[0.005949035,0.0021667036,0.9832412,0.00015981727,0.000008918938,0.0000010431104,0.000037969414,0.00014352176,0.0033512127,0.00010318891,0.0046585514,0.00017886286],"about_ca_topic_score_codex":0.0024646935,"about_ca_topic_score_gemma":0.019630838,"teacher_disagreement_score":0.035337843,"about_ca_system_score_codex":0.000098322904,"about_ca_system_score_gemma":0.00005714722,"threshold_uncertainty_score":0.99825835},"labels":[],"label_agreement":null},{"id":"W3004898529","doi":"10.3851/imp3344","title":"Molecular Pathway of Influenza Pan-neuraminidase Inhibitor Resistance in an Immunocompromised Patient","year":2018,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Zanamivir; Oseltamivir; Neuraminidase; Virology; Neuraminidase inhibitor; Biology; Population; Virus; Microbiology; Medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.05973399212992531,"score_gpt":0.36574805558314716,"score_spread":0.30601406345322185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004898529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459684,0.0021773765,0.0000057486127,0.00009147313,0.000069920134,0.0008361309,0.00001774591,0.00004221133,0.0021625375],"genre_scores_gemma":[0.99816453,0.00015711528,0.00050138455,0.00095107337,0.00008511058,0.000056933673,0.0000057532384,0.00003413538,0.00004394268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811745,0.00019144578,0.00048043492,0.0003379991,0.0004613198,0.00041138055],"domain_scores_gemma":[0.99885416,0.00005624756,0.00013377874,0.0005504191,0.00034055486,0.00006482861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002815159,0.00021395781,0.00043033002,0.00019989829,0.00007320661,0.000017845505,0.000157071,0.000090720954,0.000023750988],"category_scores_gemma":[0.00011266372,0.00017273653,0.000099735356,0.00035994814,0.0004416862,0.0001862841,0.00006319878,0.0002304255,0.000028865443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004375592,0.00059311144,0.023373142,0.00004684498,0.000070395785,0.00010636011,0.0026528372,3.535685e-7,0.9407486,0.00024393846,0.000070861184,0.027718008],"study_design_scores_gemma":[0.004481291,0.00277537,0.10411804,0.00019342684,0.0000052181163,0.0000010206669,0.00016984838,0.000018976452,0.880474,0.00022283553,0.007350781,0.00018924507],"about_ca_topic_score_codex":0.00006437526,"about_ca_topic_score_gemma":0.00003678091,"teacher_disagreement_score":0.0807449,"about_ca_system_score_codex":0.000054278084,"about_ca_system_score_gemma":0.000113439106,"threshold_uncertainty_score":0.70439917},"labels":[],"label_agreement":null},{"id":"W3007322252","doi":"10.3851/imp3346","title":"The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Osteoporosis Canada; University Health Network; St. Michael's Hospital; Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Emtricitabine; Femoral neck; Osteoporosis; Bone mineral; Meta-analysis; Internal medicine; Randomized controlled trial; Tenofovir; Relative risk; Pre-exposure prophylaxis; Surgery; Human immunodeficiency virus (HIV); Confidence interval; Viral load; Antiretroviral therapy; Men who have sex with men","score_opus":0.06372267784972224,"score_gpt":0.38213684510129964,"score_spread":0.3184141672515774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007322252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004810105,0.9923942,0.0000038987805,0.00095759565,0.000013972059,0.006311994,0.00005576086,0.00002702757,0.00018745614],"genre_scores_gemma":[0.00073217787,0.9965562,0.0000177049,0.00039898156,0.00001733686,0.00092447357,0.00010967099,0.000041834533,0.0012016167],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968825,0.0010506555,0.0010965477,0.00044914984,0.0002915952,0.00022957304],"domain_scores_gemma":[0.99734217,0.0007165656,0.0008649633,0.0009058785,0.00006940846,0.00010103808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007270189,0.00051976816,0.009383003,0.0001573139,0.00016817513,0.000024154553,0.00014758769,0.00014377722,0.00001795311],"category_scores_gemma":[0.00008624386,0.00021048263,0.0025404666,0.0009777673,0.00008367608,0.000026559388,0.00003149966,0.00033490013,0.000091759255],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006508821,0.00009845587,0.000022097558,0.6834239,0.24609688,0.000055155593,0.000024480056,1.7808846e-8,6.0457216e-7,0.000086264256,0.00023116313,0.0698959],"study_design_scores_gemma":[0.00044535854,0.001349744,0.000013160626,0.027846094,0.9198536,0.000052277752,0.0000010940786,0.000005157319,0.0000020060354,0.000006169333,0.050241984,0.00018331097],"about_ca_topic_score_codex":0.000018477183,"about_ca_topic_score_gemma":0.0000029581347,"teacher_disagreement_score":0.6737568,"about_ca_system_score_codex":0.00004195565,"about_ca_system_score_gemma":0.00006663322,"threshold_uncertainty_score":0.8583233},"labels":[],"label_agreement":null},{"id":"W3030986286","doi":"10.3851/imp3361","title":"Antiviral Activity of PLK1-Targeting siRNA Delivered by Lipid Nanoparticles in HBV-Infected Hepatocytes","year":2019,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arbutus Biopharma (Canada)","funders":"Agence Nationale de la Recherche","keywords":"cccDNA; Virology; HBsAg; Hepatitis B virus; PLK1; Viability assay; Small interfering RNA; Biology; Molecular biology; Chemistry; Cell; Cell culture; Transfection; Cell cycle; Virus; Biochemistry","score_opus":0.018159777990590365,"score_gpt":0.2744658199071646,"score_spread":0.25630604191657425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030986286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963879,0.0009959847,0.000008289519,0.00019507844,0.00016119328,0.0007306591,0.000028233402,0.000095453026,0.0013972253],"genre_scores_gemma":[0.99722546,0.0020800058,0.00016094556,0.0001730152,0.00007382639,0.000019251711,0.000017106848,0.000044773795,0.00020558518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998132,0.00019851333,0.00042484424,0.00039865987,0.0003390193,0.0005069883],"domain_scores_gemma":[0.9991298,0.00019832318,0.00019694837,0.00030363558,0.00011871584,0.00005261001],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003380221,0.0002860213,0.0007568201,0.00012899507,0.00006391833,0.000016918104,0.0001241581,0.00012538247,0.00013770653],"category_scores_gemma":[0.00011869586,0.00024659105,0.00015604573,0.00040095707,0.00014598742,0.0003063312,0.000069146605,0.00025557377,0.00010932259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003783839,0.00028087848,0.48607114,0.000029817125,0.00006001314,0.000008208355,0.0003310807,3.8650327e-7,0.501703,0.00001725573,0.00027320514,0.010846582],"study_design_scores_gemma":[0.0026241897,0.0006529355,0.34492695,0.00012351149,0.000012401661,0.000001306266,0.000040988514,0.00035166918,0.6500737,0.00002231269,0.00097264204,0.00019736464],"about_ca_topic_score_codex":0.0018668848,"about_ca_topic_score_gemma":0.0002013888,"teacher_disagreement_score":0.14837067,"about_ca_system_score_codex":0.00007445515,"about_ca_system_score_gemma":0.000070195216,"threshold_uncertainty_score":0.9999986},"labels":[],"label_agreement":null},{"id":"W3046958273","doi":"10.3851/imp3367","title":"Hepatitis B Core-Related Antigen Levels Predict Pegylated Interferon-α Therapy Response in HBeAg-Positive Chronic Hepatitis B","year":2019,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"HBsAg; Medicine; Pegylated interferon; HBeAg; Internal medicine; Hepatitis B; Gastroenterology; Lamivudine; Antigen; Chronic hepatitis; Immunology; Hepatitis B virus; Virus; Ribavirin","score_opus":0.029778533878021547,"score_gpt":0.2980232733590482,"score_spread":0.2682447394810267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046958273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987301,0.0060962364,0.00002968469,0.00089953525,0.0006513594,0.002407854,0.00017619992,0.0002834168,0.0021547386],"genre_scores_gemma":[0.9455196,0.05120419,0.000083652405,0.0008291917,0.00013607822,0.000087752036,0.00010437192,0.0001352115,0.0018999511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99614125,0.00057779346,0.0009090778,0.0008684543,0.00058747176,0.0009159208],"domain_scores_gemma":[0.9981901,0.00040883513,0.0002688793,0.0007473193,0.00024547667,0.00013937912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00082151726,0.0006235111,0.0011598035,0.00047825358,0.0001519591,0.000054012235,0.00030775796,0.0003698355,0.0010072537],"category_scores_gemma":[0.000110853485,0.00054564845,0.00030108233,0.000893134,0.00031934172,0.000408149,0.000103612576,0.00070404937,0.0008972136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005867456,0.00033833878,0.8347638,0.000020730015,0.000521594,0.00030165346,0.0026859727,0.000004797709,0.12924631,0.000062623876,0.00045630662,0.025730405],"study_design_scores_gemma":[0.008158176,0.008057084,0.93901986,0.00067886186,0.000017728493,0.000029639721,0.000036790356,0.0008173289,0.039807357,0.00011622484,0.0027142502,0.0005467072],"about_ca_topic_score_codex":0.010961244,"about_ca_topic_score_gemma":0.0026050275,"teacher_disagreement_score":0.10425604,"about_ca_system_score_codex":0.0005609666,"about_ca_system_score_gemma":0.00040503452,"threshold_uncertainty_score":0.99990594},"labels":[],"label_agreement":null},{"id":"W3196876339","doi":"10.1177/135965350801302s03","title":"The World Health Organization's global strategy for prevention and assessment of HIV drug resistance","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"HIV drug resistance; Regimen; Medicine; Developing country; Public health; Resource (disambiguation); Human immunodeficiency virus (HIV); Environmental health; Antiretroviral therapy; Economic growth; Viral load; Family medicine; Nursing; Surgery; Computer science","score_opus":0.029745058370603223,"score_gpt":0.3470594945262849,"score_spread":0.31731443615568167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196876339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95275086,0.003670816,0.002189381,0.034392413,0.0000994224,0.001683837,0.000025698384,0.000058753398,0.0051288344],"genre_scores_gemma":[0.9209571,0.0037483086,0.0048523513,0.00010507461,0.000033322827,0.000018871397,0.00005926292,0.000010550251,0.07021517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934185,0.00004444494,0.00019654255,0.00013709794,0.00014132568,0.00013874639],"domain_scores_gemma":[0.999604,0.00005238261,0.00011011751,0.00011498794,0.00008562979,0.00003287174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015232034,0.000091379865,0.00017686312,0.000023626117,0.00024070666,0.000010922878,0.000039189315,0.000015475625,0.000009461793],"category_scores_gemma":[0.0000068606696,0.000058938425,0.000035722842,0.00023912397,0.000066059205,0.00005430143,0.0000077228,0.000036847385,0.0000013794842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057988946,0.0008649944,0.79898924,0.000120269135,0.0004955463,0.000011953247,0.0009194648,0.0000015983132,0.00044798784,0.039888002,0.092989124,0.06469192],"study_design_scores_gemma":[0.007506915,0.00032724073,0.82363075,0.00020225217,0.000038077607,0.000012324417,0.00028535168,0.00006557441,0.006024171,0.0028357815,0.15885244,0.00021914976],"about_ca_topic_score_codex":0.000003853634,"about_ca_topic_score_gemma":0.00016142939,"teacher_disagreement_score":0.06586331,"about_ca_system_score_codex":0.000063530635,"about_ca_system_score_gemma":0.00025859062,"threshold_uncertainty_score":0.24034393},"labels":[],"label_agreement":null},{"id":"W338559656","doi":"10.1177/135965350801300116","title":"Characterization of drug Resistance in Antiretroviral-Treated Patients Infected with HIV-1 CRF02_AG and AGK Subtypes in Mali and Burkina Faso","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"U.S. Public Health Service","keywords":"Efavirenz; Nevirapine; Stavudine; Virology; Lamivudine; Drug resistance; Zidovudine; Genotype; Reverse transcriptase; Population; Internal medicine; Medicine; Didanosine; Cohort; Biology; Viral load; Viral disease; Human immunodeficiency virus (HIV); Antiretroviral therapy; Polymerase chain reaction; Virus; Genetics; Gene","score_opus":0.0077590531039058944,"score_gpt":0.2155871698676818,"score_spread":0.2078281167637759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W338559656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988309,0.00019491753,0.000002887346,0.0002168014,0.000011137527,0.00044500333,0.00000934466,0.000020671103,0.00026832765],"genre_scores_gemma":[0.99539965,0.00224045,0.00015594786,0.00003722453,0.0000076679835,0.000013292809,0.00016709385,0.000017135155,0.001961554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991906,0.000054123862,0.00022457959,0.00022688763,0.00014044603,0.00016332694],"domain_scores_gemma":[0.99969965,0.00002308133,0.000092971495,0.000104186685,0.00004976485,0.000030362316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058814057,0.00016129816,0.00032031102,0.00020820882,0.00003671427,0.000007014133,0.000025930096,0.00004941417,0.0000064343362],"category_scores_gemma":[0.000007677076,0.00011946656,0.000015876607,0.00037331725,0.00010817473,0.00015279565,0.000011070158,0.00007357276,0.0000021015214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012034137,0.00031608742,0.97798365,0.000030549814,0.000031111842,0.00007206891,0.0017511236,2.6417904e-8,0.017401429,0.000012304984,0.000017998094,0.001180209],"study_design_scores_gemma":[0.005687553,0.00018752819,0.9669538,0.00022153942,0.000008878043,0.000002837119,0.000019915888,0.0000071877994,0.026555665,0.0000075222624,0.00022642642,0.000121103665],"about_ca_topic_score_codex":0.000055759785,"about_ca_topic_score_gemma":0.00013047984,"teacher_disagreement_score":0.011029835,"about_ca_system_score_codex":0.000029637256,"about_ca_system_score_gemma":0.000034661683,"threshold_uncertainty_score":0.48717052},"labels":[],"label_agreement":null},{"id":"W41880533","doi":"10.1177/135965350601100804","title":"Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Zanamivir; Oseltamivir; Neuraminidase; Neuraminidase inhibitor; Virology; Biology; Mutation; Resistance mutation; Mutant; Virus; Influenza A virus; Wild type; Microbiology; Genetics; Gene; Medicine; Reverse transcriptase; Polymerase chain reaction; Coronavirus disease 2019 (COVID-19)","score_opus":0.06949167765261202,"score_gpt":0.39480818195310746,"score_spread":0.3253165043004954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W41880533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995614,0.0017130118,0.000010322016,0.00044243038,0.000026647991,0.0007641475,0.000024004159,0.000022422064,0.0013829966],"genre_scores_gemma":[0.9985729,0.00019779272,0.00018772422,0.00075111055,0.000102417835,0.00005118939,0.00000549991,0.000023276089,0.0001080932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840426,0.00016410454,0.00040692152,0.00027014033,0.00037410518,0.0003804376],"domain_scores_gemma":[0.9991041,0.0002876364,0.00008601611,0.0003292368,0.00013479289,0.000058248705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031783574,0.00020797775,0.0003295913,0.00024851802,0.00011812333,0.00005431982,0.00013155151,0.00005775193,0.000009995138],"category_scores_gemma":[0.00012700564,0.00013682379,0.00010531116,0.00052068004,0.00027203953,0.00013564382,0.000042005642,0.0002335097,0.000008842433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012023486,0.0003953511,0.89146936,0.00006708322,0.00010006898,0.00015817437,0.0030222638,0.0000911676,0.09107778,0.00027267178,0.0010168627,0.01112684],"study_design_scores_gemma":[0.0020409136,0.0007347123,0.98959744,0.0000857627,0.000013541816,0.00000804855,0.0002762815,0.00004763822,0.005173396,0.0001886614,0.0016971673,0.0001364665],"about_ca_topic_score_codex":0.00086131296,"about_ca_topic_score_gemma":0.00017304695,"teacher_disagreement_score":0.09812802,"about_ca_system_score_codex":0.00005228732,"about_ca_system_score_gemma":0.000088399924,"threshold_uncertainty_score":0.5579512},"labels":[],"label_agreement":null},{"id":"W4293221760","doi":"10.1177/13596535211067610","title":"Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada","year":2022,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; AIDS Vancouver; HIV Legal Network; St. Paul's Hospital; University of Ottawa; University of Calgary; McGill University; B.C. Women's Hospital & Health Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Cohort; Population; Proportional hazards model; Depression (economics); Hepatitis C; Prospective cohort study; Cohort study; Confidence interval; Psychiatry","score_opus":0.029970469060767405,"score_gpt":0.32066222118038823,"score_spread":0.29069175211962084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293221760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547565,0.000102931685,0.0000044368326,0.00089780573,0.00007704454,0.0012371849,0.00011467111,0.000015173856,0.0020751],"genre_scores_gemma":[0.99719656,0.00011355677,0.000007808835,0.0016599584,0.00006913862,0.00046397463,0.00029259885,0.000022773407,0.00017364485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815124,0.00049327314,0.00023941268,0.00024906083,0.0005567042,0.00031031793],"domain_scores_gemma":[0.99943084,0.00012941888,0.0000634399,0.0002662792,0.00005265343,0.00005735579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021412609,0.00014208775,0.00023936889,0.0002091978,0.00011461468,0.000020888956,0.00011453273,0.00003442573,0.0004489028],"category_scores_gemma":[0.000072113835,0.00010544605,0.000042043546,0.0005398444,0.000013439177,0.000091529546,0.000023632194,0.00023727339,0.000036605084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003261603,0.00014081295,0.96423376,0.000003997372,0.000027640532,0.0002778027,0.0013894466,0.00006794438,0.00096347986,0.000010189187,0.0007490411,0.031809755],"study_design_scores_gemma":[0.0024475444,0.00049638405,0.98426664,0.000028003276,0.000005290691,0.0000030839733,0.00027431463,0.00063742395,0.00079638656,0.000011913696,0.010912377,0.00012063497],"about_ca_topic_score_codex":0.5827058,"about_ca_topic_score_gemma":0.6539033,"teacher_disagreement_score":0.07119749,"about_ca_system_score_codex":0.001392464,"about_ca_system_score_gemma":0.00049705524,"threshold_uncertainty_score":0.4915171},"labels":[],"label_agreement":null},{"id":"W4298202204","doi":"10.1177/135965350501000711","title":"Association of the CCR5Δ32 Mutation with Clinical Response and &gt;5-year Survival following Initiation of First Triple Antiretroviral Regimen","year":2005,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Internal medicine; Viral load; Context (archaeology); Medicine; Proportional hazards model; Regimen; Cohort; Population; Oncology; Immunology; Biology; Human immunodeficiency virus (HIV)","score_opus":0.023503737585542542,"score_gpt":0.3051901995619585,"score_spread":0.28168646197641595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298202204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980601,0.00034429008,0.000017813218,0.0008390861,0.00014702624,0.00025639366,0.000032994554,0.000011462966,0.00029083525],"genre_scores_gemma":[0.9987272,0.00026884876,0.00006675556,0.000020301217,0.000023498076,0.000006372389,0.00003274092,0.000008284621,0.0008459783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985821,0.00075913436,0.00026240313,0.00014389817,0.000089847184,0.00016258696],"domain_scores_gemma":[0.99906605,0.00048036608,0.00023220193,0.00014864247,0.00006322804,0.000009488971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053783,0.000086867105,0.00022243442,0.000049690643,0.00011295651,0.0000074757572,0.00008088271,0.00012148684,0.000023434884],"category_scores_gemma":[0.00017607152,0.000055243483,0.000100289835,0.0001379249,0.000114129754,0.00012822583,0.000019740952,0.00012731814,0.000017900244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004304125,0.00023901559,0.94745106,0.0000044266617,0.00042234318,0.000001979637,0.00054116204,8.7037944e-7,0.036571175,0.00006845089,0.0003467458,0.010048654],"study_design_scores_gemma":[0.00715351,0.0017356606,0.91450655,0.000031603435,0.000036669524,0.00000161315,0.00014970796,0.000006089969,0.07260646,0.00002656131,0.0036662163,0.00007934329],"about_ca_topic_score_codex":0.000043899145,"about_ca_topic_score_gemma":0.0000894427,"teacher_disagreement_score":0.03603528,"about_ca_system_score_codex":0.000035003242,"about_ca_system_score_gemma":0.000057885434,"threshold_uncertainty_score":0.2252764},"labels":[],"label_agreement":null},{"id":"W4298363631","doi":"10.1177/135965350300800506","title":"Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AIDS Vancouver","funders":"","keywords":"Nevirapine; Viral load; Reverse-transcriptase inhibitor; Internal medicine; Proportional hazards model; Virology; Medicine; Lentivirus; Efavirenz; Gastroenterology; Immunology; Biology; Antiretroviral therapy; Human immunodeficiency virus (HIV); Viral disease","score_opus":0.049314907136050544,"score_gpt":0.32553297407748044,"score_spread":0.2762180669414299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298363631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684554,0.000211547,0.0000114766335,0.0002623303,0.00009798336,0.0009819875,0.000004728951,0.00006486838,0.001519533],"genre_scores_gemma":[0.9979499,0.00042926313,0.0004470863,0.00083487283,0.00002980744,0.000083289706,0.0000308728,0.00003207322,0.00016285172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728775,0.00039937563,0.00074892776,0.0005955566,0.00037818777,0.0005902101],"domain_scores_gemma":[0.9991023,0.00022320966,0.0001346534,0.0003484404,0.00007620469,0.00011522625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007680555,0.00037194142,0.0006817456,0.00025561152,0.00009298673,0.000042723506,0.00014221169,0.00018811206,0.0001351683],"category_scores_gemma":[0.00035964465,0.0002823728,0.000141921,0.00047432678,0.0001215765,0.00030475494,0.000027658189,0.00036140962,0.000041648265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026580228,0.0016854523,0.96751213,0.000006453966,0.00004240226,0.00008806316,0.0011941942,0.000008441087,0.0016643065,0.00010703238,0.000009823236,0.025023675],"study_design_scores_gemma":[0.012708159,0.000926765,0.97636884,0.000082143655,0.000007406017,0.0000029506377,0.00012961794,0.00003445191,0.008782144,0.00029108912,0.00036610418,0.0003003369],"about_ca_topic_score_codex":0.00014667903,"about_ca_topic_score_gemma":0.00015954643,"teacher_disagreement_score":0.024723338,"about_ca_system_score_codex":0.00020895935,"about_ca_system_score_gemma":0.00013282998,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W4299412210","doi":"10.1177/135965350200702s01","title":"Meeting Report from the 2Nd International HIV Workshop on Management of Treatment-Experienced Patients","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Internal medicine; Family medicine","score_opus":0.03668188375990694,"score_gpt":0.293695466110318,"score_spread":0.25701358235041105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299412210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757524,0.00088901387,0.0000068835866,0.0005457138,0.00027796044,0.00027464592,0.00006125175,0.000019439462,0.022172658],"genre_scores_gemma":[0.98872226,0.002539459,0.000041741074,0.000059525762,0.00002380025,0.00004754802,0.00031881858,0.000007923453,0.008238944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926174,0.00008985829,0.00018038647,0.00021544805,0.00006356049,0.00018901269],"domain_scores_gemma":[0.99949837,0.00010942441,0.00008986942,0.00026321,0.000029656223,0.0000094741235],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005688772,0.000118674616,0.00012729212,0.00002880026,0.000115630995,0.000012385847,0.00018820587,0.000048480422,0.0011295432],"category_scores_gemma":[0.0000096019,0.00006772159,0.00008382669,0.000065447704,0.00010499702,0.000047106623,0.00003185146,0.000065917746,0.0004915644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093121314,0.0036237447,0.23217787,0.0000021039357,0.0031384304,0.00018192761,0.0045201248,0.000004630051,0.014932376,0.00032837345,0.01587354,0.72428566],"study_design_scores_gemma":[0.018705811,0.0018810597,0.2673019,0.00025392725,0.00006452017,0.000011077782,0.0025706103,0.000024397834,0.1626746,0.00021284568,0.54581285,0.00048643153],"about_ca_topic_score_codex":0.00008661349,"about_ca_topic_score_gemma":0.000008129024,"teacher_disagreement_score":0.7237992,"about_ca_system_score_codex":0.000047236463,"about_ca_system_score_gemma":0.0000044703283,"threshold_uncertainty_score":0.9997836},"labels":[],"label_agreement":null},{"id":"W4302165968","doi":"10.1177/135965350801300207","title":"Amphipathic DNA Polymers are Candidate Vaginal Microbicides and Block Herpes Simplex virus Binding, Entry and Viral Gene Expression","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Microbicides for sexually transmitted diseases; Herpes simplex virus; Virology; DNA; Biology; Virus; Medicine; Population; Genetics","score_opus":0.02052160268144816,"score_gpt":0.27255495413443376,"score_spread":0.2520333514529856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302165968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584335,0.0031635885,0.0000121468265,0.00016083225,0.00009789129,0.00027991744,0.000050444654,0.00007731519,0.00031448985],"genre_scores_gemma":[0.98885715,0.00958743,0.00021582781,0.00040268738,0.0001283715,0.000016295495,0.000027768116,0.000036237958,0.0007282537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885833,0.00007278508,0.00020671157,0.00037405602,0.00014805104,0.00034008143],"domain_scores_gemma":[0.99949646,0.000031250336,0.00010243254,0.00020773127,0.000028697717,0.00013340022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007849246,0.0002722696,0.00034714985,0.00014753551,0.00040512637,0.0000343405,0.00004502037,0.00012877356,0.00007551016],"category_scores_gemma":[0.000006738768,0.0002093925,0.000072779694,0.0001301094,0.00024141067,0.00015828926,0.000035874105,0.00014497286,0.000020872518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005099573,0.00044954158,0.2526996,0.00002230742,0.00022760005,0.0003954897,0.00070221105,2.0617232e-7,0.64126223,0.000008755266,0.00045692213,0.103265174],"study_design_scores_gemma":[0.0046876124,0.0004918948,0.13535696,0.0001361521,0.000056975616,0.00047270674,0.00009025911,0.000009930284,0.8223657,0.00003200268,0.035999987,0.00029982172],"about_ca_topic_score_codex":0.00052693486,"about_ca_topic_score_gemma":0.000034092773,"teacher_disagreement_score":0.18110348,"about_ca_system_score_codex":0.00003298017,"about_ca_system_score_gemma":0.000045597393,"threshold_uncertainty_score":0.85387784},"labels":[],"label_agreement":null},{"id":"W4309322375","doi":"10.1177/13596535221127848","title":"EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B","year":2022,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Placebo; Gastroenterology; Adverse effect; Internal medicine; Dosing; Lamivudine; Hepatitis B; Hepatitis B virus; Viral load; Pharmacology; Reverse transcriptase; Reverse-transcriptase inhibitor; Immunology; Virus; Pathology; RNA; Chemistry","score_opus":0.0133994133639923,"score_gpt":0.2467197568985571,"score_spread":0.2333203435345648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309322375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948079,0.0020791232,0.000004743077,0.0012419597,0.00022455552,0.0010689399,0.00011764882,0.0000656712,0.0003894485],"genre_scores_gemma":[0.9936224,0.0035315752,0.00010250212,0.0022354822,0.00009715965,0.00014005588,0.00007021062,0.000054510547,0.00014606978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981873,0.0002006152,0.00030583714,0.0004229819,0.00043399486,0.00044928773],"domain_scores_gemma":[0.9994449,0.000050900155,0.00008919157,0.0002675835,0.000054538094,0.00009291292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019185003,0.00024634146,0.00045998945,0.00021639802,0.0002775358,0.000017279728,0.000085158164,0.000050007427,0.00016962875],"category_scores_gemma":[0.000019452613,0.00021494349,0.00006006972,0.00046475406,0.00014156132,0.00018055532,0.000051637227,0.00036558817,0.000009660832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027266864,0.0005176591,0.9781309,0.000069763104,0.00007141594,0.00015762607,0.0017675048,0.0000015911676,0.0024667375,0.000044007236,0.0021877522,0.0118584],"study_design_scores_gemma":[0.013450905,0.006827209,0.9395112,0.0001133535,0.000024311274,0.000008274633,0.000081729144,0.000045990753,0.0015901789,0.000037994305,0.038003687,0.00030516202],"about_ca_topic_score_codex":0.0055308784,"about_ca_topic_score_gemma":0.0035376202,"teacher_disagreement_score":0.038619652,"about_ca_system_score_codex":0.00025000126,"about_ca_system_score_gemma":0.00016109254,"threshold_uncertainty_score":0.8765141},"labels":[],"label_agreement":null},{"id":"W4379875283","doi":"10.1177/13596535231182505","title":"Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV","year":2023,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"LGBTQ Health, Identity, and Policy","field":"Psychology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Wellesley Institute; St. Michael's Hospital; Public Health Ontario; Toronto East General Hospital; Toronto General Hospital; University of Toronto; Women's College Hospital; Maple Leaf Medical Clinic","funders":"Canadian Institutes of Health Research; Canadian HIV Trials Network, Canadian Institutes of Health Research; Gilead Sciences","keywords":"Cobicistat; Medicine; Ritonavir; Testosterone (patch); Hormone therapy; Human immunodeficiency virus (HIV); Internal medicine; Cohort; Antiretroviral therapy; Gynecology; Viral load; Immunology; Breast cancer","score_opus":0.0447373969898414,"score_gpt":0.34226328225077934,"score_spread":0.29752588526093793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379875283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98383725,0.0010614297,0.0000026599273,0.00094803615,0.00009243805,0.00041624147,0.000027245405,0.0000454542,0.013569251],"genre_scores_gemma":[0.98907214,0.007832291,0.000014081139,0.00049569434,0.00008576608,0.00006640289,0.000009260418,0.000038078007,0.0023862612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985706,0.00012375118,0.00022237733,0.0002790798,0.00013265104,0.0006715389],"domain_scores_gemma":[0.99948466,0.00003624113,0.000059352544,0.00024125607,0.000025677884,0.00015279074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004684614,0.00016288893,0.00030058954,0.0003690431,0.00008683238,0.0000208122,0.00013391733,0.00011501786,0.00009361836],"category_scores_gemma":[0.000002778998,0.00013432243,0.000026577343,0.00055809476,0.00012938581,0.00009354465,0.0000052841115,0.00016647331,0.00005129126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043635917,0.00005237877,0.9661615,0.000018883566,0.000099560624,0.00001960276,0.012808916,3.500431e-7,0.001031338,0.00037758262,0.001075724,0.017917804],"study_design_scores_gemma":[0.0024306409,0.00049499876,0.9919454,0.000007631637,0.0000038551575,0.000006018945,0.00061673834,0.0000058370233,0.000056024932,0.00030563335,0.0039608423,0.00016637608],"about_ca_topic_score_codex":0.28814018,"about_ca_topic_score_gemma":0.08307623,"teacher_disagreement_score":0.20506395,"about_ca_system_score_codex":0.000053595537,"about_ca_system_score_gemma":0.00018468924,"threshold_uncertainty_score":0.93365526},"labels":[],"label_agreement":null},{"id":"W4391965063","doi":"10.1177/13596535241233128","title":"Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada","year":2024,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital","funders":"","keywords":"Emtricitabine; Efavirenz; Medicine; Lamivudine; Abacavir; Context (archaeology); Incidence (geometry); Darunavir; Atazanavir; Adverse effect; Internal medicine; Pre-exposure prophylaxis; Human immunodeficiency virus (HIV); Virology; Viral load; Hepatitis B virus; Men who have sex with men; Syphilis; Antiretroviral therapy","score_opus":0.009831239983374972,"score_gpt":0.24051907442377488,"score_spread":0.2306878344403999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391965063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971724,0.0008662685,0.00002478648,0.0004761654,0.00017304953,0.0009777413,0.00012668228,0.00004874543,0.00013417148],"genre_scores_gemma":[0.9850335,0.0013090677,0.0002708045,0.00003428661,0.000038675098,0.00012552628,0.00026377803,0.000018210467,0.012906114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988087,0.000054883556,0.0003343976,0.00033538896,0.00023982683,0.00022684052],"domain_scores_gemma":[0.99956805,0.000036410194,0.00005163328,0.00017536656,0.00005965732,0.00010890569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011524599,0.00013389242,0.0002959817,0.00012359279,0.00009749191,0.00004127625,0.000048404905,0.000059076327,0.000042263026],"category_scores_gemma":[0.000016800932,0.00015073986,0.00005944249,0.00061062275,0.00008610814,0.00013926606,0.000014718272,0.00009677546,0.000005983302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004095981,0.00032203886,0.96198374,0.00003798519,0.00020307563,0.00015873331,0.0005741191,0.0000030893702,0.0010679612,0.000009259859,0.0014792917,0.034119733],"study_design_scores_gemma":[0.0017306058,0.00044983203,0.9826251,0.00029870693,0.000060850864,0.000017645545,0.00016837448,0.00012396366,0.0013296746,0.0000072629487,0.013040357,0.00014759469],"about_ca_topic_score_codex":0.4972363,"about_ca_topic_score_gemma":0.79141486,"teacher_disagreement_score":0.29417858,"about_ca_system_score_codex":0.00038646223,"about_ca_system_score_gemma":0.0005746347,"threshold_uncertainty_score":0.6146993},"labels":[],"label_agreement":null},{"id":"W4417144318","doi":"10.1177/13596535251405300","title":"Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection","year":2025,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Oseltamivir; Exacerbation; Neuraminidase inhibitor; Viral load; Influenza A virus; Titer; Combination therapy; Zanamivir; In vivo","score_opus":0.03990285508201662,"score_gpt":0.32060629329390244,"score_spread":0.2807034382118858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417144318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997868,0.00024821662,0.00093293603,0.00002322405,0.0000149175285,0.0003071061,0.000010783549,0.000004883895,0.0005899198],"genre_scores_gemma":[0.9994511,0.00018353647,0.00009674708,0.00014025575,0.000010565845,0.000032695258,0.000019462217,0.000008576011,0.000057076806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992247,0.00017019665,0.00017679835,0.00016242047,0.0001651643,0.00010068909],"domain_scores_gemma":[0.99944997,0.000008798192,0.00010157884,0.00024452785,0.00018640053,0.000008745114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067935296,0.00009480607,0.00012989098,0.00006613138,0.000036705667,0.000008294019,0.00009855792,0.00008040109,0.000002166653],"category_scores_gemma":[0.000027199183,0.00006509686,0.000044301665,0.00017888391,0.00007287456,0.000012190179,0.000022909264,0.000068639274,2.0528495e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003346228,0.0002209475,0.058746587,0.000012979948,0.000086084816,8.9850694e-8,0.0002777979,0.013134703,0.90905917,0.0003739664,0.000013306287,0.017739754],"study_design_scores_gemma":[0.0033900358,0.0010037246,0.03709809,0.000072488016,0.000034156717,7.896364e-7,0.00017456201,0.029278425,0.92744714,0.0011979538,0.00013650728,0.00016609729],"about_ca_topic_score_codex":0.0003773656,"about_ca_topic_score_gemma":0.00052447134,"teacher_disagreement_score":0.021648495,"about_ca_system_score_codex":0.000009418445,"about_ca_system_score_gemma":0.00015174554,"threshold_uncertainty_score":0.26545727},"labels":[],"label_agreement":null},{"id":"W5201643","doi":"10.1177/135965350601100601","title":"Protease Inhibitor Effects on Triglyceride Synthesis and Adipokine Secretion in Human Omental and Subcutaneous Adipose Tissue","year":2006,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université Laval; McGill University Health Centre","funders":"","keywords":"Internal medicine; Endocrinology; Adiponectin; Adipose tissue; Triglyceride; Adipokine; Leptin; Lipodystrophy; Chemistry; Insulin resistance; Adipocyte; Insulin; Medicine; Cholesterol; Obesity; Immunology","score_opus":0.009731149783210574,"score_gpt":0.2822791907776764,"score_spread":0.27254804099446583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W5201643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609435,0.0011058913,0.0000039578563,0.0006327744,0.000025019053,0.0012848069,0.000010796656,0.00004431448,0.0007980901],"genre_scores_gemma":[0.9987999,0.00032495172,0.00009842417,0.00013725647,0.00009669712,0.00015579528,0.000045137556,0.00002292751,0.00031886913],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99916035,0.00006937983,0.00019811184,0.00026769782,0.00011006244,0.00019439666],"domain_scores_gemma":[0.99962413,0.00008768423,0.000056826564,0.00014762688,0.0000151816585,0.000068519344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007890304,0.0001574146,0.0002408994,0.00014829195,0.00012469426,0.000016458529,0.000022456437,0.00008472574,0.000016836291],"category_scores_gemma":[0.000009305426,0.00012879341,0.00002027764,0.000129993,0.00005090715,0.000053023374,0.000008370463,0.00012495401,0.00001617954],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031695142,0.002043084,0.14311749,0.00025110468,0.000110947134,0.0010057638,0.0003571088,0.0000010917283,0.51622456,0.0007513119,0.00028075633,0.33268726],"study_design_scores_gemma":[0.010543565,0.008338234,0.595348,0.0010488225,0.00010188898,0.00029590196,0.000024976996,0.00012956673,0.37874365,0.0007133124,0.004309656,0.00040239847],"about_ca_topic_score_codex":0.0004120168,"about_ca_topic_score_gemma":0.000028518463,"teacher_disagreement_score":0.4522305,"about_ca_system_score_codex":0.00006602389,"about_ca_system_score_gemma":0.000017085365,"threshold_uncertainty_score":0.5252043},"labels":[],"label_agreement":null},{"id":"W64237836","doi":"10.1177/135965350901400512","title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","year":2009,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Alberta; Centre hospitalier universitaire de Québec","funders":"","keywords":"Valganciclovir; Ganciclovir; Human cytomegalovirus; Viral load; Virology; Cytomegalovirus; Betaherpesvirinae; Biology; Internal medicine; Drug resistance; Gastroenterology; Medicine; Immunology; Herpesviridae; Virus; Viral disease; Genetics","score_opus":0.03267598557897407,"score_gpt":0.31964853404408783,"score_spread":0.2869725484651138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W64237836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101377,0.00084601855,0.000087338136,0.0009135276,0.00005705071,0.0011798743,0.000047604695,0.00019355821,0.0056612464],"genre_scores_gemma":[0.9901747,0.0029430604,0.00061416667,0.0013469467,0.00016868315,0.00003552042,0.000058084697,0.00009176942,0.0045670765],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963932,0.00017317187,0.00063822046,0.0008174625,0.0008129376,0.0011649894],"domain_scores_gemma":[0.9986361,0.000087497276,0.00013319819,0.0006780534,0.00017412452,0.0002909887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005061292,0.0005492621,0.0010108125,0.0005252078,0.00018522341,0.000099044824,0.0003304638,0.00026269673,0.00033490718],"category_scores_gemma":[0.00003230846,0.00036958413,0.00015761855,0.0017174676,0.00021089986,0.00033563288,0.000016288455,0.0007414275,0.00018298042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12731524,0.005106517,0.27547103,0.000105575935,0.0004646392,0.010544639,0.004362359,0.0000062443323,0.290561,0.00044367317,0.001431881,0.28418723],"study_design_scores_gemma":[0.01994701,0.0078031407,0.7931354,0.0008167476,0.0000675005,0.0002187151,0.000106102656,0.00008190984,0.15402928,0.00027254503,0.022512887,0.0010087581],"about_ca_topic_score_codex":0.00035988845,"about_ca_topic_score_gemma":0.0018339952,"teacher_disagreement_score":0.5176644,"about_ca_system_score_codex":0.00027818297,"about_ca_system_score_gemma":0.0004045244,"threshold_uncertainty_score":0.9998756},"labels":[],"label_agreement":null},{"id":"W69587150","doi":"10.1177/135965350400900503","title":"Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes","year":2004,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Interquartile range; Internal medicine; Odds ratio; Reverse-transcriptase inhibitor; Population; Regimen; Confidence interval; Logistic regression; Viral load; Antiretroviral therapy; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.04014910648780618,"score_gpt":0.3641119251427931,"score_spread":0.32396281865498694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W69587150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690425,0.0010980102,0.000032497162,0.00028876812,0.0000063740376,0.0006606924,0.00009166847,0.00001269212,0.0009050707],"genre_scores_gemma":[0.9957527,0.0038129974,0.00006650622,0.000031408017,0.000026015554,0.000017835595,0.000025096202,0.000012734481,0.0002546847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908316,0.00012734743,0.00023697165,0.00020022217,0.00017925526,0.00017301369],"domain_scores_gemma":[0.99938774,0.00012797004,0.0001429498,0.00017472533,0.00010443355,0.00006215956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120413686,0.00016972052,0.00036140418,0.00009353859,0.0001066783,0.000026241738,0.00004626928,0.000055604043,0.000010819373],"category_scores_gemma":[0.000058852645,0.00009252058,0.0001345039,0.000108785935,0.0002633275,0.00016613056,0.000018436198,0.00013246125,9.3488757e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018855016,0.00045177052,0.5518185,0.000030262183,0.0003048849,0.000006561764,0.0073838206,0.0000011847595,0.05168744,0.00037534337,0.00005020403,0.3860045],"study_design_scores_gemma":[0.007521911,0.02836149,0.86795,0.0001827298,0.00002211121,0.000005424161,0.0012703604,0.00014288024,0.094239675,0.00017284372,0.000027835635,0.00010274112],"about_ca_topic_score_codex":0.0011059376,"about_ca_topic_score_gemma":0.00003847052,"teacher_disagreement_score":0.38590178,"about_ca_system_score_codex":0.00006157974,"about_ca_system_score_gemma":0.000087040404,"threshold_uncertainty_score":0.37728798},"labels":[],"label_agreement":null},{"id":"W76024419","doi":"10.1177/135965350701200114","title":"HIV-1 drug resistance surveillance using dried whole blood spots","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; Public Health Agency of Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Drug resistance; Dried blood spot; Drug; Virology; Internal medicine; Pharmacology; Biology; Chemistry; Microbiology; Chromatography","score_opus":0.02623441622039107,"score_gpt":0.29876182322360295,"score_spread":0.2725274070032119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W76024419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984665,0.0066826954,0.0015425492,0.0011579905,0.00057088747,0.00017523055,0.000035503504,0.00009170588,0.005078482],"genre_scores_gemma":[0.9766661,0.00032208744,0.0030362087,0.0006716581,0.00009104394,0.0000012349407,0.000015955593,0.000021859798,0.019173866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985605,0.00023470797,0.00029559893,0.0003465582,0.000049181137,0.0005134938],"domain_scores_gemma":[0.999296,0.00020750784,0.000107657135,0.00030557605,0.000058770907,0.000024492405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010394773,0.00019873785,0.00032278243,0.00006926941,0.00019270266,0.000021095111,0.00022571076,0.00021433322,0.00018122104],"category_scores_gemma":[0.000034493514,0.00016020355,0.00013192474,0.000269146,0.00029375072,0.00007464749,0.00003571721,0.0002698843,0.000103537284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053976104,0.0001919043,0.028869571,0.0000069157873,0.00016829753,0.00002822358,0.00011213674,1.3937905e-7,0.95555425,0.00080680917,0.0040558996,0.009666114],"study_design_scores_gemma":[0.0018672985,0.000047938425,0.048609816,0.00003185341,0.000020372314,0.000013421387,0.00006120571,0.0000028346942,0.66485,0.00060497865,0.28353557,0.00035472645],"about_ca_topic_score_codex":0.000016493324,"about_ca_topic_score_gemma":0.00005160903,"teacher_disagreement_score":0.29070422,"about_ca_system_score_codex":0.000014703986,"about_ca_system_score_gemma":0.000023848135,"threshold_uncertainty_score":0.6532911},"labels":[],"label_agreement":null},{"id":"W77138857","doi":"10.1177/135965350801300603","title":"Inhibition of Human Metapneumovirus Replication by Small Interfering RNA","year":2008,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Respiratory viral infections research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Human metapneumovirus; Metapneumovirus; Virology; Small interfering RNA; Biology; Replication (statistics); RNA; Medicine; Internal medicine; Genetics; Gene; Respiratory system; Respiratory tract infections","score_opus":0.11924954212736902,"score_gpt":0.37798063393009723,"score_spread":0.25873109180272824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W77138857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195194,0.00034472896,0.0003045483,0.0001136785,0.000029922061,0.00034688314,0.000004226274,0.000069917754,0.0068341414],"genre_scores_gemma":[0.99816316,0.0005226192,0.0000778093,0.0001927816,0.00006613056,0.000032836582,0.000025128942,0.000024273739,0.00089526287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989908,0.000084503205,0.00029767776,0.00026044858,0.0001987018,0.00016791135],"domain_scores_gemma":[0.99924237,0.00002306807,0.000097693686,0.00047058618,0.00012139424,0.00004490139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002610541,0.00011219288,0.00023193585,0.000175573,0.0001216716,0.00000912075,0.00006613784,0.00007052492,0.00007595616],"category_scores_gemma":[0.000038241404,0.000097346405,0.000101887075,0.00030048372,0.00015265998,0.00014487372,0.000023936607,0.00018933171,0.00004061408],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011661852,0.00020068596,0.015507547,0.000013913079,0.00004126679,0.000009395971,0.00012782877,2.476153e-7,0.96721894,0.000099192686,0.0005819702,0.01608239],"study_design_scores_gemma":[0.0008783622,0.0010666277,0.027075488,0.00003148619,0.000006245588,0.000016952736,0.000017433984,0.000016640663,0.9680839,0.000064965694,0.00265726,0.000084618136],"about_ca_topic_score_codex":0.00014400938,"about_ca_topic_score_gemma":0.0000046081454,"teacher_disagreement_score":0.015997771,"about_ca_system_score_codex":0.00004399292,"about_ca_system_score_gemma":0.000030492003,"threshold_uncertainty_score":0.39696714},"labels":[],"label_agreement":null},{"id":"W82537579","doi":"10.1177/135965350300800501","title":"Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver","funders":"","keywords":"Medicine; Antiretroviral therapy; Medical prescription; Medication adherence; Intensive care medicine; Internal medicine; Human immunodeficiency virus (HIV); Viral load; Family medicine; Pharmacology","score_opus":0.04051657257031807,"score_gpt":0.35231153031812934,"score_spread":0.3117949577478113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W82537579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736304,0.0004962987,0.00065360864,0.00018158375,0.00007756597,0.0006557078,0.000013364659,0.00006339614,0.024228025],"genre_scores_gemma":[0.9880242,0.0016026706,0.0003467677,0.0006911245,0.000087989785,0.00010932887,0.000010250953,0.000021773212,0.0091058975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985293,0.00014735726,0.00020265795,0.0004004579,0.0003179131,0.00040230036],"domain_scores_gemma":[0.9993399,0.000026057805,0.00005730111,0.00029917745,0.00012253229,0.00015505246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013792962,0.00019505981,0.00027427537,0.00012503925,0.00014956818,0.00006255404,0.00012146115,0.000066702836,0.00015664239],"category_scores_gemma":[0.00007196959,0.00015432475,0.00012404029,0.00034820903,0.00014559514,0.0003965554,0.000021817865,0.0001994606,0.00009585909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060238264,0.00022394057,0.0018645246,0.000007138358,0.000040779552,0.0000058552164,0.0018001529,5.0134638e-8,0.6851283,0.0006600104,0.0011553974,0.30851147],"study_design_scores_gemma":[0.0021389865,0.01593834,0.024064265,0.00014638407,0.000005247317,0.000004740635,0.00082384184,0.000026911652,0.9319006,0.00024956636,0.024464194,0.00023690659],"about_ca_topic_score_codex":0.00012391289,"about_ca_topic_score_gemma":0.000008765998,"teacher_disagreement_score":0.30827457,"about_ca_system_score_codex":0.000038563976,"about_ca_system_score_gemma":0.000049887596,"threshold_uncertainty_score":0.62931806},"labels":[],"label_agreement":null},{"id":"W90835625","doi":"10.1177/135965350300800504","title":"Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings","year":2003,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; AIDS Vancouver; University of British Columbia; Engineers Without Borders Canada","funders":"","keywords":"Antiretroviral therapy; Immunology; Medicine; Human immunodeficiency virus (HIV); Viral load; Lymphocyte; Coinfection; Virology; Lentivirus; Viral disease; Internal medicine","score_opus":0.014705210197817222,"score_gpt":0.2849259927228821,"score_spread":0.2702207825250649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W90835625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929117,0.0025075783,0.00002132043,0.0001343165,0.00012527662,0.0021643396,0.00060837716,0.000078305944,0.0014487972],"genre_scores_gemma":[0.9969005,0.00070762826,0.00017013743,0.00027421323,0.00001828578,0.00017318479,0.00041909647,0.00004753635,0.0012894109],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99688196,0.00067580014,0.0006174126,0.00067473395,0.0001699108,0.0009801886],"domain_scores_gemma":[0.99855846,0.00044858787,0.00021872832,0.000512259,0.00018889112,0.00007306399],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011286177,0.0004113381,0.0007144632,0.00031683026,0.00020752312,0.000052668587,0.000283105,0.0003252987,0.00018383484],"category_scores_gemma":[0.00015498066,0.00034335032,0.00024909183,0.0005836891,0.00030612198,0.00017117716,0.000047970094,0.0002716985,0.00021633541],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029886847,0.0013653609,0.6361054,0.000036632147,0.0003128772,0.000022677617,0.0017462515,0.0000052779196,0.34598455,0.00015138183,0.001874273,0.009406635],"study_design_scores_gemma":[0.015862724,0.003796162,0.26656374,0.00007290012,0.000014913582,0.000012706986,0.00029388317,0.000003509619,0.68738115,0.00015007911,0.025444208,0.00040399792],"about_ca_topic_score_codex":0.0005630946,"about_ca_topic_score_gemma":0.000044241275,"teacher_disagreement_score":0.36954167,"about_ca_system_score_codex":0.0001880076,"about_ca_system_score_gemma":0.000355718,"threshold_uncertainty_score":0.99990183},"labels":[],"label_agreement":null},{"id":"W914135345","doi":"10.1177/135965350200700308","title":"Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370","year":2002,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Clinical trial; Internal medicine; Adverse effect; Observational study; Confounding; Viral load; Randomized controlled trial; Psychosocial; Immunology; Human immunodeficiency virus (HIV); Psychiatry","score_opus":0.22693459846899092,"score_gpt":0.49470534481085976,"score_spread":0.2677707463418688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W914135345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97710294,0.0001418342,0.00012812806,0.000803468,0.00007401192,0.019379366,0.00021999457,0.00003751093,0.0021127337],"genre_scores_gemma":[0.9911952,0.0007004979,0.0013250055,0.0002500433,0.00026655788,0.0039511467,0.000021289427,0.000014096981,0.0022761708],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99658924,0.0008698472,0.0014095994,0.0004227621,0.00043679966,0.00027176773],"domain_scores_gemma":[0.99812096,0.00069918565,0.00036905787,0.00038838584,0.00019323031,0.00022920198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022701242,0.00016578939,0.0007744522,0.00012953013,0.000074565214,0.00003301388,0.00020139043,0.00013761723,0.0005280021],"category_scores_gemma":[0.0038768156,0.00011522985,0.00025465403,0.0002478082,0.0006801209,0.00017787183,0.00004319048,0.00023660164,0.00008958884],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029304733,0.00055728777,0.135258,0.00003856286,0.00009916339,0.000034987483,0.00036039838,5.576352e-9,0.026749376,0.00011024843,0.011489139,0.8223724],"study_design_scores_gemma":[0.077423684,0.33269835,0.27870277,0.0059580593,0.00020547508,0.00006754476,0.0012452129,0.0025856204,0.25491777,0.0023577902,0.04259887,0.0012388873],"about_ca_topic_score_codex":0.0006230084,"about_ca_topic_score_gemma":0.00007186484,"teacher_disagreement_score":0.82113343,"about_ca_system_score_codex":0.000011337444,"about_ca_system_score_gemma":0.00005598066,"threshold_uncertainty_score":0.5781253},"labels":[],"label_agreement":null},{"id":"W94004259","doi":"10.1177/135965350701200s04.1","title":"Influenza Virus Susceptibility and Resistance to Oseltamivir","year":2007,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Manitoba","funders":"","keywords":"Oseltamivir; Neuraminidase; Neuraminidase inhibitor; Virology; Biology; Zanamivir; Virus; Infectivity; Influenza A virus; Resistance mutation; Microbiology; Drug resistance; Medicine; Genetics; Reverse transcriptase; Internal medicine; Gene; Polymerase chain reaction; Infectious disease (medical specialty)","score_opus":0.08393527582554833,"score_gpt":0.4072756966614836,"score_spread":0.3233404208359353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W94004259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561764,0.0033766665,0.00015944819,0.0005258385,0.00005671456,0.0006796335,0.000011996795,0.000098486824,0.009473576],"genre_scores_gemma":[0.989838,0.0011440394,0.0019713638,0.005534817,0.00017148956,0.000014806267,0.0000017032966,0.000027691633,0.001296095],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99828273,0.00005675305,0.00029260555,0.0004010022,0.00041072592,0.00055619224],"domain_scores_gemma":[0.9990157,0.00017436178,0.00004329284,0.00041417417,0.00017521562,0.00017725362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011169375,0.00020034949,0.00033686665,0.00015783608,0.00017632285,0.000029712024,0.000103706145,0.00008225741,0.000043902834],"category_scores_gemma":[0.00026587595,0.00015902791,0.00007082138,0.00033499533,0.00024481906,0.00013204692,0.0000802944,0.00024061433,0.00012586563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071185194,0.00028417006,0.39296874,0.00007742719,0.00016344234,0.000106527645,0.0018951767,1.7160492e-7,0.5044397,0.0017320861,0.0036228125,0.08759123],"study_design_scores_gemma":[0.0018596426,0.000532623,0.6912194,0.00005475716,0.000007524154,0.0000024435722,0.00012335679,9.449873e-7,0.099838726,0.0006694043,0.20548922,0.00020196819],"about_ca_topic_score_codex":0.0001140121,"about_ca_topic_score_gemma":0.0004545795,"teacher_disagreement_score":0.40460095,"about_ca_system_score_codex":0.00007323897,"about_ca_system_score_gemma":0.000047324393,"threshold_uncertainty_score":0.648497},"labels":[],"label_agreement":null},{"id":"W97603576","doi":"10.1177/135965350300800605","title":"Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance","year":2003,"lang":"en","type":"review","venue":"Antiviral Therapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Drug resistance; Biology; Resistance mutation; Nucleoside; Mutation; Nucleoside analogue; Antiretroviral therapy; Virology; Genetics; Medicine; Human immunodeficiency virus (HIV); Viral load; RNA; Gene","score_opus":0.0705908247958759,"score_gpt":0.38020921021209636,"score_spread":0.30961838541622044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W97603576","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003454843,0.994714,0.0000030204094,0.00041187645,0.0002583937,0.0019770674,0.00011867221,0.00005126027,0.002120231],"genre_scores_gemma":[0.000061175735,0.9904192,0.0012925728,0.0008793937,0.00016368068,0.000051268264,0.0002785927,0.00010494465,0.006749171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580455,0.0006476695,0.001914578,0.00078662863,0.0004276401,0.00041890796],"domain_scores_gemma":[0.9981135,0.00017176993,0.00073061173,0.0006819218,0.00011153809,0.00019062347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011086633,0.00072569103,0.0043067494,0.00023115448,0.000079917,0.000019061396,0.00017342504,0.0003613764,0.00010547741],"category_scores_gemma":[0.00010677299,0.0005187788,0.0013366241,0.00062878424,0.0003385361,0.00012993903,0.000027827331,0.0005767419,0.00006572696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013980441,0.0005606346,0.0016245951,0.071773306,0.0010521383,0.0003943036,0.000059285598,2.95875e-10,0.0000047283424,0.00016811852,0.05687718,0.8673459],"study_design_scores_gemma":[0.0014645099,0.0003198488,0.00007487939,0.14623053,0.0012960528,0.000034371547,0.000008927119,6.935671e-8,0.000015243991,0.000014242862,0.8501623,0.00037898403],"about_ca_topic_score_codex":0.000011239419,"about_ca_topic_score_gemma":0.0000049922655,"teacher_disagreement_score":0.8669669,"about_ca_system_score_codex":0.000069542526,"about_ca_system_score_gemma":0.00045013818,"threshold_uncertainty_score":0.99972636},"labels":[],"label_agreement":null}]}